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ABSTRACT 
USING AN IN VITRO-IN VIVO CORRELATION FOR THE  
‘BIOEQUIVALENCE BY DESIGN’ DEVELOPMENT OF AN IMMEDIATE RELEASE 
CARBAMAZEPINE PRODUCT 
 
 
 
By 
Douglas G. Steinbach 
December 2018 
 
Dissertation supervised by James K. Drennen, III, Ph.D. 
The quality of a drug product may be characterized by the consistency with which its indicated 
clinical effect, and safety profile, is experienced by the patient.  The concept that such quality should 
be built into a product is at the core of the United States Food and Drug Administration’s (FDA) quality 
by design (QbD) initiative.  This vision for pharmaceutical product development emphasizes the risk-
based identification of critical quality attributes (CQA) which summarize a product’s performance, the 
efficient refinement of critical product/process parameters (CPP) that can affect such attributes, and the 
systematic development of CPP limits, which assure appropriate performance of CQAs.  For a tableted 
drug product, a cornerstone CQA is dissolution. 
 v 
 
Often, a formulation and/or manufacturing process can change during a patient’s course of treatment, 
potentially jeopardizing the consistent performance of the drug product.    Regulatory agencies typically 
require that sponsors demonstrate how the generic/post-change product is bioequivalent to the 
reference/pre-change product.  While in vivo clinical trials are one strategy for demonstrating this, 
sponsors typically prefer in vitro dissolution tests as an alternative.  During these in vitro test, the F2 
metric is commonly used to assess dissolution profile similarity.  This work sought to compare the F2 
method with an alternative method, on the basis of errors in bioequivalence.  The alternative method was 
based on the use of a physiologically based in vitro-in vivo correlation (PB-IVIVC) model that had been 
nested within a clinical trial simulation platform.  The PB-IVIVC method provides a direct link from 
dissolution performance to clinical performance.  Thus, when it is used to refine a CPP-vs-dissolution 
response surface, based on the performance of reference product, the assurance of clinically defined 
bioequivalence can be directly built into a model tablet system.  
The model drug product for this work was an immediate release carbamazepine tablet.  Carbamazepine 
was selected as the model active pharmaceutical ingredient because it has a narrow therapeutic index and 
is designated as a class II compound (i.e. high permeability, low solubility) according to the FDA’s 
biopharmaceutics classification system (BCS). As such, this compound is identified within the FDA’s 
scale-up and post-approval change guidance as possessing elevated risk for biononequivalence when 
changes are imposed to its formulation and/or manufacturing process.   
After gathering single dose in vitro-in vivo data from the literature, the construction of the PB-IVIVC 
began according to a two step process.  Here, the respective parameters for the rate and extent of each 
product’s absorption were calculated using classical pharmacokinetic modeling and then regressed 
against each product’s rate and extent of dissolution.  Next, the classically defined clearance parameter 
was replaced using a physiologically based clearance model.  This allowed routinely available population 
 vi 
 
pharmacokinetic data to be combined with first principles of human physiology, for the mechanistic 
prediction of intersubject variability via correlated Monte Carlo simulations.  This PB-IVIVC was then 
used to not only define the CPP ranges for the model carbamazepine tablet system that would directly 
provide for bioequivalent performance, but to perform a post hoc assessment of the CPP ranges conferred 
by the use of  F2 statistic.  Ultimately, the results showed that when the product’s CPPs were refined 
using the F2 statistic the was higher risk of biononequivalence was higher when comparted to a product 
that had been refined using the PB-IVIVC.  It is intended that this work support the movement of 
product/process optimization practices away from methods that result in rigid factors of unknown clinical 
significance, and towards those that are focused on efficiently achieving specific clinical objectives. 
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Chapter 1. Introduction 
 
1.1     Bioequivalence Assessment: Current Practice and Associated 
Issues 
The first pharmaceutical regulations were born from society’s need for quality drug 
products.  A concept common to most definitions of pharmaceutical quality involves meeting 
or exceeding patients’ needs.  For individuals on established medication regimens, quality is 
largely defined in terms of consistency.  The expectation is that the medication will perform 
consistently throughout the duration of therapy.  Bioequivalence studies are used by sponsors 
to assure consistent product performance despite the occurrence of product variations (e.g. 
scale up, post approval changes [SUPAC], and therapeutic conversion to generic product).  
Drug products are considered bioequivalent by the Food and Drug Administration (FDA) 
when there is no statistical difference in the rate or extent of absorption between the 
comparators.1  In vivo and in vitro methods may be used to establish bioequivalence 
according to the Code of Federal Regulations (CFR) Title 21.2     
Generic drug applications typically rely on at least one in vivo clinical trial for 
bioequivalence as the cornerstone of their abbreviated new drug application.  Such trials have 
often been considered the most rigorous means of assessing bioequivalence.  The statistical 
assessment of bioequivalence requires that inter-subject variability be accounted for 
during the calculation of the critical values of a hypothesis test or confidence interval.  
Traditionally, inter-subject variability is estimated within the treatment periods of 
conventional bioequivalence studies.   These studies typically rely on a small cohort (n 
≈ 24) of young healthy patient volunteers who generally undergo a single dose of the 
test and reference drug products. The reliability of inter-subject variability estimates 
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can be increased by i) using clinical trials in the actual patient population, and ii) 
performing them on the scale of trials conducted during the second and third clinical 
development phases.  The time and overhead demands that such large scale trials place on 
pharmaceutical sponsors, however, is substantial.  This reality, along with the ethical 
limitations associated with the performance of in vivo trials in a clinical population for the 
sole purpose of quality assessment results in the avoidance of such measures during the 
assessment of bioequivalence.  However, this necessary compromise often results in the 
tenuous assertion that the inter-subject variance estimates defined by the pharmacokinetic 
conditions expressed in the healthy, single-dosed bioequivalence study populations are 
representative of those PK conditions expressed by the actual patient population during day-
to-day clinical practice.  The reliance upon this assertion can lead to erroneous inferences 
being drawn in in vivo trials aimed at the assessment of consistent product performance.  
Other factors that limit the reliability of bioequivalence testing include: the ethical restrictions 
that limit testable strengths, the study design limitation associated with narrow therapeutic 
index drugs the often subjective nature of efficacy/toxicity, and the appropriateness of 
washout periods.3,4   
Brand drug sponsors encounter activities related to the assurance of bioequivalence 
during changes to a product or manufacturing process.  Unlike generic drug sponsors, the 
sponsors of new drugs typically avoid the clinical demonstration of pre-vs-post change 
bioequivalence.  This avoidance is due, in part, to the minimal amount of information yielded 
from traditional in vivo bioequivalence trials (i.e., pass or fail), the absence of long-term 
safety data, and the large amount of resources required to run a clinical trial, and the expenses 
due to downtime.  In vitro approaches are more expedient and resource sparing.  Here, the 
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similarity of dissolution profiles is typically evaluated using an empirical USP window 
criteria, or in the absence thereof, the F2 statistic.5,6   A limitation of this approach is that 
inter-subject variability is no longer accounted for by these quality measurements.  Such 
methods do not provide for the continuous movement toward a risk-based and science-based 
approach of pharmaceutical quality as articulated in the Pharmaceutical CGMPs for the 21st 
Century and echoed by Dr. Janet Woodcock (the FDA’s acting director for the Center for 
Drug Evaluation and Research).7,8  In a perspective article, Woodcock identified the primary 
cause of most pharmaceutical quality issues to be a weakly defined link between critical 
quality attribute (CQA) measurements and clinical performance citing dissolution based 
biowavers as a specific example of where this can occur.9   
The concept that a strong link between the surrogates of in vivo performance and 
clinical response is essential for the efficient assurance of quality is a foundational principle 
this work.  An example of the ramifications stemming from a weak link between a quality 
measurement and clinical significance can be seen in the 2012 recall of 300mg extended 
release generic product of  Buproprion (trade name Wellbutrin XL).  The generic sponsor 
was attempting to bring to market two strengths of an extended release Buproprion product:  
150 mg and 300mg.  The 150mg generic drug product had a sufficiently wide therapeutic 
plasma concentration window. Thus, it was approved for the market following a traditional 
in vivo generic-vs-brand in bioequivalence trial.  The 300mg dose however, was associated 
with an increased risk of seizures, making clinical trials for bioequivalence prohibitive.  
Therefore, after the 150mg was approved the FDA approved the 300mg form in 2006 based 
on 1) the formulation of the 300mg generic product being proportionally equivalent to the 
150 mg generic product, and 2) satisfactory compendial (USP) dissolution tests of the 300 
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mg product.  Unfortunately, reports of increased side effects or reduced efficacy (subjectively 
defined) began soon after the generic entered the market.  In vivo clinical trials were 
performed in 2012, showing a significant difference between the performance of brand and 
generic formulations, ultimately necessitating a product recall.   
A literature review by Desmarais et al. suggests the Bupropion incident may not be 
isolated.10  The researchers examined the PubMed database to find works related to adverse 
events following the brand-to-generic switching of psychotropic medications.  The work 
notably excluded pharmacokinetic studies conducted with healthy volunteers unless it 
contained data relevant to the clinical population.  The researchers expressed significant 
concerns when the results indicated a large and growing body of literature reporting an 
increased risk of adverse events following switches.  Similarly, several large scale (n > 1500) 
case-control studies have specifically found that changes in anticonvulsant drug formulation 
involving generics was a risk factor for emergency or hospital-level treatment of epilepsy 
(OR: 1.78 to 1.81).11-12  The combined evidence in the literature suggests that the origin of 
bioequivalence related failures is multifaceted, resulting, in part, from the practical 
limitations of conventional clinical methods and the absence of clinically relevant quality 
specifications. 
While a strong link between the surrogates of in vivo performance and clinical response 
is critical for the market entry of generic drug products, it is also important for navigating the 
product/process changes that can occur over the lifecycle of a brand or generic product.  The 
inevitable reality of change events is evident in the focus of recent ‘scale-up/post-approval 
change’ regulatory documents (e.g., see ICH Q12 draft guidance).  A theme shared by this 
and other documents is an emphasis on how a sponsor’s possession of advanced product and 
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process knowledge can contribute to a reduction in the number of subsequent regulatory 
submissions.  The assurance of such flexibility comes from effectively incorporating 
knowledge–driven tools and strategies within the initially approved Pharmaceutical Quality 
System.  Thus, product/process changes can be made with less need for extensive regulatory 
oversight prior to implementation due to prior approval.  According to the CFR, one of the 
most informative and preferred methods by the FDA for the overall determination of 
bioequivalence is one that correlates in vitro tests with human in vivo bioavailability data.  
However, current IVIVC (in vitro-in vivo correlation) guidance documents and literature 
focus on illustrating best practices for extended release products that are Biopharmaceutical 
Classification System (BCS) class I and III.  Therefore, research on the development of 
adequate surrogates for clinical performance (and the illustration of such practices) is 
critical for immediate release products that are BCS class II.  This is especially critical for 
therapies that are associated with a narrow therapeutic index. 
The model drug in this dissertation is carbamazepine.  The difference between the toxic 
plasma concentrations and the minimum effective plasma concentration for this compound 
is approximately three fold and as such is generally considered to have a ‘narrow therapeutic 
index’.  Additionally, the release performance of tableted formulations containing 
carbamazepine as the active pharmaceutical ingredient (API) has been demonstrated to be 
sensitive to product/process variability.  These features, combined with the biochemical 
properties which place it in the category of a BCS class II compound, makes a solid oral 
dosage form of carbamazepine a high-risk product from a bioequivalence perspective. 
Therefore, carbamazepine was considered a suitable model system for this project.  
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1.2.     Hypothesis, Specific Aims, and Purpose 
The intent of this work is to strengthen the understanding between quality 
assessment measurements and clinical performance according to quality by design 
(QbD) principles. This dissertation is based on the central hypothesis that,  
for an immediate release carbamazepine product, 
a physiologically-based IVIVC, coupled with a clinical trial simulation 
platform, provides a more accurate estimation of bioequivalence than 
the conventional F2 similarity criterion during the comparative 
assessment of test vs. reference product performance. 
Given this, four specific aims were performed for the assessment of the central 
hypothesis of this dissertation.   
Specific Aim 1: 
Develop an IVIVC for an immediate release carbamazepine product using 
a classical pharmacokinetic model 
-●- 
The ability of an IVIVC to predict an entire plasma concentration profile given a 
product’s dissolution performance enhances its meaningfulness. This is often achieved 
by constructing a hierarchical framework around a pharmacokinetic model.  The goal 
of the first specific aim is to construct an IVIVC that can predict the entire plasma 
concentration profile by parameterizing its pharmacokinetic model using mean plasma 
concentration profiles of carbamazepine products in a normal healthy population.  In 
using plasma data as the basis for pharmacokinetic parameterization, the approach is 
termed: top down pharmacokinetic modeling (i.e. pharmacokinetic parameters are 
solely informed by the plasma concentration profiles). 
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Specific Aim 2: 
Account for population level pharmacokinetic variance within the 
pharmacokinetic model of the in vitro-in vivo correlation by appropriately 
integrating physiologically based inter-subject variability  
-●- 
Equivalence testing requires that variance of the response be taken into consideration 
during the assessment.  The identification of population-level pharmacokinetic 
variance typically relies of inefficient large-scale in vivo trials (i.e. top down).  In this 
work, pharmacokinetic variance will be accounted for from the bottom up by coupling 
the results of quantitative pharmacologic assays performed in vitro, with systemic 
physiologically based pharmacokinetic modeling and simulation. 
 
 
Specific Aim 3: 
Define a formulation for an immediate release carbamazepine tablet and model 
its change in dissolution performance as a function of defined critical attributes  
-●- 
The mathematical equations used to model the immediate release dissolution 
behavior of a tablet can be manipulated to generate a host of profiles ranging from 
mono-exponential curves to sigmoidal shapes. Specific aim three ensures that the two 
bioequivalence assurance methods identified in the hypothesis are compared across 
a realistic spectrum of dissolution profiles.   
 
Specific Aim 4: 
Derive a distribution of clinical responses resulting from use of an F2-based 
equivalence criteria and compare with that derived from a physiologically based 
IVIVC on the basis of type I/II errors in bioequivalence  
-●- 
The fourth specific aim of this work is the culmination of the first three specific 
aims.  After defining the dissolution performance of the benchmark product, this 
specific aim uses the physiologically based IVIVC (developed from specific aims 
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one and two) to process the interpolated F2 dissolution profiles (from specific aim 
three) and generate a distribution of clinical responses.  This F2-distribution of 
clinical responses can then be compared against the reference distribution of clinical 
responses representing all of the responses that would be bioequivalent to the 
benchmark product.  This will be performed through integration of the respective 
probably density functions. 
 
While IVIVCs are of significant interest to regulatory agencies, and the subject of much 
research, their approval rate remains relatively low.   This is despite the compounding costs 
to society and sponsors that stem from unintended delays to product development timelines 
due to a sponsor’s inability to assure that an observed difference in dissolution performance 
is inconsequential.  The use of an IVIVC provides a path towards avoiding such delays as 
they provide a more informative interpretation of pivotal dissolution tests.  The intention of 
this dissertation is to provide a streamlined framework to facilitate the development of a 
population level IVIVC via physiologically-based pharmacokinetic modeling and 
simulation for informing clinically-based decision making during product development. 
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1.3.     Advancing Pharmaceutical Quality: In vitro-In vivo Correlation 
Models  
According to an FDA guidance document entitled “Extended Release Oral Dosage 
Forms: Development, Evaluation, and Application of In vitro/In vivo Correlations” 
there are three in vitro-in vivo correlation (IVIVC) levels: A, B, and C. The differential 
criteria for these three levels have been generally accepted by numerous regulatory 
agencies and scientific communities.  The levels differ primarily in theamount of detail 
required of both input and output data. The defining characteristic of a level A IVIVC 
is the ability to predict the entire in vivo time course from the in vitro data.  A level B 
IVIVC uses the principles of statistical moment analysis (e.g., the output is defined in 
terms such as the mean residence time);  it does not uniquely reflect the actual in vivo 
plasma level curve because a number of different in vivo curves will produce similar 
mean residence time values.  Similarly, a Level C correlation does not reflect the 
complete shape of the plasma concentration time curve;  instead, it draws a relationship 
between an amount dissolved at a given time and some summary pharmacokinetic 
parameter such as the area under the curve (AUC), maximum plasma concentration, or 
the time of the maximum plasma concentration. 
Level A correlations are the most common type of correlation provided in NDAs 
submitted to the FDA according to guidance documents and other regulatory 
literature.13 This is because the the level A IVIVC is considered the most informative.  
The specifics for establishing a level A correlation is left up to the sponsor.  Examples 
cited in the guidance document make reference to convolution and deconvolution 
methods; however, numerous methods for creating a level A IVIVC exist.  A 
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subsequent section will detail the areas of commonality and differentiation among these 
methods. 
1.4.     Theoretical Background for Project  
The feasibility of this project is based on the founding principles of the Biopharmaceutical 
Classification System established by Amidon et al. and subsequently adopted by the FDA.14,15  
This system is based on solubility and permeability and is used, in part, to guide expectations 
concerning the rate limiting step of absorption; i.e., dissolution rate limited, permeability 
limited, and solubility–permeability limited.  Here, the systemic absorption of a high 
permeability, low solubility drug is considered dissolution rate limited.  Amidon et al. justified 
such expectations by combining the Noyes-Whitney Equation and a first-order absorption rate 
model to describe the fraction of drug absorbed (see eq. 1.4.1).   
 
Eq. 1.4.1)  
𝐹௔ = 1 − [
𝑘௣௘௥௠
𝑘௣௘௥௠ − 𝑘ௗ௜௦௦
𝑒𝑥𝑝 (−𝑘ௗ௜௦௦𝑇௔௕௦)]
− [
𝑘ௗ௜௦௦
𝑘ௗ௜௦௦ − 𝑘௣௘௥௠
𝑒𝑥𝑝 (−𝑘௣௘௥௠𝑇௔௕௦)]  
where, 
𝑘௣௘௥௠ = permeation rate 
𝑘ௗ௜௦௦ = dissolution rate 
𝑇௔௕௦ = the transit time 
through the absorption site 
 
The existence of a dissolution rate limited scenario was illustrated by calculating 
lim௞೛೐ೝ೘→ஶ  Eq.1.4.2. (see eq. 1.4.2 for result).  If the rate of permeation into the systemic 
circulation is instantaneous relative to the rate of drug dissolution (i.e., solubilized drug is 
immediately absorbed and sink conditions are  
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effectively generated; 𝑘௣௘௥௠>>𝑘ௗ௜௦௦), systemic absorption can be considered limited by the 
rate of dissolution. 
 Eq. 1.4.2)     lim
 ௞೛೐ೝ೘ஶ
[𝐹௔]  = [1 − 𝑒𝑥𝑝 (−𝑘ௗ௜௦௦𝑇௔௕௦) ]   
In the seminal work, Amidon et al. describe expectations concerning possibility of 
successfully developing an in vitro-in vivo correlation for immediate release products 
based on solubility and permeability. Table 1.4.1 presents these expectations, which were 
subsequently adapted in guidance documents released by numerous regulatory agencies.  
Table 1.4.1  In vitro-in vivo Correlation Expectation for Immediate Release Products Based on 
Biopharmaceutics Class (Adapted from Amidon et al. (1995) 14) 
Class Solubility Permeability In vitro-In vivo Correlation Expectation 
I High High 
In vitro-in vivo correlation expected if dissolution rate is 
slower than gastric emptying rate, otherwise limited or no 
correlation 
II Low High 
In vitro-in vivo correlation expected if in vitro dissolution 
rate is similar to in vivo dissolution rate, unless dose is 
very high 
III High Low Absorption (permeability) is rate determining and limited or else no in vitro-in vivo correlation with dissolution rate  
IV Low Low Limited or no in vitro-in vivo correlation is expected 
A limited correlation means that the dissolution rate, while not the absolute rate controlling step, may be similar to the 
absorption rate; thus, the extent of correlation will depend on the relative rates 
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Chapter 2. Literature Survey 
 
The major areas of interest and implication for this work include i) events that 
require the assessment of bioequivalence, ii) the approaches used to assess 
bioequivalence, iii) in vitro-in vivo correlation modeling, and iv) physiologically based 
modeling.  Therefore, this document will begin by reviewing these concepts using 
pharmaceutical science literature.  Additionally, it is a reality of the pharmaceutical 
industry that drug product development activities are shaped by federal guidances and 
regulations. Therefore, this section also covers regulatory policies pertinent to the 
assessment of bioequivalence in the pharmaceutical industry.   
 
2.1 The Assessment of Bioequivalence 
2.1.1 Regulations, Guidances, and Examples 
Title 21 of the Code of Federal Regulations (CFR) governs food and drugs within the 
United States by the Food and Drug Administration. Sections 200 and 300 include 
regulations pertaining to pharmaceuticals.  The specific sections in the CFR which i) 
identify the circumstances that require the assessment of bioequivalence, and ii) discuss 
the methods for its evaluation, are identified in Table 2.1.1.1. 
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Section 320.21 specifically references the role of bioequivalence studies with respect to 
abbreviated new drug applications (ANDAs) and supplements to new drug applications 
(NDAs).  The regulations of this section may be summarized as in the following table. 
 
 
Table 2.1.1.1. Relevant Sections of the Code of Federal Regulations Related to BA/BE 
21CFR section Type of provision/information 
314.94(a)(9) Chemistry, manufacturing, and controls; permitted changes in inactive ingredients for parenteral, 
otic, ophthalmic, and topical drug products 
320.1  Definitions of bioavailability, pharmaceutical equivalents, pharmaceutical alternatives, and BE 
320.21 Regulatory requirements related to submission of in vivo bioavailability and bioequivalence data 
320.22 Criteria for waiver of evidence of in vivo bioavailability or bioequivalence data 
320.23 Basis for measuring in vivo bioavailability or demonstrating bioequivalence 
320.24 Types of evidence to measure bioavailability or establish bioequivalence 
320.25 Guidelines for the conduct of an in vivo bioavailability study 
320.26 Guidelines on the design of a single dose in vivo bioavailability or bioequivalence study 
320.27 Guidelines on the design of a multiple-dose in vivo bioavailability study 
320.28 Correlation of bioavailability with an acute pharmacological effect or clinical evidence 
320.29 Analytical methods for an in vivo bioavailability or bioequivalence study 
320.30 Inquiries regarding bioavailability and BE requirements and review of protocols by the FDA 
320.38 Retention of bioavailability samples 
320.63 Retention of bioequivalence samples 
 Adapted from the CFR and Midha et al. (2009) 16 
Table 2.1.1.2. Summary of  Requirements for Submission of Bioequivalence Data 
cited in 21CFR320.21  
A
N
D
A
s 
 Any sponsor submitting an abbreviated new drug application to FDA shall include in 
the application either: 
 
 Evidence demonstrating that the drug product that is the subject of the abbreviated 
new drug application is bioequivalent to the reference listed drug  
 
 Information to show that the drug product is bioequivalent to the reference listed 
drug which would permit FDA to waive the submission of evidence demonstrating 
in vivo bioequivalence [i.e. a biowaiver] 
Su
pp
le
m
en
ts
 to
 
N
D
A
s 
 Any person submitting a supplemental application to FDA shall include in the 
supplemental application the evidence or information set forth in the section above if 
the supplemental application proposes any of the following changes: 
 
 A change in the manufacturing site or process, including a change in product 
formulation or dosage strength, beyond the variations provided for in the approved 
application 
For full text of CFR title 21 section 320.21 see: [17]
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Events which may necessitate submission of bioequivalence data are identified in section 
320.21 as “changes beyond those provided for in the approved drug application.” Such 
changes can often occur over the lifecycle of a product.  Section 314.70 provides further 
detail regarding the nature of a proposed change by identifying three categories: minor, 
moderate, and major.  The classifications are based on the “potential to have an adverse 
effect on the identity, strength, quality, purity, or potency of the drug product as these 
factors may relate to the safety or effectiveness of the drug product.”  Determining the 
magnitude of this potential adverse effect is performed during the review process of the 
application for change approval.  However, it can be stated that the FDA typically errs on 
the side of caution, often electing to require in vivo assessments of bioequivalence in the 
absence of rigorously supported justification(s) for the waiver of such trials (i.e., 
biowaiver).  Examples for minor, moderate and major changes are provided in section 
314.70.  A selection of notable instances are contained in Table 2.1.1.3.   
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Table 2.1.1.3. Summary of the Severity of Changes to New Drug Applications  
Cited in 21CFR314.70 
Examples Examples 
Se
ve
ri
ty
 o
f c
ha
ng
e 
M
in
or
 
 
 The deletion or reduction of an true colorant 
 Replacement of manufacturing equipment with that of the same design and 
operating principles  
 Change in the size and/or shape of a nonsterile solid dosage form container 
without a change in system  
 
M
od
er
at
e 
 
 Change in the container closure system 
 An increase or decrease in biopharmacutical production scale during finishing 
steps that involves different equipment 
 Addition to a specification or changes in the methods or controls to provide 
increased assurance that the drug substance or drug product will have the 
characteristics of identity, strength, quality, purity, or potency that it purports or is 
represented to possess 
 
M
aj
or
 
 
 Changes that may affect drug substance or drug product sterility assurance  
 Changes in the synthesis or manufacture of the drug substance that may affect the 
impurity profile and/or the physical, chemical, or biological properties of the drug 
substance 
 A change in the manufacturing site or a change in the manufacturing process, 
including a change in product formulation or dosage strength, beyond the 
variations provided for in the approved application. 
 
For full text of CFR title 21 section 314.70 see: [18] 
 
The CFR is considered to be federal law.  Therefore, sponsors must interpret the 
document as legally-binding regulations.  The FDA, in an effort to complement the CFR, 
periodically releases “Guidance for Industry” documents.  Guidance documents represent 
the Agency's current thinking on a particular subject. They do not create or confer any 
rights for or on any person and do not operate to bind FDA or the public.  The primary 
guidance document concerning the regulatory imposition of studies for the assessment of 
post-approval bioequivalence is entitled, Immediate Release Solid Oral Dosage Forms; 
Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In vitro 
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Dissolution Testing, and In vivo Bioequivalence Documentation (henceforth referred to as 
the SUPAC guidance).   
 
This SUPAC guidance provides the following support to industry: 
i)  a framework of product lifecycle management categories within which 
changes occur  
ii)  examples of levels of change that can occur within each category  
iii)  suggested chemistry, manufacturing, and controls (CMC) tests for each level 
of  
change 
 
iv)  in vitro dissolution tests and/or in vivo bioequivalence tests for each level of 
change  
v) documentation to support the change. 
The four specifically described categories in which a change can occur are identified as i) 
changes to the components and composition of the drug product ii) site changes iii) changes 
in the batch size (scale-up/scale-down), and iv) changes to the manufacturing process.  The 
differences in these categories are described in Table 2.1.1.4. 
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Table 2.1.1.4. Post Approval Change Categories as Defined in the SUPAC Guidance 
Category of  
SUPAC-defined Change Description 
Components and composition 
Focuses only on [batch-wise] changes in excipients and not on changes in 
the amount of drug substance 
Site  
Changes in location of the site of manufacture for both company-owned 
and contract manufacturing facilities 
Batch size  
(scale-up/scale-down) 
Postapproval changes in the size of a batch from the pivotal/pilot scale 
biobatch material to larger or smaller production batches call for 
submission of additional information in the application.  
Scale-down below 100,000 dosage units is not covered by the SUPAC 
guidance 
Manufacturing 
Changes that may affect both equipment used in the manufacturing 
process and the process itself. 
For full text of SUPAC Guidance see: [19]
 
The SUPAC guidance echoes the CFR by identifying up to three levels of change within 
each category (now referred to as levels 1, 2 and 3).  Some of the general examples used 
in the SUPAC guidance broadly mirror those found in the CFR.  However, the guidance 
moves a step beyond the qualitative criteria used in the CFR (e.g.,likelihood of detectable 
impact vs. potential to have an adverse effect, respectively) by citing quantitative examples 
and invoking the concepts of therapeutic range, solubility, and permeability in definitions 
and examples.  In each category, the levels are uniquely defined, with a guiding principle 
of maintaining pharmaceutical quality (i.e., consistently meeting the needs of the patient) 
over varying degrees of change.   
Level 1 changes are defined as component and composition changes that are unlikely 
to have any detectable impact on quality and performance (e.g., nonfunctional colorants).  
An example of level 1 changes includes changes to excipients that do not effect API 
performance characteristics.  Such changes are cited as percentage-wise (w/w) changes of 
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total formulation, less than or equal to the following ranges and predicated on the sum of 
all excipient changes being < 5%: 
 “filler”        ±5 
“starch disintegrant” (or other)     ±3 (±1) 
“binder”       ±0.5 
Ca or Mg stearate lubricant (or other)    ±0.25 (±1) 
talc glidants (or others)      ±1 (±0.1) 
“film coating”        ±1 
It is minimally suggested that such changes be formally filed with the FDA for prior 
approval.  Instead, the suggestion is to document level 1 changes as part of the sponsor’s 
annual report. 
 Level 2 changes to excipients are broadly considered as those that “could have a 
significant impact on formulation quality and performance.”  Suggestions for the 
assessments of consistent performance, and the filing of the associated documentation, for 
a level 2 change vary depending on three prefaced factors of the API in the drug product 
whose excipients are undergoing some change, namely the therapeutic range (i.e., narrow 
or non-narrow), solubility (i.e., low or high), and permeability (i.e., high or not high).  
Identified examples of level 2 excipient changes can include the technical gradte of an 
excipient.  Additionally, examples of level 2 changes are once again identified as changes 
in the relative percent, only now the  when the degree of change is double than those 
thatwhat could be considered a level 1 changes.  Here, specific dissolution tests are 
recommended for BCS class I, II (e.gi.e., Carbamazepine), and III with the suggestion for 
in vivo bioequivalence documentation still being dnone if the situation meets the previous 
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BCS-based dissolution test. If the dissolution tests are not metdo not meet the requirements 
for level 2, then the recommendation is to refer to level 3 changes. Level 3 changes are 
those that are “likely to have a significant impact on formulation quality and performance.”  
Suggestions for the assessments of consistent performance, and the filing of the associated 
documentation, for a level 3 change vary depending on the therapeutic range, solubility, 
and permeability of the drug product’s API.  Some cited examples  
of level 3 changes are: 
 Any qualitative and quantitative excipient changes to a narrow therapeutic index drug  
beyond the level 1 ranges 
 Level 1 and 2 changes that occur in BCS class 4 drugs (i.e. low permeability and low 
solubility) 
 Changes in the excipient ranges of all drugs beyond those considered to be level 2  
 
A generally defined dissolution test is recommended for all level 3 changes (i.e. multi-point 
dissolution profile from the application/compendial medium at 15, 30, 45, 60 and 120 
minutes or until asymptote).  Additionally, a full bioequivalence study is recommended.  
However, the bioequivalence study may be waived where an acceptable IVIVC has been 
established.  Based on this information, it can be expected that in vivo bioequivalence 
assessment will be required by the FDA for the approval of excipient changes to an 
immediate release carbamazepine product (due to carbamazepine’s narrow therapeutic 
index and status as BCS Class 2) beyond those identified as level 1, unless a suitable IVIVC 
exists.     
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Changes to an approved manufacturing process are the other instance were 
bioequivalence trials are recommended by the SUPAC guidance.  Specifically, such trials 
are recommended for level 3 manufacturing process changes.  This level includes processes 
change such as a change from wet granulation to direct compression of dry powder.  Here, 
the same recommendations for the performance of dissolution trials and bioequivalence 
hold true, as as previously described in the case of level 3 excipient changes. 
It should be noted that the descriptions for the specific level of change are not defined 
in totality;the level is defined as part of the iterative review process.  
 
2.1.2 Current practices for the Assessment of Bioequivalence 
Current approaches for the demonstration of bioequivalence can be classified as 
being performed either in vitro or in vivo.  Section 320.24 in the CFR describes types of 
evidence to measure bioavailability or establish bioequivalence.  The following summary 
of in vivo and in vitro approaches, in descending order of accuracy, sensitivity, and 
reproducibility, are acceptable for determining the bioavailability or bioequivalence of a 
drug product: 
1. a) An in vivo test in humans in which the concentration of the active ingredient in 
the plasma is measured as a function of time (i.e. a pharmacokinetic method) 
b) An in vitro test that has been correlated with and is predictive of human in vivo 
bioavailability data (i.e. an IVIVC) 
2. An in vivo test in humans in which the concentration of the active ingredient in 
the (urinary) excretions of subject are measured as a function of time.  
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3. An in vivo test in humans in which an appropriate acute pharmacological effect of 
the active moiety, and are measured as a function of time (i.e. a 
pharmacodynamic method) 
4. Well-controlled clinical trials of safety and effectiveness, for purposes of 
demonstrating bioequivalence. This approach is one of the least accurate, 
sensitive, and reproducible of the general approaches for measuring 
bioavailability or demonstrating bioequivalence.  
5. A compendial in vitro test acceptable to FDA (i.e. USP based dissolution test) 
 
Interestingly an IVIVC is in fact the most preferred method for bioequivalence 
determination after pharmacokinetic methods. 
 
2.1.2.1 In vivo Assessment of Bioequivalence 
A detailed protocol, including study objective(s), patient inclusion criteria, dosing 
schedules, a study design, and statistical methods, must be identified before a human 
in vivo trial is conducted.   
The objective of bioequivalence trials, as found in the pharmaceutical literature, are 
based, typically, on the 21CFR320.1 definition of bioequivalence and the FDA 
guidance documents on bioavailability and bioequivalence studies.  They generally 
recapitulate the objective for bioequivalence studies stated in the SUPAC guidance: 
“To compare the rate and extent of absorption of the drug product for 
which the manufacture has been changed, as defined in this guidance, 
to the drug product manufactured prior to the change.” 
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The patient inclusion criteria for in vivo bioequivalence trials is typically shaped by 
ethical constraints.  It is untenable to expose a patient who is medically dependent on 
a certain drug product to a potentially toxic/ineffective product for the sole purpose of 
determining bioequivalence. As such, bioequivalence studies are typically conducted 
in healthy patients.  Also, dosing schedules can again be ethically constrained by the 
side effect profiles of medications.  Most bioequivalence trials therefore utilize a single-
dose format as evidenced in a 2009 retrospective study conducted by several FDA 
officials regarding bioequivalence trials of generic drug products approved by the 
agency from 1996 to 2007.20  
 
2.1.2.2 Trial design 
Prospective experimental designs are used to analyze the effect of independent 
variables. In vivo bioequivalence trials typically follow the characteristics of a 
randomized controlled trial (RCT).  According to the Cochrane Collaboration, RCTs 
are highly regarded because they are designed specifically to minimize bias.  By 
randomly assigning participants to groups, for example, the likelihood that the groups 
will differ on important baseline characteristics that confound the assessment of an 
intervention (whether the investigator knows them or not) is minimized.  The majority 
of regulatory documents recommend a two-treatment, two-period crossover study with 
an equal number of subjects randomly assigned to each of the two dosing 
sequences.21,22  These regulatory documents typically make provisions that alternative 
methods can be selected if appropriate.  To maintain efficiencies, however, the most 
common design employed is the 2-by-2 crossover design. This design allows each 
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subject to serve as their own control, providing an increase in statistical power.  This is 
important because the statistical power of a simple parallel trial would be extremely 
limited when considering that most clinical trials rely on only 24 to 36 healthy 
patients.20  
The 2-by-2 crossover designs means that there are two product groups (i.e. the 
reference product and the test product) and two treatment sequences (test product 
administration “crossed over” to reference product administration and vice versa; see 
Figure 2.1.2.2.1).   
 
 
 
 
 
 
 
 
 
 
Given the absorption and elimination kinetics for carbamazepine, this type of study can 
take over two weeks (in addition to the setup time for such a trial).23  Other higher-
order designs exist but are rarely used;  such methods account for high within-subject 
variability.  However, as recent FDA draft guidance states, carbamazepine has low 
within-subject variability. 24 
Figure. 2.1.2.2.1 Illustration of a 2-by-2 Crossover Study Design 
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2.1.2.3 Trial Analysis 
Variability in outcomes is a hallmark trait of higher order biologic systems.  It is 
unrealistic to expect ‘test’ and ‘reference’ responses to ever be exactly identical.  
Therefore, in vivo methods utilize intervals to define acceptable degrees of difference.  
When analyzing the results of a clinical trial for bioequivalence, a generally stated goal 
is to determine whether it is reasonable for one to expect the difference between test 
and reference responses to exceed reasonable limits, given the observed data.  In 
statistical terms, the expected value for a normal distribution of responses is the mean.  
In frequentist (classical) statistics, the standard deviation of a normal distribution is the 
basis for defining the certainty with which the mean of a sample from a population (i.e. 
subjects in a clinical trial) is said to be known.    Based on this, FDA has adopted the 
two one-sided test (TOST) procedure described by Schuirmann et al.25-27  The level of 
bioequivalence most commonly recommended is average bioequivalence, there are 
however other less frequently employed levels of bioequivalence which require higher 
order study designs.1 
Schuirmann’s TOST procedure begins by defining the hypotheses to be tested, 
Eq. 2.1.2.3.1      𝐻଴ଵ =  𝜇் − 𝜇ோ  ≤  𝜃௅      𝑣𝑠     𝐻௔ଵ = 𝜇் − 𝜇ோ >  𝜃௅  
  and 
Eq. 2.1.2.3.2      𝐻଴ଶ =  𝜇் − 𝜇ோ ≥  𝜃௎      𝑣𝑠     𝐻௔ଶ = 𝜇் − 𝜇ோ <  𝜃௎     
Hypothesis 2.1.2.3.1 is tested to verify that the average bioavailability of the T product 
does not exceed a lower limit (𝜃௅). Hypothesis 2.1.2.3.2 is tested to verify that the 
average bioavailability of the T product does not exceed an upper limit (𝜃௎).   In both 
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equations, the null hypothesis (H0#) represents bioinequivalence.  This setup is the 
reverse of the ordinary view of hypothesis testing.  During conventional hypothesis 
testing the null hypothesis is usually the hypothesis of interest, but the set up in the 
equations is more applicable for bioequivalence assessment. Here, the type I error (α) 
is declaring the drugs to be bioequivalent, when they are not. By setting up the 
hypothesis as shown, the consumer’s risk is protected.  The two hypothesis tests can 
performed using one sided t-tests 
Eq. 2.1.2.3.3 𝑇௅ =
൬𝑌𝑇−𝑌𝑅൰−𝜃𝐿
𝜎෡ 𝑑ඨ
1
𝑛1
+ 1𝑛2
> 𝑡(𝛼, 𝑛ଵ + 𝑛ଶ − 2)   
and 
Eq. 2.1.2.3.4 𝑇௎ =
൬𝑌𝑇−𝑌𝑅൰−𝜃𝑈
𝜎෡ 𝑑ඨ
1
𝑛1
+ 1𝑛2
 > 𝑡(𝛼, 𝑛ଵ + 𝑛ଶ − 2)  
where 𝑌  is the average response of the T product, 𝑌ோ is the average response of the R 
product, 𝑛ଵ is the number of observations in the T product, 𝑛ଶ is the number of 
observations in the R product, and 𝜎ොௗ is the pooled sample standard deviation of period 
differences from both sequences (see Equations 2.1.2.3.3 and 2.1.2.3.4).  It is considered 
an unbiased estimator of the true standard deviation (𝜎ௗ) in the absence of carryover 
effects.   
 𝜎ොௗ =  ට𝜎ොௗ
ଶ (2.1.2.3.5)  
where, 
  𝜎ොௗ
ଶ =  ଵ
௡భା௡మିଶ
∑ ∑ (𝑑௜௞ − ?̅?∙௞)ଶ
௡ೖ
௜ୀଵ
ଶ
௞ୀଵ   and   𝑑௜௞ =
ଵ
ଶ
(𝑦௜ଶ௞ − 𝑦௜ଵ௞) 
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Thus, the TOST procedure confirms bioequivalence if, and only if, 𝐻଴ଵ and 𝐻଴ଶ are 
both rejected at a predefined -level; otherwise stated, when both |𝑇௎| and |𝑇௅| are 
greater than test statistic: 𝑡(𝛼, 𝑛ଵ + 𝑛ଶ − 2). 
 
2.1.2.4 In vitro Demonstration of Bioequivalence 
2.1.2.4.1 Dissolution-based Biowaivers 
The waiver of in vivo bioequivalence studies is federally provided under certain 
conditions by 21CFR320.22.  This type of a waiver is referred to as a biowaiver.  The 
circumstances stated in the CFR provides, for certain drug products, that bioequivalence 
may be demonstrated by evidence obtained in vitro in lieu of in vivo data is summarized in 
the following Table 2.1.2.4.1.1. 
Table 2.1.2.4.1.1. Highlights of Requiments of Bioavailability and Bioequivalence 
Assessments as Cited in 21CFR320.22 
Bioequivalence may be demonstrated by evidence obtained in vitro in lieu of in 
vivo data under one of the following criteria:  
1) The drug product is in the same dosage form, but in a different strength, and is 
proportionally similar in its active and inactive ingredients to another drug product for 
which the same manufacturer has obtained approval and the following criteria are met: 
a) The bioavailability of the other drug product has been measured 
b) Both drug products meet an appropriate in vitro test approved by FDA, and 
c) The applicant submits evidence showing that both drug products are 
proportionally similar in their active and inactive ingredients. 
 
2) The drug product is, on the basis of scientific evidence submitted in the biowaiver 
application, shown to meet an in vitro test that has been correlated with in vivo data. 
 
3) The drug product is a reformulated product that is identical, except for a different 
color, flavor, or preservative that could not affect the bioavailability of the 
reformulated product, to another drug product for which the same manufacturer has 
obtained approval and the following conditions are met: 
a) The bioavailability of the other product has been measured, and 
b) Both drug products meet an appropriate in vitro test approved by FDA. 
 
For full text of title 21 section 320.22 of the CRF see: [28] 
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The critical role an IVIVC can play for the approval of a biowaiver application (as 
referenced in criterion 2 of the previous summary table) is another example of its value.   
As before, there are FDA guidance documents to augment section 320.22 of the CFR.  One 
such document is entitled Waiver of In vivo Bioavailability and Bioequivalence Studies for 
Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification 
System Guidance.  This guidance explains how biowaivers can be requested for an IR solid 
oral dosage forms based on its BCS class.  The guidance notes that, "when combined with 
the dissolution of the drug product, the BCS takes into account three major factors that 
govern the rate and extent of drug absorption from IR solid oral dosage forms: (1) 
dissolution, (2) solubility, and (3) intestinal permeability."  However, this guidance is 
focused on BSC class I/III products and does not address BCS-based biowaivers for the 
narrow therapeutic index drugs.  Therefore, it is of little help for drugs such as 
carbamazepine (i.e. BSC class II and a narrow therapeutic index).   
Immediate release BCS class II products are discussed (albeit briefly) in the FDA’s 
1997 guidance entitled Dissolution Testing of Immediate Release Solid Oral Dosage 
Forms with no preclusions concerning the breadth of the therapeutic index.  This document 
specifically mentions BCS class II products in two sections: i) Approaches for Setting 
Dissolution Specifications for a New Chemical Entity and, ii) In vivo-In vitro Correlations.  
For dissolution specification setting, the guidance notes that “a two-point dissolution 
specification, one at 15 minutes to include a dissolution range (a dissolution window) and 
the other at a later point (30, 45, or 60 minutes) to ensure 85% dissolution, is recommended 
to characterize the quality of the [BCS class II] product.”  For IVIVCs, the guidance only 
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states that an IVIVC may be possible with BCS class II products as opposed to BCS classes 
I and III.  
  
2.1.2.4.2 F2 Analysis 
It is noted in the 1997 Dissolution Testing of Immediate Release Solid Oral Dosage 
Forms guidance single-point dissolution tests and specifications have been employed in 
evaluating scale-up and post-approval changes.  This test may be appropriate for assuring 
consistent product quality and performance for certain minor changes. For more major 
changes however it is recommended that an entire dissolution profile comparison for 
similarity be performed under identical conditions for the product before and after the 
change(s).  Indeed, this guidance, the biowaiver guidance, and the SUPAC guidance all 
state that dissolution profiles may be compared using a similarity factor (F2). 
F2 is a logarithmic reciprocal square root transformation of the sum of squared error.  
This represents a measurement of the similarity in the percent (%) dissolution between 
the two curves.  This metric will be calculated using the mean dissolution profile of the 
two products (test and reference), using the same time points for both the profiles (e.g., 
15, 30, 45, 60 minutes). 
100}] )T-(R(1/n)+log{[150=f 0.5-
2n
1)=(t tt2
   
In this equation, n is the number of time points, Rt is the dissolution value of the reference 
(prechange) batch at time t, and Tt is the dissolution value of the test (postchange) sample 
at time t.  Curves are identical if F2 is 100.  FDA guidances state that generally, F2 values 
greater than 50 (50-100) ensure sameness or equivalence of the two curves and, thus, of 
the performance of the test (postchange) and reference (pre-change) products. 
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2.1.2.5 IVIVC Development  
2.1.2.5.1 Levels of IVIVCs 
There exist three levels of IVIVC: A, B, and C.  A level C IVIVC establishes a 
relationship between an amount dissolved at a specific time and a summary 
pharmacokinetic parameter (e.g. AUC, Cmax, Tmax).A level B IVIVC uses the principles 
of statistical moment analysis. The mean in vitro dissolution time is compared to either 
the mean residence time or to the mean in vivo dissolution time.  A level A IVIVC focuses 
on the “the relationship between in vitro dissolution and the in vivo input rate.”  According to 
regulatory documents, a level A IVIVC is the most informative.  Guidance points out that 
“whatever the method used to establish a level A IVIVC, the model should predict the entire 
in vivo time course from the in vitro data”. 
 
2.1.2.5.2 Existing Methods for IVIVC Development 
There are numerous approaches to developing an IVIVC.  They can be considered as either 
a one-step or a two-step procedure.  The direct differential equation based method described 
by Buchwald is a defining example of a one-step procedure.29  This method, and others like 
it, directly relate the time-profiles of in vitro dissolution rates and in vivo plasma 
concentrations by using a one compartment pharmacokinetic models and a corresponding 
system of differential equations.”  Here, the rate of in vivo input is connected to the rate of in 
vitro dissolution through a time scaling/shifting function that was simultaneously 
parameterized with the rates of clearance using fitting algorithms (e.g. Nelder-Mead).  These 
types of methods can be advantageous because they can recover in vivo plasma profiles from 
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several formulations directly from the in vitro dissolution data in a “single [modeling] step”.  
However, these methods can be subject to overfitting.  This can be avoided by placing 
constraints on the parameters of the pharmacokinetic model parameters and time scaling 
factors that are guided by a priori information. 
Two step methods are typically referred to as deconvolution-convolution based methods.  
In the first stage, the in vivo absorption profile (fraction absorbed vs. time) is deconvoluted 
from the plasma concentration profile. Systematic methods for the deconvolution of the in 
vivo absorption profile have been notably described by Wagner & Nelson, and Loo & 
Riegelman.30,31  Other methods, based on noncompartmental analysis, exist for deconvoluting 
of the in vivo absorption profile exist (e.g. Wagner32; Wang & Nedelman33; Gibaldi & 
Perrier34) however they often require many assumptions to handle the underlying 
pharmacokinetic behavior.  Nevertheless, once the in vivo absorption profile has been 
deconvoluted, the second stage is focused on regressing the in vivo absorption profile to the 
in vitro dissolution profile.  This is typically accomplished by any host of regression models 
wherein the in vitro dissolution profile is the independent variable and the in vivo input profile 
is the dependent variable.  The model most frequently desired to achieve a satisfactory 
recovery of the plasma concentration profile is a linear model.  However, sometimes nonlinear 
models such as the Weibull or Hill models are necessary.  The reliance upon  what is 
essentially a regression model is why some authors prefer to call IVIVCs in vitro-invivo 
regressions (IVIVRs).35  A graphical representation of the two step IVIVC procedure and the 
one step IVIVC procedure can be found in the following Figure 2.1.2.5.2.1. 
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2.1.2.5.3 Regulatory Perspectives on IVIVC Development 
While there are several guidance documents and sections in the CFR that make reference 
to the utility of IVIVCs, few specifically address the area of IVIVC development 
methodologies. The FDA guidance entitled Dissolution Testing of Immediate Release Solid 
Oral Dosage Forms is one such guidance that briefly discusses this area.  As its title implies, 
IVIVC development is referred to in only in the larger context of dissolution test development. 
With respect to IVIVCs, this guidance focuses on how the presence or absence of clinical 
differences should be used to develop the dissolution test.  It described how at least three 
batches that differ in the in vivo as well as the in vitro performance should be used to develop 
an IVIVC.  The guidance notes how “If the batches show differences in in vivo performance, 
then in vitro test conditions can be modified to correspond with the in vivo data to achieve an 
in vitro-in vivo correlation [and likewise modified for equivalence if no in vivo difference is 
found].”  This document does not detail how to evaluate an IVIVC for predictability. 
The guidance does state that, very often, the in vitro dissolution test is found to be more 
sensitive and discriminating than the in vivo test.  It goes on to note that this is not entirely 
undesired.  This is because, from a quality assurance point of view, a more discriminative 
dissolution method could indicate possible changes in the quality of the product before in vivo 
performance is affected.  However, this scenario is primed to raise inappropriate cause for 
concern when the link between the in vitro quality measurement and clinical significance is 
poorly defined. 
The guidance document which does specifically address IVIVC development and 
evaluation is entitled Extended Release Oral Dosage Forms: Development, Evaluation, and 
Application of In vitro/In vivo Correlations (henceforth referred to at the IVIVC guidance).  
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While no guidance document is rigidly prescriptive, this one is geared towards extended 
release products.  Therefore, its recommendations must be carefully interpreted when 
referenced in the context of immediate release products. Nevertheless, the document is the 
most instructive piece of regulatory literature available on the topic of IVIVCs.  The guidance 
divides its discussion between general discussions on “developing the correlation” and 
IVIVC-level specific recommendations.  The first general comments state how, despite the 
existence of commonly used approaches, the strategy used to develop an IVIVC is largely the 
prerogative of the sponsor.  This is stated with the understanding that any IVIVC must be 
reviewed before it can considered fit for sponsor-proposed purposes that are regulatorily 
approved.  The following points summarize the key general recommendations of the 
guidance: 
 The review of > 3 formulations with different release rates is considered optimal  
 In vivo comparison is to be made using a single crossover study 
 If one or more of the formulations (highest or lowest release rate formulations) 
does not show the same relationship between in vitro dissolution and in vivo 
performance compared with the other formulations, the correlation may still be 
used within the range of release rates encompassed by the remaining formulations 
 Once a discriminating system is developed, dissolution test conditions should be 
consistent across formulations during IVIVC development 
 With respect to the discussion of level A IVIVCs, the guidance specifically recommended 
that the release rates for each formulation studied should differ “adequately” (e.g. by 10%).  
Moreover, this difference should result in comparable in vivo profile differences (e.g. a 10% 
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difference in the pharmacokinetic parameters of interest (𝐶௠௔௫ or 𝐴𝑈𝐶) between each 
formulation).  
Methodology for the evaluation of IVIVC predictability is an active area of investigation 
and a variety of methods are possible and potentially acceptable.36 The agency’s stated IVIVC 
evaluation approaches was developed according to the objective of a level A IVIVC, i.e. to 
establish a predictive mathematical model describing the relationship between an in vitro 
property and a relevant in vivo response.  As such, the proposed evaluation approaches focus 
on the estimation of predictive performance or, conversely, prediction error.  The guidance 
notes that the evaluation of prediction error should be guided by intended application of an 
IVIVC and the therapeutic index of the drug. 
Two distinct aspects of predictability are discussed by the IVIVC guidance: internal and 
external predictability.  Evaluation of internal predictability is based on the initial data used to 
define the IVIVC model. Evaluation of external predictability is based on additional test data 
sets.  Both aspects are not recommended in all instances.  However, in the case of narrow 
therapeutic index drugs such as carbamazepine, the external predictability of the correlation 
should be evaluated along with internal predictability.  According to the guidance, internal 
predictability is established when the average absolute percent prediction error (% PE) of 10% 
or less for 𝐶௠௔௫ and 𝐴𝑈𝐶. In addition, the % PE for each formulation should not exceed 15%.  
Likewise, the external predictability is established when the average absolute percent 
prediction error (% PE) of 10% or less for 𝐶௠௔௫ and AUC establishes the predictability of the 
IVIVC.  Non-compartmental reference methods for determining 𝐶௠௔௫ and 𝐴𝑈𝐶 are 
identified in guidance documents and detailed by Shargel et al. The methods include the 
trapezoidal approach for 𝐴𝑈𝐶 calculation, analytical integration of spline interpolations for 
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the plasma concentration profile, and the absorption-elimination rate derived max 
concentration.37   
 
2.1.3 Emerging Trends and Alternatives in the Assessment of in vivo 
Bioequivalence 
 
 Equivalence testing is used to provide statistical statements about parameter estimates 
by relating them to intervals of effect sizes considered practically important rather than 
just to an effect size of zero.  The tests are specific examples of applied inferential 
statistics.  As such, there are a host of different inferential techniques that can be used to 
accomplish tests of equivalence.  The options can largely be classified as either Bayesian 
or classical (i.e. frequentist) techniques.  A frequentist framework considers that, for a 
given model parameter θ, there exists a fixed value, and the data represents a random 
sample from a larger population. They are based on the expected results of hypothetically 
repeated samples, generated by the same sampling process.  Bayesian inference considers 
observed data as fixed and model parameters random.  Bayesian inference is described 
probabilistically through the use of probability distributions for model parameters. Simply 
stated, a Bayesian approach allows for a researcher to make statements such as: “the 
probability that a parameter θ lies in the range  0.8-1.2 is 95%.”  By contrast, the equivalent 
frequentist statement is: “if the same experiment is repeated many times and intervals are 
computed for each experiment, then 95% of those intervals will contain the true value of 
the parameter.”   
 Alternatives to the classical TOST procedure for assessing bioequivalence includes the 
Anderson and Hauck test. 38  This method uses a hypothesis test statistic 𝑇஺ு to directly 
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test 𝐻଴ rather than testing 𝐻଴ଵ and 𝐻଴ଶ independently.  Ennis and Ennis proposed an 
expansion of the Anderson and Hauck test that controlled type I error.39  In their work, 
they recommended adjusting the non-centrality parameter using a positive constant c to 
ensure that the Type I error remains at or below a nominal level.  Additionally, there are 
nonparametric alternatives to the classical parameters procedures discussed thus far.  They 
can be considered in a unified manner by treating them as variations of a rank 
transformation procedure.  Of nonparametric methods, the Wilcoxon rank-sum test 
(WRS; otherwise known as the Wilcoxon-Mann-Whitney test) is arguably the most 
appropriate method due to a 2x2 crossover trial being composed of a pair of 
sequences.40,41  Several examples exist in the literature where this method was used 
during bioequivalence assessment.42-47  A common critique of non-parametric 
methods is that they are considered to be less efficient than their parametric 
counterparts. For example, the rank correlation test has an efficiency rating 0.91, see 
Table 5.6 from Triola.   That is to say, for all other things being equal, the 
nonparametric rank correlation test requires 100 sample observations to achieve the 
same results as 91 sample observations analyzed through parametric linear correlation.  
This assumes the requirements for the parametric method are satisfied.  When 
extrapolated to a clinical trial, this difference could be significant.  However, 
satisfying the assumptions of a specific distribution, such as normality, are not 
required for the use of nonparametric methods as they are with parametric methods. 
 The assessment of bioequivalence can be performed using several Bayesian 
approaches.  In the literature, procedures have been constructed by attempting to 
answer one of two questions: Does the evidence offered by the data support a model 
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representing bioequivalence or biononequivalence? What percent of the posterior 
distribution for the treatment effect (i.e. AUC mean) in a random effects model of 2x2 
crossover lies outside of a relevant interval? The first question has been notably 
addressed by Ghosh and Khattree, the second by Fluehler et al.48,49  Ghosh and Khattree 
described how hypothesis testing can be accomplished by calculating the Bayes’ factor 
between two competing hypotheses.  Their method is based on principles established 
by Harrold Jefferys and Alan Turning for the Bayesian comparison of two models.50,51  
The approach is especially useful when using uninformative prior distributions on 
model parameters. 
 The approach by Fluehler, et al. focuses on integrating a specific region of the 
posterior probability distribution for the treatment response, i.e. the treatment-wise 
AUC responses.  It is essentially a Bayesian interval hypothesis test.  As such the results 
can be easily interpreted in probabilistic terms and distributional assumptions can be 
customized.  Bayesian interval hypothesis testing estimates the probability of a model 
parameter (𝜃) satisfying a given inequality, e.g. 𝑃(𝐻଴) = 𝑃(−𝛿 ≤ 𝜃 ≤ 𝛿) =  𝑃( 𝜃 ∈
[−𝛿, 𝛿]).  Evaluation is accomplished by simulating, to convergence, a posterior 
distribution of model parameters and testing the rate at which 𝜃 lies in the test interval: 
𝑃෠(𝐻଴) =
ଵ
்
∑ 1{ఏ∈[ିఋ,ఋ]}்ଵ  where 1{௙} is an indicator function returning 1 when  f is true 
and 0 when false. 
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2.2 Model Drug: Carbamazepine  
2.2.1 Background 
 
Figure 2.2.1.1. The chemical structure of carbamazepine 
The model drug in this study is carbamazepine.  Carbamazepine was discovered by 
chemist Walter Schindler in Switzerland (1953). It was first marketed as a drug to treat 
trigeminal neuralgia in 1962 and has been approved in the United States since 1974 under 
the trade name Tegretol® (Ciba-Geigy, today owned by Novartis International AG).52-54  
According to archived ANDA approval reports the first-time generic for Tegretol was 
approved in August of 1986.  The application was sponsored by Inwood Laborites Inc, Ltd.  
Oral preparations consist of various solid dosage forms, including immediate release 
formulations, controlled-release formulations, and an oral suspension. The marketed 
formulations include tablets of 100, 200, or 400 mg, chewable tablets of 100 or 200 mg, 
controlled-release tablets of 100, 200, or 400 mg, and a suspension of 100 mg/5 mL. tablet 
preparations with extended release profiles have been developed to reduce peak-related 
toxic effects and to decrease variations in plasma carbamazepine concentrations during the 
dosage interval.55  In addition to the commercially available oral preparations, an 
intravenous preparation has recently (October 2016) gained approval in the US under the 
trade name Carnexiv™ (Lundbeck A/S, Copenhagen, Denmark).  Intravenous 
formulations prior to this point were developed and used for research purposes only. 
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Carbamazepine is an iminostilbene and a structural conjugate of the tricyclic 
antidepressant drug imipramine (Figure 2.2.1.1). Its labeled indications include specific 
forms of epilepsy and trigeminal neuralgia.  It has been shown to be effective in the 
treatment of simple partial, complex partial, and generalized tonic-clonic seizures, but it is 
ineffective against generalized absence seizures.56-59  Carbamazepine and the 
anticonvulsant drug phenytoin have been shown to be effective in treatment of partial 
seizures and tonic-clonic seizures when they are used alone or as initial therapy, and both 
carbamazepine and phenytoin are drugs of first choice in the treatment of such seizure 
disorders.60-61 However, carbamazepine may be more effective in the treatment of complex 
partial seizures when complete seizure control is used as an end point.62 Carbamazepine is 
an effective anticonvulsant drug in experimental animals, and it has an anticonvulsant 
profile that is similar to that of phenytoin.63-66 It is effective against maximal electroshock 
seizures at nontoxic doses but is not active against subcutaneous metrazol-induced 
seizures. Carbamazepine may also be effective in the short-term and long-term treatment 
of manic-depressive illness, and it is the drug of choice for treatment of trigeminal 
neuralgia.67,68 It is administered to adults in doses of 10 to 20 mg/kg/day to achieve total 
plasma concentrations of 6.5 + 3 µg/mL.69,70 The lower range of plasma concentrations are 
adequate to control seizures in patients with primary or secondarily generalized tonic-
clonic seizures alone, but the higher plasma concentrations are often required to treat 
seizures in patients with partial seizures with or without tonic-clonic seizures.71 
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2.2.2 Mechanism of Action  
The mechanism of action for carbamazepine is unknown according to the package insert 
for Tegretol®.  However, several pharmacologic mechanisms of action for carbamazepine 
have been independently agreed upon in the literature.  They can be generally classified under 
two categories, including i)  activity on neuronal voltage gated sodium ion channels and ii) 
synaptic activity on specific receptors and neurotransmitters, most notably those related to 
the N-methyl-D-aspartate (NMDA) system.72  The former mechanism of action is 
commonly held as the primary mechanism responsible for carbamazepine’s antiepileptic 
properties.  This viewpoint is a result of the established relationship between voltage gated 
sodium ion channels, the propagation of action potentials, and the pathophysiology of 
electrical signals in epileptic disorders.73 
  Early efforts aimed at explaining a basic physiologic description of carbamazepine’s 
antiepileptic mechanism of action are found in the reports by Krupp (1969) and subsequently 
Honda and Allen (1973).74,75  Using electrical stimulation, Krupp reported that 
carbamazepine caused an reduction in amplitude and an increase in latency and duration of 
signals in the peroneal and sciatic nerves of rabbits.  Honda and Allen demonstrated that 
carbamazepine reduced the spontaneous firing of action potentials recorded from peripheral 
nerves immersed in isotonic sodium oxalate or phosphate solutions.  Additionally, in 
controlled electromyography studies performed by Heshkowitz, et al. carbamazepine was 
demonstrated to limit sustained high frequency tetany of muscle bundles without affecting 
the conduction of single action potentials.76  This was demonstrated at therapeutic free 
carbamazepine serum concentrations of  >1 µmol/L (4.2 µg/mL).  Ultimately, a more 
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pharmacologic description of carbamazepine’s activity on sodium channels was specified 
through the performance of studies using voltage-clamp techniques.77,78  Notable studies are 
listed in Table 2.2.2.1 along with the cell systems in which they were performed. 
 
Carbamazepine was shown in these studies to slow the rate of recovery from inactivation and 
to shift the voltage dependency of steady-state inactivation to more negative voltages by 
producing a frequency and voltage dependent blockade of the sodium ion channels.  This 
pharmacologic explanation of carbamazepine’s mechanism of action agreed with the initial 
physiologic studies and additionally indicated that the blockade appeared to be selective for 
the inactive form of the closed sodium ion channel. 
 
2.2.3 Pharmacokinetics 
Carbamazepine pharmacokinetics have been qualitatively described in FDA 
documents to demonstrate low within subject variability.24 This section will go over the 
absorption, distribution, metabolism, and excretion (ADME) properties of carbamazepine 
which describe the absorption, distribution, metabolism and elimination characteristics 
of the drug. 
 
Table 2.2.2.1  Carbamazepine Method of Action: Voltage-Clamp 
Studies 
 
Cell System Reference 
peripheral nerve and muscle cells 79, 80 
neuroblastoma cells  in culture 81, 82 
human NT2-N cells in culture 83 
acutely dissociated hippocampal neurons 83, 84, 85 
rat brain type IIA sodium channels stable expressed in CHO cells 86 
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2.2.3.1 Absorption  
Oral absorption characteristics are defined by the rate and extent of absorption.  The extent 
of absorption is typically described in terms of bioavailability, F.  The overall extent of oral 
bioavailability Foral of a drug can be expressed by the following equation 
Eq. 2.2.3.1 𝐹௢௥௔௟  =  𝑓௔ ∙ 𝐹௚ ∙ 𝐹ு  
where the fraction of drug absorbed (fa) is the fraction of the dose entering the cellular space 
of the enterocytes, Fg is the fraction of the drug entering the enterocytes that escapes first-
pass gut wall metabolism (equivalent to 1 - EG, the intestinal extraction ratio) and FH is the 
fraction of drug entering (or by-passing) the liver that escapes first-pass hepatic metabolism 
and biliary secretion (equivalent to 1 - EH, the hepatic extraction ratio). 
𝐹௢௥௔௟ has several subcategories but the most informative is the absolute bioavailability.  
This type of oral bioavailability is calculated by dosing a drug by both an intravenous and 
oral route.  The area under the plasma concentration profile (AUC; area under the curve) is 
then calculated for both routes of administration and the dose normalized oral-to-intravenous 
ratio is defined as the absolute bioavailability.87     
Marino et al. used stable labeled carbamazepine in an intravenous formulation and 
commercially available tablets to calculate 𝐹.  Its estimated value was 78% with a reported 
coefficient of variation equal to 30.8%.  This range was similar to the range of 75% to 85% 
estimated through the recovery of radio labeled carbamazepine in urine and feces after 
single-dose administration reported by Faigle and Feldmann.88  Data from different studies 
suggest that the oral bioavailability of carbamazepine is similar whether given as 
conventional tablets, solutions, suspensions, syrups, or newly developed chewable or 
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sustained-release formulations.89-96  Notably, Levy et al. did demonstrate a slight food effect 
was present in the case of carbamazepine wherein the bioavailability was increased when 
taken with food (approximately 20% relative increase in 𝐹 on average which broadly varied 
and was not statistically significant).97   This effect is generally believed to be the result of an 
increase in the solubilization of the drug by the presence of food and the physiologic response 
therein.   
Interestingly, Levy et al. also examined the relative bioavailability of carbamazepine.  
Here, carbamazepine tablets and bulk powder were supplied by the Ciba-Geigy Corporation. 
Since the drug is poorly soluble in water, a propylene glycol solution at a concentration of 
20 mg/ml was prepared for oral administration. Both formulations were given to six normal 
drug-free volunteers (3 male, 3 female) in good health. Their mean age was 25.8 ± 3.8 yr and 
mean weight was 69.3 ± 18.8 kg. All were Caucasian, and none had any significant medical 
history. Physical examinations and clinical laboratory studies conducted prior to the study 
and every 2 weeks during the study revealed no significant medical findings. The subjects 
fasted overnight, took the drug with 100 ml of water, and fasted for 3 hours. Sixteen blood 
samples were collected over a 72 hour period at 0,0.5, 1, 1.5, 2, 3,4,5,6,7, 8, 10, 12,24,48, 
and 72 hours (see Figure 2.2.3.1). The relative bioavailability was calculated using the 
following equation: 
𝐵𝑖𝑜𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = (஺௎஼)೟ೌ್೗೐೟×௞೐,೟ೌ್೗೐೟(஺௎஼)ೞ೚೗ೠ೟೔೚೙×௞೐,ೞ೚೗ೠ೟೔೚೙ × 100 . 
The relative bioavailability of the tablet compared to the solution was 79 % (p < 0.05) and 
ranged between 56% and 109 %.  This value agrees with the absolute bioavailability of 
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carbamazepine from intravenous dosing studies of Marino et al.  Therefore, it is reasonable 
to assume that the contribution of metabolism from the gut is minimal. 
 
 
 
 
 
 
 
 
 
The fraction absorbed at a given time in Equation 2.2.3.1 can be determined using the 
rate of absorption (ka).  For a one compartment model, the rate value is typically calculated 
using the method of residuals or using the Wagner-Nelson method.  Shargel, et al. describe 
these methods in detail.  The method of residuals separates the initial exponential phase of a 
biexponential plot of plasma concentration against time by extrapolation of the terminal 
elimination rate constant.37  The Wagner-Nelson method estimates the loss of drug from the 
gastrointestinal tract over time, whose slope is inversely proportional to ka.  Its methodology 
is based on calculating partial 𝐴𝑈𝐶𝑠. 
Figure 2.2.3.1 Relative Bioavailability Study by Levy et al. 
Plot of average serum carbamazepine concentration vs time following the administration of 6 
mg/kg propylene glycol solution (○) and Tegretol Tablet (●). Adapted from Levy (1997) 97 
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Carbamazepine, like many small molecules, has been demonstrated to be orally absorbed 
by passive diffusion.98,99  This mode of absorption is characterized by the permeability of a 
molecule though the apical and basolateral cell membranes of the intestinal epithelium.  
Permeability can be estimated by a variety of means.100  The permeability of carbamazepine 
has been estimated in Caco-II permeability assays to be 22.8 × 10ି଺cm/s. 101,102  
Additionally, studies performed using the Ussing chamber technique in rodents have 
reported the apparent permeability of carbamazepine to be 15.2 + 5 × 10-6 cm/s.  Such in 
vitro permeability methods however often require calibration to effective permeability (𝑃௘௙௙) 
of humans in vivo.  This value is derived from gut perfusion experiments such the Loc-i-Gut 
technique.  Lennernäs et al. performed such a study where ‘high permeability’ characteristics 
(i.e. 2-4 × 10-4 cm/s as defined by Amidon at al. and the FDA) were verified  with a Peff,CBZ 
≈ 4*10-4 cm/s. 103  This value serves a primary drug-dependent parameter for the 
physiologically based prediction of oral drug absorption described by Jamei et al.104 
Olling et al. used the MoR to calculate ka, reporting the absorption half-lives of four 
different carbamazepine products including the reference product, Tegretol®, from a relative 
bioavailability study.105  A similar study including Tegretol® was perfomed by Meyer et al. 
in 1992.  The details of these studies will be discussed in greater detail later.  However, it is 
interesting to note that the absorption rates for the common drug product reported in the 
studies were in good agreement: 0.23 vs 0.24 hr-1, respectively.  This consistency is observed 
despite different subjects being used in the two studies and a seven year difference between 
when the trials were performed. 
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2.2.3.2 Metabolism 
Carbamazepine has been reported to undergo >97% hepatic metabolism via three 
pathways: epoxidation and hydroxylation by CYP3A4, CYP3A5, and CYP2C8 and 
glucuronidation by UGT2B7.106-110  Carbamazepine also strongly stimulates the 
transcriptional upregulation of genes involved in its own metabolism through RNA 
analysis.111,112  The only form of the drug that has been demonstrated to be therapeutically 
active is its unmetabolized form, with little (< 3%) carbamazepine being excreted unchanged. 
Mechanistic drug-drug interactions via CYP3A4 and CYP2B6 induction are well 
documented and can complicate the use of carbamazepine in polytherapy.113,114   
Cazali et al. performed studies to characterize the in vitro and in vivo inhibitory effect of 
a new anticonvulsant, saquinavir, on the metabolism of carbamazepine.  The performance of 
their study required the performance of control studies on carbamazepine alone.  Human 
liver microsomes (HLMs) and cDNA-expressed CYP enzymes were used for the in vitro 
experiments where nonspecific binding was controlled for during the calculations. 
Pharmacokinetic data from epileptic children and healthy adults were used for the 
carbamazepine and saquinavir in vivo studies, respectively. Carbamazepine 
biotransformation by human liver microsomes (Vmax=10.3 nmol min-1nmol-1 P450, 
apparent Km=362 uM), cDNA expressed CYP3A4 (Vmax= 1.44 nmol min-1nmol-1P450, 
apparent Km= 335.5 uM), and cDNA expressed CYP2C8 (Vmax=0.669 nmol min-1nmol-
1P450, apparent Km=757uM) was reported by the authors.  The findings from this study 
were supported by the findings from similar studies that reported the intrinsic clearance 
(𝐶𝑙௜௡௧ = 𝑉௠௔௫/𝐾௠) of carbamazepine in both HLMs and other cDNA-expressed CYP 
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enzyme systems including CYP3A5 (Vmax=1.17 nmol min-1nmol-1P450, apparent 
Km=119uM).115-117   
Staines et al. in 2004 reported the results of studies aimed at identifying the uridine 
diphosphate glucuronosyltransferase (UGT) isoform responsible for the N-glucuronidation 
of carbamazepine.  They developed a sensitive liquid chromatography/mass spectrometry 
assay to quantify carbamazepine glucuronidation.  There, the researchers reported that 
carbamazepine is specifically glucuronidated by human UGT2B7.  The kinetics of 
carbamazepine glucuronidation in human liver, kidney, and intestine microsomes were 
reported in their study and shown to be consistent with those of recombinant UGT2B7, which 
displayed a Km value of 214 uM and Vmax value of 0.79 pmol/mg/min.  This was the first 
example of primary amine glucuronidation by UGT2B7. 
Oscarson et al. studied the global induction response of drug-metabolizing enzymes, 
drug transporters, and nuclear receptors using liver sampled from epileptic patients treated 
with carbamazepine and control subjects.  They confirmed the induction of several genes 
previously shown to be inducible in vitro, including multiple cytochrome P450 (CYP) genes 
in the CYP1A, CYP2A, CYP2B, CYP2C, and CYP3A subfamilies, as well as glutathione 
S-transferase A1, UGT 1As, the drug transporter ABCC2, and the nuclear receptors CAR 
(constitutive androstane receptor) and PXR (pregnane X receptor).  Additionally, the 
research reported the relative increase in the expression of the CYP isoforms for treated 
patients.  These values were then used to inform induction factor calculations (i.e. max 
induction value; Indmax).  Almond et al. specifically reported the CYP3A4 Indmax and IndC50 
for carbamazepine using RNA quantification in hepatocytes across serial carbamazepine 
concentrations (21.9 fold and 58.7uM, respectively).  The autoinduction characteristics of 
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CYP2C8 and CYP3A4 deconvoluted by application of the mechanistic framework for the 
prediction of drug-drug interactions laid were out by Almond et al.118  The approaches 
predicted the extent and time-course of enzyme induction in vivo based on in vitro 
experimentation using serial dosing, probe substrates, and  knowledge of the percent 
contributed toward total clearance by each enzymatic isoform.119,120  
 
2.2.3.3 Distribution 
Carbamazepine is a neutral and lipophilic compound that easily crosses the blood–
brain barrier and other biologic membranes of the body and rapidly distributes to various 
organs and tissues.  A study by Takayasu et al. simultaneously assayed carbamazepine and 
its metabolites by gas chromatography-mass spectrometry (GC-MS) in body fluids and 
organ tissues taken from victims in five autopsy cases.121  The concentrations of 
carbamazepine were generally much higher in organ tissues than in blood and urine, and 
were higher in the liver than in the lung in three cases.  Practically speaking, however, the 
concentration of interest for clinical purposes is the concentration in the plasma.  The 
volume of distribution (Vd) represents a volume that must be considered in estimating the 
amount of drug in the body from the concentration of drug found in the sampling 
compartment i.e. the plasma.  A reliable means by which this value can be calculated is 
through serial plasma collections following i.v. dosing.  This was performed by Marino et 
al.122  The researchers developed an intravenous, stable-labeled (SL) formulation in order 
to characterize carbamazepine pharmacokinetics in patients. Ninety-two patients received 
a 100 mg infusion of SL-carbamazepine as part of their morning dose. Blood samples were 
collected up to 96 hours after drug administration. Plasma drug concentrations were 
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measured with LC-MS and concentration-time data were analyzed.  The weight 
normalized volume of distribution was 1.11 L/kg with a standard deviation of 0.26.  Given 
the study design, this value represented a Vd at steady state and was observed to be 
consistent across the subpopulations of the study.  The value reported is in agreement with 
those reported by other researchers. 123-126  The combined interpretation of these works is 
that the Vd of carbamazepine can vary from 0.8 to 2 L/kg in adults and older children.   
The value of Vd can be shaped in large part by the binding of drug to plasma proteins.  
The two most common plasma binding proteins are human serum albumin (HSA) and α1 
acid-glycoprotein (AGP).  The acidic nature of AGP means that most of the drugs that bind 
to it are basic ones with pK values of 8 or higher, which implies that such drugs are 
positively charged at physiologic pH.  Indeed is it clear from binding studies, which have 
included carbamazepine as a model drug, that HSA accounts mainly for the binding of 
acidic and neutral drugs (i.e. carbamazepine) whereas AGP associates more readily with 
basic drugs.127-135  Indeed the studies that have been performed in vitro using equilibrium 
dialysis methods have shown that the unbound carbamazepine fraction for AGP is 25%, a 
value that agrees with the in vivo free fraction reported by Marino et al. 
  
2.2.3.4 Elimination 
Carbamazepine is eliminated by biotransformation followed by urinary and biliary 
excretion of the parent drug and the formed metabolites with less than 5% of the drug being 
excreted unchanged.136 After administration of a single oral dose of 14C-labeled 
carbamazepine, 72% of the radioactivity was excreted in the urine, and the remaining 28% 
was recovered in feces.137 
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2.2.4 Carbamazepine Historical Issues with Bioequivalence  
All available generic carbamazepine products are designated as AB as defined in a 
publication entitled Approved Drug Products With Therapeutic Equivalence Evaluations 
(commonly known as the Orange Book).  It contains therapeutic equivalence evaluations for 
FDA approved multisource prescription drug products.  Drug products are considered to be 
therapeutic equivalents only if they are pharmaceutical equivalents for which bioequivalence 
has been demonstrated, and they can be expected to have the same clinical effect and safety 
profile when administered to patients under the conditions specified in the labeling.  Drug 
products are considered pharmaceutical equivalents if they contain the same active 
ingredients, are of the same dosage form and route of administration, and are formulated to 
contain the same amount of active ingredient and to meet the same or compendial or other 
applicable standards (i.e., strength, quality, purity, and identity).  Drug products that FDA 
considers to be therapeutically equivalent to other pharmaceutically equivalent products 
include those for which: 
(1) there are no known or suspected bioequivalence problems; these are designated AA 
(2) actual or potential bioequivalence problems have been resolved with adequate in vivo 
and/or in vitro evidence supporting bioequivalence (designated as ‘AB’). 
Despite the AB status of carbamazepine, the use of generic versus brand-name antiseizure 
medications, such as carbamazepine, have attracted much attention and debate.  This is a 
results of studies such as that performed by Krauss et al.138  Using pharmacokinetic data 
submitted to the FDA, the researchers found that while most generic antiseizure drugs 
provide total drug delivery similar to the reference product, differences in peak 
concentrations were more common.  Additionally, these researchers identified how switches 
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between generic products caused greater changes in plasma drug concentrations than generic 
substitution of the reference product.   
In 1992 Meyer et al. performed studies to assess the in vitro dissolution and in vivo 
bioavailability of brand carbamazepine (Tegretol®; product 1) and three lots from a generic 
manufacturer (Pharmaceutical Basics Inc.; products 2, 3 and 4) which were reported to have 
clinical failures.139  This study is an important source of in vitro-in vivo data for 
carbamazepine. The in vitro tests were performed using the compendial dissolution method 
for carbamazepine: type II dissolution apparatus, 75 rpm paddle speed and 900 ml of water 
containing 1% sodium laurel sulfate at 37○C.  The in vivo study was performed in twenty-
four, nonsmoking males. Their ages ranged from 21 to 35 years and their weights ranged 
from 61 to 93 kg.  All subjects had normal clinical chemistry laboratory values, including 
reticulocyte counts and serum iron.  The subjects did not ingest any drugs for twenty-one 
days and avoided alcohol for forty-eight hours prior to any carbamazepine dose.  The subjects 
were randomly divided into four groups and each group received a single 200mg dose of 
each of the four medications in a different sequence.  There was a twenty-one day washout 
period between doses.  After an overnight fast, each of the subjects receive one of the 
products with 180ml of room temperature water.  No food was allowed until a standard meal 
was served 4 hours after dosing.  Ten milliliter blood samples were obtained just before doing 
and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 25, 49, 73, 97, 121, and 169 hours after dosing.  Acceptable 
accuracy and precision was indicated by the quantitative analysis of triplicate fortified plasma 
quality-control samples containing 0.43, 1.6, and 3.1 ug/ml of carbamazepine along with 
each set of unknown plasma samples.  The between day and within day coefficient of 
variation for these assays was < 10% and < 4% respectively.   
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The wide range of in vitro results are shown in Figure 2.2.4.1. Using the USP 
specficication for carbamazpine (i.e. bewteen 45% and 75% dissolved at 15 minuites and 
that not less than 75% of the drug be dissolved within 60min) it was shown that: i) products 
2 and 4 fail the dissolution requirements; ii) product 1 meets the dissolution requirements; 
iii) product 3 meets the dissolution requirements despite being faster than product 1. 
The respective range of in vivo results are shown in Figure 2.2.4.2. An analysis of the 
elimination rates between the study periods demonstrated no statistical difference.  However, 
there were some statistical differences among the clearance rates between the products.  
Additionally, there were some statistical differences between some of the summary 
pharmacokinetic metrics across the different products.  These differences are reported in 
Table (2.2.4.1.).  In the discussion of the study the authors stated that the source(s) of 
Figure 2.2.4.1. Dissolution profiles of four 200mg carbamazepine tablet 
products. (○) Product 1; (●) Product 2; (■) Product 3; (▲) Product 4 [Meyer et 
al. (1992) 139] 
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difference in performance was unknown.  However, they referenced how moisture storage 
conditions have been demonstrated to result in dissolution and bioavailability changes (likely 
due to dihydrate conversion) and this may been a contributing factor in their work.140  
Additionally, the authors stated that the manufacturer had suggested the cause to be related 
to a change in the source of the raw carbamazepine and/or changes in particle size of the 
active ingredient.   
 
 
 
 
 
 
 
 
 
 
 
Table. 2.2.4.1. Summary of Meyer et al. 1992 results 
Parameter Product 1 Product 2 Product 3 Product 4 
Cmax  (ug/ml) 1.89     (20)* 1.15     (62)** 2.69     (18)*** 1.40     (39)** 
Tmax   (hr) 15.9     (51)† 13.6     (74) †,†† 8.3       (72) ††  19.6     (78) † 
AUC (ug ● hr/ml) 134.8   (15)※ 80.9     (48)※※ 154.2   (18) ※※※ 104.5   (30) ※※※※ 
kel      (hr -1) 0.0183 (15)‡,‡‡ 0.0173 (19) ‡‡ 0.0191 (16) ‡ 0.0177 (16) ‡‡ 
Number in parenthesis is the coefficient of variation; % 
Differences in the number of row-wise symbols denotes a statistically significant difference (p > 0.05) 
Figure 2.2.4.2. Plasma profiles of four 200mg carbamazepine tablet 
products. (○) Product 1; (●) Product 2; (■) Product 3; (▲) Product 4 
[Meyer et al. (1992) 139]  
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Another study that investigated biononequivalence issues specifically related to 
differences in the side effect profile of immediate release carbamazepine products was 
performed by Olling et al.  This work was performed in response to several publications over 
the years leading up to the work describing the occurrence of side effects after changing from 
one carbamazepine product to another.141-145  In different countries experiments were started 
to find some explanations for these reports. 146-148  The studies seemed to indicate that 
between-product differences in the rate of absorption might be responsible for the occurrence 
of switch-related side effects.   
The Olling el at. study, like the previous Meyer et al. work (1992), represents an important 
source of in vitro-in vivo data for carbamazepine.  In this study, the subject sample was again 
taken from a normal healthy volunteer population (i.e. the results of routine laboratory tests 
on blood and urine of the volunteers were within normal ranges).  Eighteen healthy, non-
smoking volunteers, ranging in age from 20 to 38 years, weighing 49 to 88 kg were enrolled.  
Included in the study were three 200 mg carbamazepine products with large differences in 
compendially measured dissolution rates (Figure 2.2.4.3.), as well as the innovator product 
Pharmachemie, Lot no. 92 A 21 NF (product A), 200 mg Centrafarm, Lot no. 92 E 18A 
(product B), Pharbita, Lot no. 920401 (product C) and Tegretol® Ciba Geigy 200 mg, Lot 
no. 92 F 22 (product D).  All of the products were licensed and were purchased from a 
hospital pharmacy. 
The study protocol used volunteers that were currently not receiving medication. The 
volunteers were to abstain from alcohol use 24 hour prior to the first study day until the end 
of the study. The administration of the drugs was accomplished in a four-way randomized 
cross-over design with 2 week washout periods. Before administration the volunteers fasted 
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overnight. After administration of the products the volunteers were instructed to sit in an 
upright position for the first 4 hours. Standardized meals were given 4 and 10 hours postdose. 
Blood samples were taken just before dosing and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 
24, 28, 32 48, 56, 72, 80 and 96 hours postdose and analyzed using a suitable HPLC method 
(i.e. linear over the range of 0.05–6 ug/mL plasma and the variability less than 10%).   
The qualitative differences in the in vitro dissolution rates of the four products investigated 
were in the same order as the in vivo absorption rates after administration of the products to 
healthy volunteers. 
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All of the summary pharmacokinetic metrics obtained from product A are statistically 
significantly different (p < 0.05) from the reference product D. Product B did not show any 
significant difference from product D. For product C all pharmacokinetic characteristics 
Figure 2.2.4.3. Dissolution (top) and plasma (bottom) profiles of four 
carbamazepine 200 mg products in 1% lauryl sulphate (Paddle method): 
product A (); product B (); product C (▲); product D (). Adapted from: 
Olling (1992) 105 
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except the AUC values are significantly different (p < 0.05) from product D.  The summary 
pharmacokinetic metrics are contained in Table 2.2.4.2. 
 
Table. 2.2.4.2. Summary of Olling et al. 1999 results 
Parameter Product A Product B Product C Product D 
Cmax    (ug/ml)          3.2  (31)          5.9  (27)          6.1  (26)          4.5  (18) 
AUC   (ug ● 
hr/ml) 
         246 (25)          294 (29)          292 (24)          295 (20) 
t1/2,abs   (hr)          16   (63)          3.8  (184)          1.9  (263)          13   (62) 
t1/2,el   (hr)          39   (18)          34   (18)          32   (16)          34   (15) 
Number in parenthesis is the coefficient of variation; % 
 
 
The extent of absorption (i.e. 𝐴𝑈𝐶) of products B and C were well within the range of 
acceptance (0.8–1.20) for bioequivalence. With respect to the 𝐶௠௔௫ values, however, none 
of the test products were bioequivalent with Tegretol as the 90% confidence intervals are out 
of the 0.75–1.35 range. When Olling et al. examined the product-wise differences in they 
observed the measured side effects followed the same pattern for the total adverse events as 
for the of the Cmax values. 
Carbamazepine was one of the medications investigated in a 2010 literature review 
performed by Desmarais et al. focusing on the development of clinical deterioration and 
decreased tolerability associated with switching from brand-name to generic psychotropic 
medications. 149  The results of that work specific to carbamazepine are summarized in the 
following Table.   
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Table 2.2.4.3. Literature findings concerning Carbamazepine brand-generic 
switches 
 
 
Finding Ref 
Increased seizures after generic substitution 150,151-154 
Decreased levels after generic substitution 150,152  
Toxicity and increased levels after generic substitution 155,156 
Adrenal decompensation after generic substitution in a patient on hydrocortisone 157 
90% CI of AUC of generic not within 80–120% of original. 158 
Shorter average time to Cmax with generic 159 
More neurological side effects with generic 160 
Shorter mean time to Δ of medication, more central nervous system side effects 
with generic 
161 
Source for references [149] 
 
While these studies were focused on clinical outcomes, a Spanish pharmacoeconomic study 
suggested that if 9% of epilepsy patients treated with original carbamazepine were switched 
to generic carbamazepine, annual per-patient cost would rise 38-fold due to the accidents, 
deaths,  emergency visits, and days off work associated with the anticipated increased 
number of seizures.162   
The AB status of Carbamazepine products requires that the in vitro and/or in vivo 
bioequivalence criteria has been satisfied.  How then could the studies of table 2.2.4.3 be 
reconciled with this status?  Consider how meeting compendial USP dissolution criteria is 
often used to justify the waiver of in vivo studies.  This is done on the basis that the acceptable 
windows for the dissolution profiles are derived for classical in vivo trials for bioequivalence.  
However, the in vitro tests are still limited by the same the shortcomings of in vivo methods 
previously described.  This may be a possible explanation for the cited findings, the 
interpretation of which suggests a disconnect between the Orange Book recommendations 
and best clinical practices.   
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2.2.5 Material Characteristics and Physical Chemistry 
  For decades, carbamazepine has served as a model compound for groups engaged in the 
study of crystal polymorphism.  A portion of the seminal research article published by 
Grzesiak et al. focused on definitively identifying each of the four anhydrous polymorphs of 
carbamazepine.163  In that work they reexamined the reported data for the anhydrous 
polymorphs of cabrmazepine in the literature.164-183.  From that work, it was evident that 
early on the nomenclature of polymorphs was inconsistent, leading to confusion and 
misidentification of forms (see Table 2.2.5.1).  Since then the most common approach to 
classifying the carbamazepine polymorphic forms is as follows: 
 form I – triclinic cell 
 form II – which is trigonal 
 form III – P-monoclinic cell  
 form IV – C-centered monoclinic polymorph (see Figure 2.2.5.1) 
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   Table 2.2.5.1. Nomenclature of the four carbamazepine polymorphsa 
Year Reference Triclinic Trigonal P-Monoclinic C-Monoclinic Method of Confirmation 
1968 164 I ⸺ III ⸺ Melting behavior 
1975 165 C3 C2 C1 ⸺ PXRD, IR 
1981 166,167 ⸺  ⸺ Monoclinic ⸺ Crystal Structure 
1984 168 III II I ⸺ PXRD, DSC 
1984 169 III II I ⸺ PXRD, DSC 
1986 170 I II,IV III ⸺ PXRD, DSC 
1986 171 Α ⸺ β ⸺ PXRD, DSC 
1987 172 I ⸺ III IIb PXRD, DSC 
1987 173 ⸺ α, Trigonal β ⸺ Structure, PXRD, 
DSC, IR 
1991 174 I ⸺ III ⸺ DSC, preparation 
1991 175 Γ α β ⸺ Preparation 
1992 176 I ⸺ III ⸺ IR, melting 
behavior 
1996 177 I ⸺ III ⸺ PXRD 
1997 178 Triclinic ⸺ ⸺ ⸺ PXRD 
2000 179 ⸺ α β ⸺ PXRD, SEM 
2000 180 I ⸺ III ⸺ PXRD, DSC 
2000 181 I ⸺ III IIb PXRD, DSC, IR 
2002 182 ⸺ ⸺ ⸺ IV, C-Monoclinic Structure 
2003 163 I II III IV XRD, DSC, IR 
a Each form was verified by the listed method as well as the method of preparation of each form.
Adapted from Grzesiak et al. (2003) 
b These forms are most similar to C-monoclinic CBZ, however, differences noted in the text exist. 
PXRD – powder X-ray diffraction; IR – infrared spectroscopy; DSC – differential scanning calorimetry; SEM – scanning electron 
microscopy 
 
 
According to Grzesiak et al., the four forms are close in energy, the stability order at room 
temperature is: III > I > IV > II.  Thermochemical data from Upadhyay et al. indicate an 
enantiotropic relationship between polymorphs III and I. As shown in Figure 2.2.5.1., free 
energy curves of carbamazepine polymorphs intersect at 360.5K, below the melting of both 
the forms. This confirms the enantiotropic relationship between them. 
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Form III (P-monoclinic) shows the lowest free energy of all forms at and below room 
temperature. Among the forms, Šehić et al. established that the anhydrous form III is the 
most commonly encountered form.184  The form II (trigonal) is the least stable of all 
anhydrous forms.  Fast transformation of the trigonal form has made it very difficult to 
determine its melting point, and therefore the thermodynamic relationship of this polymorph 
to other anhydrous forms is still unclear.185   
All four polymorphs of carbamazepine share a common hydrogen bonding pattern 
resulting in a dimer with two amide–amide hydrogen bonds according to the Cambridge 
Crystallographic Data Centre.  Observed polymorphism results from the alternative 
possibilities of packing these dimers into a stable crystal structure: forms I and II have similar 
Figure 2.2.5.1. Configurational phase diagram of carbamazepine polymorphs. 
Adapted from Grzesiak et al. (2003) 163 
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packing of dimers, with offset π–π stacking of the aromatic rings as the main interaction 
between neighboring dimers. In forms III and IV aromatic rings form both π–π stacking and 
edge-to-face contacts in an interlocked packing arrangement (see Figure 2.2.5.1).186 
 
 
 
While there is no officially released FDA specification for the reference polymorphic 
form of carbamazepine, a publication by L. Yu et al. provides some regulatory insight.  The 
article was entitled Regulatory considerations of pharmaceutical solid polymorphism in 
Abbreviated New Drug Applications (ANDAs), in it reviewed the impact of polymorphism 
on drug product manufacturability, quality, and performance.  Carbamazepine was a 
particular example in this work.  It was noted that “Approved ANDAs for carbamazepine 
Figure 2.2.5.1. Packing diagrams of carbamazepine polymorphs: (a) form I, (b) 
form II, (c) form III, and (d) form IV (Cambridge Crystallographic Data 
Centre). 
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utilize the corresponding drug substance β-form [form III], presumably due to the unique 
solubility and processability characteristics associated with this form.”  This will be an 
important concept when comparing the performance of different generic carbamazepine in 
later sections. 
The dihydrate of carbamazepine has been studied in numerous publications.187-200 Like 
anhydrous polymorphs, there can exist different configurations of hydrates (i.e. 
stoichiometric or nonstoichiometric201,202). To assess the potential for different hydrate forms 
of carbamazepine dehydrate, McMahon et al. characterized materials by thermal analysis 
(TGA and DSC) and spectroscopic techniques, including 13C solid-state nuclear magnetic 
resonance (13C SSNMR) and variable-temperature Fourier transform (FT) Raman 
spectroscopy.203 The thermodynamic behavior of the dihydrate obtained form III was 
different than the one produced from form I.  However, water was readily lost from 
dihydrates III and I in a similar manner, when maintained isothermally at 25 °C in the TGA. 
Additionally, the powder X-ray diffraction patterns and spectroscopic data were almost 
identical between all of the hydrate formations.  Therefore, the observed differences were 
hypothesized to be the result of trace anhydrous original polymorph existing in the dihydrate 
phase.  This was proposed to act as a seed, regenerating the original polymorph under 
conditions where liberated hydrate water cannot readily escape from around the sample 
during dehydration. Thus, they concluded that there is no evidence supporting the existence 
of two different dihydrate forms.  This supported the findings of Khoo and Harris et al that 
carbamazepine exists as a channel hydrate.204,205 
In addition to understanding the polymorphic forms and hydrate forms of carbamazepine, 
another important feature of a drug is its ionizability and octanol-water partition-coefficient 
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(logP).  It is known from an examination of the chemical structure that carbamazepine does 
not contain any ionizable groups.  It can therefore be considered a neutral compound.  This 
is an important feature as it can inform the evaluation of dissolution methods.  Additionally, 
according to the scientific literature, it is generally agreed that the logP of carbamazepine is 
approximately 2.2 suggesting high lipophilicity and permeability.  Such knowledge supports 
the findings of Lee et al., where it was reported how carbamazepine is poorly soluble and its 
dissolution is independent of pH.206 
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2.3 QbD initiatives – PBPK Modeling and Simulation 
Quality by Design (QbD) is a systemic approach to development that begins with 
predefined objectives and emphasizes product and process understanding and process 
control, based on sound science and quality risk management to meet patient needs using 
clinical information and safety targets in the Quality Target Product Profile (QTPP).207   In a 
September 2017 speech Dr. Scott Gottleib, at the very start of his tenure as FDA 
commissioner,  stated how the FDA will continue taking new steps to modernize how 
sponsors can evaluate clinical information, and how FDA reviews these data as part of the 
regulatory process for efficient assurance of QbD.  He stated how this enhanced review 
process will involve a more widespread use of modeling and simulation, and high 
performance computing clusters cross FDA review programs.  These efforts take aim at one 
of the main challenges of efficient QbD drug development: translating in vitro observations 
to in vivo performance.   
The role of predictive biopharmaceutic methods in QbD has been emphasized in recent 
conferences and workshops sponsored or co-sponsored by the FDA.208,209  Areas of focus 
include the following: 
 the mechanisms of in vitro release 
 physiology in relation to drug absorption, and  
 in silico models that mimic in vivo release characteristics  
Leveraging such knowledge as a tool to facilitate the implementation of QbD is a key 
concern.  The domain of physiologically based pharmacokinetic modeling unifies these 
concepts in a way that greatly facilities clinical trial simulation, allowing for quantitative 
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predictions through the mechanistic integration of prior knowledge. The growing 
commitment to increase the use of PBPK modeling and simulation on the part of industry 
sponsors and regulatory agencies is obvious in a review of the current literature.  Researchers 
from the FDA’s Office of Clinical Pharmacology published an article in 2013 on the utility 
of modeling and simulation in drug development and regulatory review.210  The researchers 
looked at the 33 INDs/NDAs received between 2008 and 2012 containing PBPK modeling 
approaches as part of that work.  Figure 2.3.1 shows the distribution of submitted INDs and 
NDAs containing physiologically based pharmacokinetic modeling and/or simulation over 
that time period.    
 
 
Here the increasing support in PBPK modeling is visible by the  increasing trend in PBPK 
utilization on the part of industry sponsors.  Interestingly, the authors of this data stated that 
the paralleling of this practice by the agency has been de novo (i.e., US FDA initiated).  They 
note that increased use physiologically based pharmacokinetics has been a help to the 
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Figure 2.3.1. The number of PBPK applications contained in IND/NDA 
submissions or developed by US FDA reviewers from 2008 to 2012. (Adapted 
from Huang et al. (2013) 211) 
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regulatory review process by aiding the characterization of pharmacokinetics in a variety of 
complex clinical scenarios that would be unable to test using traditional methods in vivo.  The 
clinical applications covered by the PBPK models in Figure 2.3.1 are broken down by topic 
in Figure 2.3.2. 
  
 
It is observable in this Figure that, at the time of the study, the majority of PBPK applications 
were related to drug-drug interactions.  The authors discussed two emblematic case studies 
where major drug development questions were answered using PBPK modeling.  The first 
case was concerning the combined use of in vitro inhibition data and PBPK modeling and 
simulation to provide for a more focused performance of clinical drug-drug interaction 
studies.211  The second case used a similar extrapolation approach to test unstudied drug 
interaction scenarios.  The work ultimately allowed for labeling which read, “There is no 
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Figure 2.3.2. Areas of applications in the 33 PBPK submissions in IND/NDA 
received by US FDA’s Office of Clinical Pharmacology from 2008 to 2012. (Adapted 
from Huang et al. (2013) 211) 
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clinically relevant effect of moderate CYP3A inhibitors on the pharmacokinetics of [the 
sponsor’s active ingredient].”212  The language was justified using in silico simulations thus 
sparing a lengthy and costly clinical drug-drug interaction trial.  Other questions that can be 
addressed using PBPK modeling and simulations are summarized in Table 2.3.1. 
 
Table 2.3.1  Summary of general regulatory questions addressed using PBPK modeling and 
simulations 
Main enzymatic pathways of drug;  
Interacting drug/ substrate relationships 
Regulatory questions addressed related to PBPK modeling and 
simulations 
N
ew
 M
ol
ec
ul
ar
 E
nt
ity
 (N
M
E)
 is
…
 
a CYP inhibitor in vitro (I/Ki > 0.1) 
The magnitude of DDI with a CYP substrate in vivo? 
a CYP substrate An in vivo DDI study with a CYP inhibitor has been conducted when 
NME was dosed orally. Can PBPK simulation predict the magnitude 
of DDI when NME is given intravenously? 
a CYP substrate and also renally excreted Can PBPK simulations predict the magnitude of DDI in subjects with 
varying degrees of renal impairment (mild, moderate, or severe)? 
a CYP inhibitor in vitro (I/Ki > 0.1) 
metabolized by multiple CYPs in the liver 
Can PBPK simulations predict the magnitude of DDI with a CYP 
substrate in vivo? 
Can PBPK simulations predict the magnitude of DDI with CYP 
inhibitors? 
Can PBPK simulations predict PK in subjects with hepatic 
impairments? 
a substrate of a polymorphic CYP in vitro Can PBPK simulations predict the PK in extensive, intermediate, or 
poor metabolizers of this CYP? 
a CYP substrate and an in vivo DDI study 
using a  specific inhibitor dose has been done 
Can PBPK simulations predict the magnitude of DDI using a 
different inhibitor dose as recommended by the FDA? 
a CYP substrate and an in vivo DDI study  
 has been conducted with a CYP inhibitor 
Can PBPK simulations predict the magnitude of DDI with a CYP 
inducer? 
a TDI of a CYP Its single-dose PK data are available:Can PBPK simulations predict 
dose- and time-dependent PK after multiple dosing?Can PBPK 
simulations predict TDI in vivo? 
metabolized in the liver In vivo data are available in hepatically impaired subjects taking 
lower than recommended doses of NME. Can PBPK simulations 
predict PK of NME in hepatic impairment patients taking 
recommended doses? 
metabolized by multiple CYPs Can PBPK simulation be used to predict fractional metabolism based 
on enzyme kinetic studies in vitro? 
NME’s adult PK data are available Can PBPK simulations help determine the optimal doses for pediatric studies? 
NME and its meta. both inhibitors of a CYP Can PBPK simulation predict the DDI potential of the NME? 
CYP, cytochrome P450; DDI, drug–drug interactions; FDA, US Food and Drug Administration; NME, new molecular entity; PBPK, physiologically 
based pharmacokinetic; PK, pharmacokinetic; TDI, time-dependent inhibitor. (Table adapted from Zhao et al (2011)213) 
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2.4 PBPK Modeling and Simulation – Technical Components 
2.4.1 Fundamental differences between PBPK modeling and classical PK 
modeling 
A spectrum of unique approaches exist for learning the clinical pharmacology of a drug, 
via pharmacokinetic modeling,.  The classical approach to pharmacokinetic model, also 
known as a “top-down” model, is constructed using clinical data with model parameters and 
covariance estimated statistically. Typically there is a central compartment representing 
plasma that can be linked to one or more peripheral compartments via rate constants.  When 
defined in terms of rate constants, the model parameters do not generally have any 
physiological meaning but can be used to provide more interpretable pharmacokinetic 
descriptors such as systemic clearance and volume of distribution.  Clearance in classical 
pharmacokinetic modeling refers to the volume of plasma cleared of drug per unit time via 
metabolic or excretion processes.  The volume of distribution refers to the volume required to 
occupy the total amount of drug in the body at the concentration observed in plasma.  While 
useful for the concise and standardized representation of both the preclinical and clinical 
experimental results, classical methods have limitations.  These approaches do not readily 
incorporate population-level covariate information from either the drug or physiology a 
priori. 214   
Covariates are accounted for in classical population-level pharmacokinetic modeling 
through an observational top down process known as nonlinear mixed effects (NLME) 
modeling.215  An exhaustive explanation of NLME methods is beyond the scope of this 
dissertation, therefore a brief summary of the main methods will be discussed.  The “mixed 
effects” in NLME is so called because in the modeling procedure some parameters are 
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assigned to vary across individuals and are considered random effects while others are 
constant and considered fixed effects.  There are essentially three functional components of a 
NLME model: i) the structural model, ii) the statistical error model, and iii) the covariate 
model.  The structural model describes the typical concentration time course within the 
population.  The statistical model accounts for random variability (residual error) in 
concentration within the population.  The covariate model explains variability predicted by 
subject characteristics (covariates).  Nonlinear mixed effects modeling software (e.g. 
NONMEM, Phoenix NLME) brings dependent/independent data together with models and 
applies an estimation method for parameterization for the structural, covariate, and statistical 
residual models that describe the data.216   
To illustrate an NLME method consider the following single-compartment intravenous-
bolus plasma concentration model:  
𝐶௝ =
𝐷
𝑉ௗ
exp ൤
−𝐶𝑙 ∙ 𝑡௝
𝑉ௗ
൨ 
where 𝐶௝ is the mean plasma concentration at time j from a population, 𝐷 is the dose at t = 0, 
𝑉ௗ is the volume of distribution for the population, and 𝐶𝑙 is the clearance for the population.  
If one was to assume that the 𝐶𝑙 changes randomly between the individuals from the study 
population and Vd was fixed, the NLME modeling would begin by using the following 
equation: 
𝐶௜௝ =
𝐷
𝑉ௗ
exp ቈ
−(𝐶𝑙 + 𝑛௜) ∙ 𝑡௜௝
𝑉ௗ
቉ 
where 𝑛௜ is the deviation of the ith subject’s clearance from the mean Cl for the population.  
Accounting for the residual error of this model is accomplished by addition of the residual 
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model which can be expressed additively, proportionally, exponentially, and through a 
combination thereof in the following ways, respectively: 
𝐶௜௝ =
𝐷
𝑉ௗ
exp ቈ
−(𝐶𝑙 + 𝑛௜) ∙ 𝑡௜௝
𝑉ௗ
቉ + 𝜀௜௝ 
𝐶௜௝ =
𝐷
𝑉ௗ
exp ቈ
−(𝐶𝑙 + 𝑛௜) ∙ 𝑡௜௝
𝑉ௗ
቉ ∙ (1 + 𝜀௜௝) 
𝐶௜௝ =
𝐷
𝑉ௗ
exp ቈ
−(𝐶𝑙 + 𝑛௜) ∙ 𝑡௜௝
𝑉ௗ
቉ ∙ exp (𝜀௜௝) 
𝐶௜௝ =
𝐷
𝑉ௗ
exp ቈ
−(𝐶𝑙 + 𝑛௜) ∙ 𝑡௜௝
𝑉ௗ
቉ ∙ ൫1 + 𝜀ଵ,௜௝൯ + 𝜀ଶ,௜௝ 
A covariate model can be added to this equation to describe various clearance-patient 
relationships (e.g. 𝐶𝑙 = 𝑓(𝑎𝑔𝑒, 𝑤𝑒𝑖𝑔ℎ𝑡, 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 𝑠𝑡𝑎𝑡𝑢𝑠, 𝑒𝑡𝑐.)) in the following way: 
𝐶௜௝ =
𝐷
𝑉ௗ
exp ቈ
−(𝜃ଵ + 𝜃௞,௜𝑥௞,௜ + 𝑛௞,௜) ∙ 𝑡௜௝
𝑉ௗ
቉ + 𝜀௜௝ 
where 𝐶𝑙 is a linear function of kth clinical factor x specific to the ith subject with intercept 𝜃ଵ 
and slope 𝜃௞,௜.  Here, 𝑛௞,௜ now represents the deviation of subject i from the population mean 
of 𝑥௞,௜.   
The approaches for estimating coefficients of covariates and pharmacokinetic models 
have undergone several evolutions since the early NLME modeling efforts.  Most share the 
concept of parameter estimation based on minimizing an objective function value (OFV).  The 
OFV often uses maximum likelihood estimation and is expressed as minus twice the log of 
the likelihood describing how closely the model predictions (given a set of parameter values) 
match the data (maximum likelihood = lowest OFV = best fit).   
 73 
 
In population modeling, calculation of the likelihood comes with an analytical challenge.  
When fitting population data, predicted concentrations for each subject depend on the 
difference between each subject’s parameters (Pi) and the population parameters (Ppop) and 
the difference between each pair of observed (Cobs) and predicted (cˆ) concentrations. 
Therefore, a marginal likelihood needs to be calculated based on both the influence of the 
fixed effect (Ppop) and the random effect (η).  The challenge is that analytical solutions for 
the marginal likelihood do not exist.  Thus, several methods have been developed for 
approximating the marginal likelihood while searching for the maximum likelihood. Initial 
methods were generally identified as first-order (FO) methods.  The first was developed by 
Sheiner and Beal and was based on a “first order” Taylor expansion of the pharmacokinetic 
model under the assumption that all 𝑛௞,௜ = 0.217  Since then, Lindstrom and Bates developed 
a similar method; however, their approximation included the conditional estimates of 𝑛௞,௜ and 
is referred to as the First Order Conditional Estimation (FOCE) method.218  The FOCE 
method is, in general, the most common method used in NLME estimation for population 
pharmacokinetic modeling.  However, with the advent of multi-core computer processors, 
high computational demand methods yielding more stable parameter estimates from sparser 
data, such as the Quasi-Random Parametric Expectation Maximization method, are 
becoming more efficient.219  The advantages of these methods is that they follow a Bayeian 
framework, and, as such, can provide posterior estimates of the covariates and parameters 
with associated variance estimates.  These variance estimates can be used in IVIVC 
simulations as demonstrated by Bondi, Bigora et al.  O’Hara et al.,  Soto et al., and others.220-
222 
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Sound statistical practice suggests the addition of covariates should be based on some 
statistical criteria, such as Akaike Information Criterion (AIC), Bayes Information Criterion 
(BIC), p-values, log likelihood, etc.; significant covariates will lead to a reduction in the inter-
subject variability (ISV)  and residual variability.  The error model should be selected to 
preserve homoscedasticity, which can be assessed based on a plot of the residuals versus the 
predicted plasma concentrations for the case presented.  For more information on NLME and 
how it relates to population pharmacokinetic modeling, see the comprehensive three-part 
tutorial by Mould and Upton.223-225 
A fundamental limitation of NLME modeling for the classical estimation of population 
level covariates and pharmacokinetic parameters is that they can only be derived after the 
study has been performed, and critical parameters such as the elimination rate can only be 
resolved to units of  inverse time.  Thus, the ability to predict the pharmacokinetics of a similar 
drug, or extrapolate the pharmacokinetics to a different physiology a priori is significantly 
restricted. Unlike this “top down” modeling, a physiologically-based pharmacokinetic 
modeling is considered “bottom-up.”   This is because it uses information from i) human 
physiology/pathophysiology, and ii) detailed biological processes and interactions to 
mechanistically describe drug absorption, disposition, and elimination.  While this type of 
pharmacokinetic modeling can be parameterized using the same computational methods as 
with the classical method, the compartments of the physiologically-based structural model are 
now based on different organs and tissues in the body.  These compartments are then 
connected by tissue flow rates that are a function of cardiac output.  While these models can 
still provide classical pharmacokinetic parameters (see previous paragraph), the means by 
which this is achieved is more translatable.  The very units of the parameters provide a clear 
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way by which a dose in healthy volunteers can be extrapolated to one in a clinically relevant 
population, so long as the relevant physiological properties of the target population are 
available.  Developing a pathophysiologic understanding at the level of quantitative systems 
pharmacology is becoming more and more the prelude to the modern drug discovery process.   
The principles used for physiologically based pharmacokinetic modeling are not new.  
The use of differential equations parameterized using known physiological variables to 
represent a quantitative mechanistic framework by which the absorption, distribution, 
metabolism, and excretion (ADME) of drugs may be modeled can be traced back to as early 
as 1937.  At that time, Teorell used multi-compartmental models to integrate biological and 
physiological components for the simulation of pharmacokinetic data.226  What has changed 
since that time is computer technology, an improved understanding of human 
physiology/pathophysiology, and an increased availability of highly representative in vitro 
systems which can act as surrogates for in vivo reactions relevant to ADME through a process 
known as in vitro in vivo extrapolation (IVIVE).  The performance of such in vitro trials are 
typically termed distribution-metabolism pharmacokinetic (DMPK) studies.  Advancements 
in the domain of DMPK studies have grown exponentially since sub-optimal DMPK 
properties were recognized approximately 25 years ago as a major contributor to the failure 
of potential new therapies in early clinical trials.227 Such advancements were paralleled by 
database innovations and evolutions in computational technology.  This provided a greater 
ability to integrate these studies within physiologically based pharmacokinetic modeling 
framework for the performance of computationally demanding simulations. 
Proponents of physiologically-based pharmacokinetic modeling believe that learning the 
clinical pharmacology of a drug, and developing a model to describe it, should not start with 
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the first clinical study.  Rather, it is suggested to use in vitro tests, quantitative structure-
activity relationships (QSARs), and physiologically based models to specifically define the 
details of what in vivo studies are absolutely necessary and in doing so work to eliminate 
studies that are doomed to fail.  Leading researchers within the FDA’s Office of Clinical 
Pharmacology have published a perspective article on best practices when using 
physiologically based pharmacokinetic modeling and simulation to address clinical 
pharmacology regulatory questions.  In the article, the discussion is based on the “predict-
learn-confirm” paradigm for the physiologically-based population pharmacokinetic modeling 
in an optimized drug development process (see Figure 2.4.1.1).228  These cycles are based on 
screening lead compounds into candidate drugs by determining potency against the target, 
physicochemical properties, and basic in vitro data such as metabolic stability and cytochrome 
P450 inhibition assessment. Subsequent in vitro studies can be aimed at establishing, and if 
necessary optimizing, in vivo efficacy so that pivotal in vivo trials can be performed with better 
quality compounds and subsequent clinical questions can be answered with greater certainty 
and efficiency. 
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Predict 
Learn 
Confirm 
Apply 
 Model construction 
o Start from discovery and first in 
human predictions 
 Model Refinement 
o Further experimental data 
o Estimation of parameters based on clinical data 
o Sensitivity analysis of uncertain parameters 
 Model’s recovery of clinical data 
 Model application to a specific 
question 
Figure 2.4.1.1 “Predict-Learn-Confirm” Paradigm for Physiologically Based Population 
Pharmacokinetic Modeling 
Adapted from Suri et al (2015)228 
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2.4.2 Functional Components of a PBPK Model  
As stated in the previous section, physiologically based pharmacokinetic models use 
differential equations parameterized using known physiological data to represent a 
quantitative mechanistic model structure by which the ADME of drugs may be modeled. The 
availability of networked, open source data libraries has greatly facilitated the performance of 
physiologically based pharmacokinetic simulations.  The data that feed into a physiologically 
based pharmacokinetic model can be classified as either drug-dependent or drug-independent.  
Drug-independent data can also be called the system components of the model.  These 
components are defined by population level estimates of the basal physiology and 
pathophysiology of the in vivo study subjects.  Some examples of these components include 
tissue flow rates, organ volumes, and gut segment transit times.  Huang et al. discussed how 
these drug-independent components are shaped by intrinsic and extrinsic patient factors.  
Some examples of intrinsic patient factors included age, allometric correlations, race, organ 
dysfunction, disease, pregnancy, gender, and genetics.  In the context of PBPK modeling, 
researchers have databases at their disposal that describe the drug independent parameters of 
populations with the following conditions: health-impaired elderly,229 pediatric,230 
pregnancy,231 obesity,232 comorbid diseases such as cirrhosis233,234 and chronic kidney failure, 
235 and smoking. 236  These data, often collected from rigorously conducted federal health 
interview studies (e.g., NHANES, NHIS, EHIS, etc.) have allowed the covariance between 
age, gender, height, weight and other anthropomorphic values to be modeled by researchers.  
Data libraries based on meta-analysis of these reports are maintained by many PBPK software 
providers (so called  ‘population libraries’). 237  These libraries provide the means by which 
the required drug independent parameters can be generated using correlated Monte Carlo 
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sampling techniques to effectively generate in silico patients.  These databases have been 
integrated into modeling efforts to account for changes in hepatic blood flow, CYP 
abundance, liver volume, hematocrit, and liver/renal function as a function of disease or age, 
for the prediction of human pharmacokinetics in atypical subpopulations.238,233,234  This 
practice occupies the growing domain of clinical trial simulation research.239  The specifics 
of such methodologies in the context of this work will be introduced in subsequent sections. 
While understanding the physiologic factors that influence key ADME mechanisms for a 
particular compound is important, the ultimate success of a prediction also requires well-
defined and well-measured drug dependent parameters.  The drug-dependent parameters of a 
physiologically based pharmacokinetic model can be broken down into pharmacologic and 
physical categories.  The pharmacologic drug dependent parameters define values such a 
permeability, intrinsic clearance of drug on a per enzyme basis, protein binding, etc.  For 
carbamazepine, some of the important drug-dependent ADME properties and methods for 
their determination have been discussed in section 2.2.   
After conversion to relevant units, in vitro values can directly be used as inputs for 
physiologically based mechanisms, in conjunction with extrinsic factors (e.g., blood-binding 
data), to parameterize specific pathways such as clearance.  Here, assumptions of the pathway 
define how the data is used.  In the case of clearance from liver blood flow, for example, 
Poulin et al. showed how well-stirred models can be used to predict clearance based on a 
combination of in vitro drug dependent data and a priori knowledge of human physiology.240  
This work was based on the publication of Proctor et al.  In this foundational work, a model 
was developed for how whole organ intrinsic drug clearance may be predicted from 
recombinantly expressed CYPs (𝑟ℎ𝐶𝑌𝑃) based on the works of Houston et al and Iwatsubo 
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et al. 241-243  The specific case of predicting liver clearance can be accomplished using the 
following equation: 
Eq. 2.4.2.1 
  𝐶𝐿𝑢 ௅,௜௡௧ (௨௡௕௢௨௡ௗ) = ൬∑ ∑
ூௌா ೛,೐×௏೘ೌೣ,೛,೐(ೡ೔೟ೝ೚)×ா௡௭ಽ,೛,೐
௄೘,೛,೐
∗ ଵ
௙௨೔೙೎
௠
௘ୀଵ
௡
௣ୀଵ ൰ … 
× 𝑀𝑃𝑃𝐺𝐿 × 𝐿𝑖𝑣𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡  
where, ISEF (intersystem extrapolation factor) is a dimensionless number used as a direct 
scaler to convert data obtained with a 𝑟ℎ𝐶𝑌𝑃 system, 𝑉௠௔௫,௣,௘(௩௜௧௥௢) is the Michalis-Menten 
rate constant representing the maximum velocity of the in vitro metabolism assay incubation 
for the 𝑝௧௛ clearance pathway of the 𝑒௧௛  enzyme isoform, 𝐸𝑛𝑧௅,௣,௘ is the percent abundance, 
𝐾௠,௣,௘ is the Michalis-Menten rate constant representing the concentration that corresponds 
with ൫0.5 ∙ 𝑉௠௔௫,௣,௘(௩௜௧௥௢)൯, 𝑓𝑢௜௡௖ is the fraction unbound in the metabolism assay 
incubation, and 𝑀𝑃𝑃𝐺𝐿 is the microsomal protein per gram of liver. The ISEF is calculated 
by the following equation,  
Eq. 2.4.2.2 𝐼𝑆𝐸𝐹௣,௘ =
஼௅೔೙೟(ு௅ெ)
஼௅௨ ೔೙೟,೛,೐(௥௛஼௒௉)×஼௒௉ೕ ௔௕௨௡ௗ௔௡௖௘(ு௅ெ) 
 
where 𝐶𝐿௜௡௧(𝐻𝐿𝑀) is the intrinsic clearance in human liver microsomes, 
𝐶𝐿𝑢 ௜௡௧,௣,௘(𝑟ℎ𝐶𝑌𝑃) is the intrinsic clearance of the recombinant enzyme system, and 
𝐶𝑌𝑃௣,௘  𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒(𝐻𝐿𝑀) refers to the abundance of the 𝑒௧௛ CYP in the liver sample(s) 
used to determine the 𝐼𝑆𝐸𝐹.  Proctor et al. described how the application of ISEFs in IVIVE 
exist along three levels, reflecting a balance between confidence in extrapolation and high-
throughput compatibility. 242 
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Poulin et al. used the ISEF framework of Proctor et al. to model hepatic metabolic 
clearance of highly bound drugs.244  The researchers evaluated the performance of this IVIVE 
methodology and others using a data set of 25 compounds which including acidic, basic, and 
neutral model drugs.  The ability to predict in vivo clearance from in vitro data is shown in 
Figure 2.4.2.2. Comparison between predicted and observed human clearance in this Figure 
returned a high correlation R2 = 0.95. 
Figure 2.4.2.1. The incorportation of ISEFs into in vitro-in vivo extrapolation. 
HTS – high throughput system.   Adapted from Proctor (2012) 242 
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Similar to that of Proctor et al., Jamei et al. showed how a IVIVE methodology could be 
used for predicting the effective permeability of the gastrointestinal tract. 245  Jamei et al. then 
demonstrated how this prediction could be combined with an understanding of gastric transit 
times, gastrointestinal physiology/pathophysiology, and assumptions of gastrointestinal fluid 
dynamics to achieve a mechanistic prediction of population-level of oral drug absorption. 
 There is an extensive range of drug-specific and physiologic parameters which can be 
defined during drug development and used for the mechanistic prediction of pharmacokinetic 
model parameters. Although, not all parameters are needed in all circumstances depending on 
both the simulation mode and the models chosen.  For example, the tissue:plasma partition 
coefficient required by a physiologically based pharmacokinetic models to describe the 
accumulation of drug within a specific organ would require data that is not needed for the one 
compartment distribution model.  A list of some of the typical names, values (and units), 
source of the parameter values, and assumptions being made are provided in Table 2.4.2.1. 
Figure 2.4.2.2. The solid line indicates the best fit (unity). Dashed lines on either side of 
unity include a factor of two and three. Cross (red), circles (green), and squares (blue) 
indicate bases, neutrals, and acids, respectively. CL - clearance (mL/(min kg)). Adapted 
from Poulin et al (2012) 244 
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Table 2.4.2.1. Sample Input Parameters of Drug for Physiologically Based  
Pharmacokinetic Modeling 
Sample parameter Sample assumptions and references 
Compound type  Summary of clinical pharmacology studies in NDA submission 
Molecular weight  Summary of clinical pharmacology studies in NDA submission 
LogP Measured value. Summary of clinical pharmacology studies in NDA submission 
pKa  NA (neutral compound) 
Solubility (mg/ml)   Measured at pH 7.4. Summary of clinical pharmacology studies in NDA submission 
Particle size radius (mm)  Monodispersed. Summary of clinical pharmacology studies in NDA submission 
B/P ratio 1  Measured value from in vitro experiments. Summary of clinical pharmacology studies in 
NDA submission 
fp Measured value from in vitro experiments. Summary of clinical pharmacology studies in 
NDA submission 
fu,gut Assumed and tested plausible using sensitivity analysis 
Fa Predicted using Caco-2 Papp data246; assumed first-order absorption kinetics 
Ka (l/h)  Estimated from single-oral-dose study in young adults using compartmental analysis; 
summary of clinical pharmacology studies in NDA submission 
Qgut (l/h) Predicted using the software’s built-in method 
Papp  Measured value using Caco-2 cell lines; summary of clinical pharmacology studies in 
NDA submission 
In vitro transporter 
P-glycoprotein (P-gp) 
Jmax (pmol/min) 
Km (mM) 
Measured value in vitro; not an inhibitor of P-gp; not a substrate and inhibitor of other 
transporters; summary of clinical pharmacology studies in NDA submission 
 
In vitro CYP inhibition: 
IC50 (mM) 
Measured value in vitro ; not an inhibitor of major CYP other than CYP2D6 (see below); not a 
CYP inducer; summary of clinical pharmacology studies in NDA submission 
Ki on CYP2D6 (mM) 
 
Measured value from in vitro experiment using human liver microsomes; summary of clinical 
pharmacology studies in NDA submission 
Predicted Vss (l/kg)  Predicted using the software’s built-in method247 ; observed mean value from the i.v. study in 
young adults = 3.5 l/kg 
CLi.v. (l/h) From i.v. study in young adults; summary of clinical pharmacology studies in NDA submission 
CLR (l/h) From i.v. study in young adults; summary of clinical pharmacology studies in NDA 
submission248 
CYP3A4 CLint 
(ml/min/pmol) 
Retrospectively calculated using CLi.v. and well-stirred hepatic clearance model , assuming 80% 
of total hepatic metabolism; summary of clinical pharmacology studies in NDA submission 
CYP1A2 CLint 
(ml/min/pmol) 
Retrospectively calculated using CLi.v. and well-stirred hepatic clearance model, assuming 20% 
of total hepatic metabolism; summary of clinical pharmacology studies in NDA submission 
B/P ratio, blood-to-plasma ratio; CLint, intrinsic clearance; CLi.v., clearance after intravenous administration; CLR, renal 
clearance; Fa, fraction absorbed; fp, fraction unbound in plasma; fu,gut, apparent unbound fraction in enterocytes; IC50, 
inhibitor concentration that causes 50% inhibition of enzyme/transporter activities; i.v.,  intravenous; Jmax, maximum rate of 
transporter-mediated efflux or uptake; Ka, first-order absorption rate constant; Ki, reversible inhibition constant; Km, 
Michaelis constant; LogP, logarithm of the octanol–water partition coefficient; NA, not applicable; NDA, new drug 
application; Papp, apparent passive permeability; pKa, logarithmic acid dissociation constant; Qgut, hypothetical blood flow 
term that is used to complex interplay among passive intestinal permeability, active transport, enterocyte drug binding, blood 
flows to enterocytes, and gut metabolism; Vss, volume of distribution at steady state. 
Adapted from Zhaoet al (2012) 214 
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The work of Zhao et al. visually summarizes the structure of data-types and equations 
within a PBPK modeling framework. 249  In that regulatory review article, members of the 
FDA’s Office of Clinical Pharmacology used the frameworks Huang et al. and others to 
describe the drug-dependent and drug-independent components of physiologically based 
pharmacokinetic modeling applications.  Sections a. and b. of Figure 2.4.2.3. represent the 
work’s summative adaptation of the previous two efforts.250    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4.2.3. a and b. Relationship between the proposed physiologically based 
pharmacokinetic model and extrinsic/intrinsic factors that impact drug exposure (a) Intrinsic and 
extrinsic patient factors to be accounted for during simulations.  (b) Components of the PBPK 
model. Illustration modified from Huang et al (2008) 250 
b.  a.  
Extrinsic Factors: 
 Drug-drug interactions 
 Environment 
 Medical practice 
 Regulatory requirements 
 EtOH 
 smoking/diet 
 Etc. 
Intrinsic Factors: 
 Age 
 Race 
 Organ dysfunction 
 Disease 
 Pregnancy 
 Gender 
 Genetics 
 Etc. 
System Components  
(drug-independent): 
perfusion rates, volumes, transit times, etc. 
Drug-dependent 
Components: + 
Effects on human 
physiology directly 
included in model Central Compart.
Liver
Portal Vein
Enterocytes
PO Dose
Gut
Metabolism
Liver Metabolism
Renal Elimination
Qvilli
QPV
QHV QHA
Lumen Fluid of GI
Villi Capillary
ADME, PK, PD, and 
MOA 
 
 Metabolism 
 Active transport 
 Passive diffusion 
 Protein binding 
 Drug–drug 
interactions 
 Receptor binding 
 Etc. 
The advanced dissolution, absorption and 
metabolism model (ADAM model) 
Predict, learn, confirm 
PBPK Model 
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2.4.3 IVIVC-based Clinical Trial Simulation  
Clinical trial simulations represent an approach to answer deterministic questions by 
accounting for the inherent stochastic variability of biology via random sampling algorithms. 
This iterative approach generates a trial population in silico with inter-individual differences 
via Monte Carlo sampling from user-defined distributions.  The name for such sampling was 
coined by Stanislaw Ulam and John von Neumann in 1945 for the gambling capital in Europe 
(Ulam’s uncle apparently liked to gamble and this was his inspiration) while in Los Alamos, 
New Mexico working on the Manhattan Project (development of the atomic bomb) 
(Metropolis 1987).  If the model were 𝑌 =  𝑥 +  𝜀 where 𝜀 is a random draw from some 
probability density function (PDF) then the process considered is deterministic if when 
performed repeatedly the outcome converges to a reproducible outcome.   
The use of Monte Carlo simulation can also be performed during classical NLME 
modeling of population pharmacokinetics.  Bondi used NLME to define the coefficients of 
relevant patient covariates in an IVIVC model.251   He then resampled from their posterior 
levels of uncertainty to assess the performance of different delayed release products.  A key 
advantage of physiologically based pharmacokinetic models is the ability to include sources 
of physiological and biochemical variability in the system parameters and to simulate the 
expected pharmacokinetics in a population of individuals rather than for an average subject.  
A virtual population can be generated from values and formulae describing demographic, 
anatomical, and physiological variables using a correlated Monte Carlo approach.39 Equations 
describing distributions of system parameters for the physiologically based pharmacokinetic 
model are derived from distributions of data based on real populations and patients. This 
allows prediction of variability before clinical studies in contrast to a NLME approach 
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(population pharmacokinetic analysis), which requires prior clinical data to characterize 
variability. Being able to assess variability in a population is particularly important when 
considering the risk, as it is usually a few individuals with certain characteristics that are of 
more concern than the average individual. 
In the case of physiologically simulated hepatic clearance, individualized liver weights 
are generated by first randomly sampling from a user defined distribution of ages and genders.  
Next, a sample is drawn from marginal age-vs.-gender-vs.-height-vs.-weight probability 
distribution.  This distribution is defined by the results of rigorously conducted federal health 
interview studies (e.g. NHANES, NHIS, EHIS, etc.).  Body surface area (BSA) is then 
calculated from this information using the following equation: 
Eq. 2.4.3.1   𝐵𝑆𝐴 (𝑚ଶ) =  ටு௧.௜௡ ௖௠ × ௐ௧.௜௡ ௞௚
ଷ଺଴଴
 . 
With BSA determined, liver volumes can be individualized based on the work of Johnson et 
al.252  In this work, equations were developed based on simple regression against BSA and 
multiple regression of liver volume with weight, height, BSA, age, gender, race, 
methodology, and year of publication as covariates. The equation to describe liver volume 
was selected according to the AIC, precision and bias and following visual inspection of 
residual errors and observed vs. predicted plots:  
 
Eq. 2.4.3.2  𝐿𝑖𝑣𝑒𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 =  0.722 ∗  𝐵𝑆𝐴ଵ.ଵ଻଺   
 
These coefficients represent the best, meta-level fit of the dataset in the Johnson et al study.  
The simulation process would be able to create individualized estimates of these values based 
on the reported levels of uncertainty from that study.  The fit of this liver volume vs. BSA 
model for the data is shown in Figure 2.4.3.1.  Each individualized liver volume is then 
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multiplied by a sample from a probability density function describing liver densities.  This 
parameter sampling process can then be repeated until Equation 2.4.2.1 and its components 
are fully parameterized for a single in silico patient.   
 
 
 
 
 
 
 
 
253 
The number of in silico patients is usually defined by the objective of the simulation study 
and the variability in the parameters.  Greater variably requires more patients to reach a 
stable estimation of the pharmacokinetic metric of interest.   
By its nature, a physiologically based pharmacokinetic model is based on the first 
principles of human physiology.  This allows the developers of such models to uniquely 
leverage the findings of high throughput in vitro DMPK studies that now are the foundation 
of preclinical drug development efforts.  More and more sponsors have been able to 
successfully account for  population variability when considering the risk associated with 
drug-drug interactions through the performance of  simulations over these models.  It is the 
hope of this work to illustrate how the utility of a physiologically based pharmacokinetic 
modeling and simulation can and should be extended beyond the preclinical and clinical 
Figure 2.4.3.1.  The model fit for liver volume vs body surface area described by 
Johnson et al. Adapted from Johnson et al (2005) 254 
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phase of drug development, existing as a post-approval tool that iteratively refines itself to 
facilitate the lifecycle management process.  
 
Chapter 3: Development of an IVIVC Framework for 
Immediate Release Carbamazepine Using a “Top Down” 
Approach 
 
3.1 Introduction  
A strong link between the surrogates of in vivo performance and clinical response is 
essential for the efficient assurance of quality. At the center of many definitions for 
pharmaceutical quality is the concept of consistently meeting the needs of the patient.  The 
CFR states that one of the most preferred methods for the assurance of consistent 
performance is the use of in vitro dissolution tests that have been correlated with in vivo 
performance.  There are three in vitro-in vivo correlation (IVIVC) levels according to a 
FDA guidance documents: A, B, and C.  The levels differ by the amount of detail output 
by the correlative model.  For example, a Level C IVIVC draws a relationship between 
an amount dissolved at a given time and summary pharmacokinetic parameters such as 
the area under the curve (AUC), maximum plasma concentration, or the time of the 
maximum plasma concentration.  This level does not reflect the complete shape of the 
plasma concentration-time profile.  Similarly, a level B IVIVC does not uniquely 
reflect the actual in vivo plasma level curve.  It uses the principles of statistical moment 
analysis to regress an amount dissolved at a particular time against a pharmacokinetic 
metric such as the mean residence time.  A level A IVIVC predicts the entire in vivo 
time course from the in vitro data.  This level of IVIVC has been identified as the most 
informative by the FDA and other health authorities.  In this chapter, all future 
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references to an IVIVC made without ‘level’ specification should be considered as 
level A IVIVCs . 
The model drug product for this work is an immediate release Carbamazepine 
tablet. Carbamazepine is considered as a first line therapy drug for the treatment of 
partial and tonic-clonic seizures.  One of the reasons for carbamazepine’s efficacy is 
its high permeability, allowing it to readily diffuse across the blood brain barrier.  This 
is the product of carbamazepine’s lipophilic structure, a characteristic that also 
translates into poor aqueous solubility.  The high permeability of carbamazepine, along 
with its low solubility in aqueous systems, position it within the second class (II) of the 
FDA’s biopharmaceutical classification system (BCS) based on the work of Amidon 
et al.  In that work, the likelihood of an IVIVC for class II compounds was favorable.  
This expectation of Amidon et al. was a result of dissolution of such compounds often 
being the rate-limiting step for the absorption.  
Given the complexity of pharmaceutical drug products, health agencies do not 
define a unified method for how an IVIVC should be developed.  Regulators do 
acknowledge that in order to maximize the utility of an IVIVC, certain bespoke 
modeling decisions must be made.  Despite the reality of such individuality, certain 
core IVIVC components do exist that are common between applications.  Specifically, 
all level A IVIVCs can be considered as hierarchical in nature with the overarching 
framework being a pharmacokinetic model.    Pharmacokinetic modeling seeks to take 
a complex phenomena, such as the rise and fall of a drug substance’s plasma 
concentration, and describe it as a function of parameters within a mathematical model.  
Models can be classified into many different categories.  Using the nomenclature of 
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DiStefano and Landaw, pharmacokinetic models can generally be broken down into 
two types: models of data and models of systems.254  In a pharmacokinetic model of 
data, the model parameters are derived from, and fitted to, available clinical data.255  In 
the pharmacokinetic literature, this approach has grown to be referred to as ‘top down’ 
pharmacokinetic modeling.  This type of pharmacokinetic modeling will be the 
approach used to the develop the IVIVC in this chapter.  
In addition to the pharmacokinetic model, an IVIVC cannot exist without a model 
that transforms in vitro drug release data into an in vivo input for the defined pharmacokinetic 
model.  Generally, the approaches for deriving this model are classified as either one- or two-
step procedures.  A two-step procedure was used in this work.  The typical two-step 
procedure is based on a deconvolution-convolution process.  The classical approach to this 
method is to derive an absorption profile that, when input to the pharmacokinetic model, 
recovers the observed plasma concentration for each drug product used in the development 
of the IVIVC.  For a typical one compartment open model, this input profile may be derived 
using either the standard Wagner Nelson method or the method of residuals.  Once the 
respective in vivo input profiles are determined, they are pooled and regressed against the in 
vitro release rates.  Thus, subsequent in vitro-in vivo transformations can be performed using 
this model.   This chapter will take a parallel approach to such a methodology.  It will be 
based on constructing a model that relates the parameters that define the rate and extent of 
absorption within a pharmacokinetic model to those that define the rate and extent of in vitro 
dissolution model.   
This chapter is focused on the first specific aim of this work: the development of 
an IVIVC for an immediate release carbamazepine product using a classical 
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pharmacokinetic model.  It begins by describing the methodology behind how a level 
A IVIVC for immediate release Carbamazepine was developed.  The chapter identifies 
the in vitro-in vivo data that were ultimately used during modeling activities.  It then 
goes on to describe the types of models that were used to represent the data and how 
the accuracy of the models was assessed.  The chapter concludes by presenting and 
discussing the performance of the IVIVC.  
 
3.2 Methods and Materials  
3.2.1 In vitro-In vivo Data 
The data for this study was collected from 1992 and 1998 publications by Meyer et 
al. and one previous work by Olling et al.  Data was digitized using an open source 
tracing software. All of the studies were 4-by-4 crossover studies.  Table 3.2.1.1 
describes the type of demographics, protocol details, type of in vitro experiments, and 
the levels of in vitro and in vivo results.  In this work, the 1992 Meyer et al and Olling 
et al. data was used to train the IVIVC model.  The 1998 Meyer et al. data was used to 
test the model. 
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Table 3.2.1.1 Details of in vivo studies for IVIVC model development 
Author  
[Reference]  Meyer ‘92  Olling ‘99 Meyer ‘98 
Subjects 
24 healthy, nonsmoking males; 
21-35 y.o.; weighing 61-93kg 
 
18 healthy; nonsmoking 
volunteers, 20-38 y.o.; 
weighing 49-88 kg 
20 healthy, nonsmoking subjects; 
16 males and 4 females; 22-36 
y.o.; weighing 50-98 kg 
Protocol 
Medication / Alcohol 
Abstinence:  21 / 2 days 
 
Products: Tegretol® and 3 lots 
from a marketed generic 
 
Study Design:  
 Randomized 4X4 
 single, overnight fasted, 
200mg dose with 180 ml of 
room temp water 
 21d washout between 
treatments 
 Standard meal 4 hrs after 
dose 
Medication  / Alcohol 
Abstinence:  “no active 
therapies” / 1 day 
 
Products: Tegretol® and 3 
marketed generics 
 
Study Design:  
 Randomized 4X4 
 double, overnight fasted, 
200mg dose with 150 ml 
of room temperature 
water 
 14 day washout between 
treatments  
Medication / Alcohol Abstinence:  
21 / 2 days 
 
Products: Tegretol® and 3 
marketed generics 
 
Study Design:  
 Randomized 4X4 
 single, overnight fasted, 
200mg dose with 180 ml of 
room temp water 
 21d washout between 
treatments 
 Standard meal 4 hrs after 
dose 
Level of in 
vivo results 
Entire plasma concentration profile with variance  
estimates on AUC, Cmax, Tmax, elimination rate 
Meyer 92’= over 168 hours      Olling =  over 100 hours Meyer 98’= over 168 hours 
In vitro 
experiments
USP Method:  type II apparatus; 75 rpm;  
900ml of water containing 1% sodium lauryl sulfate (SLS) 
Level of in 
vitro results 
Entire Dissolution Profile 
Meyer 92’= over 90 minutes       Olling =  over 120 minutes           Meyer 98’= over 90 minutes     
 
 
All of the plasma data was collected using HPLC and the calibration was demonstrated to 
be linear over the following ranges: 0.05 – 4.03 ug/ml, 0.05 – 4.0 ug/ml, and 0.05 – 6.0 
ug/ml for the Meyer et al 1992,  Meyer et al 1998, and Olling et al. studies, respectively.  
The digitized in vitro-in vivo data is shown in figure 3.2.1.1. 
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Figure 3.2.1.1. In Vitro In Vivo Data 
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3.2.2 Modeling Overview 
The modeling activities of this chapter proceeded in three phases: i) “top down” 
pharmacokinetic modeling, ii) dissolution modeling, and iii) in vitro-in vivo 
modeling.  The pharmacokinetic modeling allowed each plasma concentration profile 
to be expressed as a function of the elimination rate (ke), the volume of distribution 
(Vd), the bioavailability/fraction of drug absorbed (F), and the rate of drug absorption 
(ka).  The dissolution modeling provided a means to reduce a product’s entire 
dissolution profile into several key dissolution model parameters to represent the rate 
and extent of dissolution.  Finally, two generalized linear models were used to relate 
the dissolution model parameters for each product to their respective absorption terms 
for the ultimate recovery of the plasma concentration profiles. 
 
3.2.2.1 Pharmacokinetic Model 
With the data from the reference studies digitized, the next step was modeling the 
plasma concentration profile from the ‘top down’.  This was accomplished with a 
standard single-compartment model for oral absorption (see eq. 3.2.2.1).  Here, 𝑘௘ is 
the first order elimination rate constant, 𝑘௔ is the first order absorption rate constant, 𝐹 
is bioavailability, and 𝑉ௗ is the volume of distribution. 
Eq. 3.2.2.1.1)  ௗ஼೛
ௗ௧
= (𝐹 ∙ 𝑘௔ ∙ 𝐷𝑜𝑠𝑒 ∙ 𝑒ି௞௔∙௧)/𝑉 − ൫𝑘௘ ∙ 𝐶௣൯ 
  ቀintegrated form: 𝐶௣ =
ி∙஽௢௦௘∙௞ೌ
௏∙(௞ೌି௞೐)
∙ [𝑒ି௞೐∙௧ − 𝑒ି௞ೌ∙௧]ቁ 
This model was used for both the 1992 and 1998 Meyer et al. studies. However, a 
slightly amended pharmacokinetic model was used for the Olling et al. data given that 
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this study used two 200 mg doses administered simultaneously.  The two doses were 
accounted for in the differential equation describing the rate of drug change in the 
plasma in the following way: 
Eq. 3.2.2.1.2)  ௗ஼೛
ௗ௧
= 2(𝐹 ∙ 𝑘௔ ∙ 𝐷𝑜𝑠𝑒 ∙ 𝑒ି௞ ∙௧)/𝑉 − ൫𝑘௘ ∙ 𝐶௣൯ 
The parameterization of equations 3.2.2.1 and 3.2.2.2. commenced by assessing 
whether the elimination followed a first order process.  This was confirmed via the 
presence of linearity in the log-transformed terminal phase of the plasma concentration 
profile.  Once confirmed, the slope of this linear region is the (statistically) unbiased 
estimation of 𝑘௘.  The value of 𝑘௔ was determined following the calculation of 𝑘௘ using 
the method of residuals.256  𝑉ௗ was defined using an aggregate of i.v. dosing trials from 
literature using the following equation: 
Eq. 3.2.2.1.3)   𝑉ௗ = 𝐷𝑜𝑠𝑒/(𝑘௘[𝐴𝑈𝐶]଴ஶ)  
where [𝐴𝑈𝐶]଴ஶ is the area under the curve from time zero to infinity.  The value for this 
parameter has be previously defined by Marino et al. and others to be approximately 
70 L (see literature survey on Carbamazepine; section 2.2 ).  The bioavailability of a 
product, 𝐹, was calculated using the Nelder-Mead least squares fitting algorithm within 
WINNONLIN (Certara – Princeton, NJ).  The AUCs calculated in this study were 
determined using the following equation: 
Eq. 3.2.2.1.4)  𝐴𝑈𝐶 = ஽௢௦௘∙ி
௞೐∙௏೏
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Models were compared on the basis of Akaike Information Criterion (AIC) and 
goodness of fit was determined by calculating the root mean squared error (RMSE), 
and 𝑅௔ௗ௝௨௦௧௘ௗଶ : 
Eq. 3.2.2.1.5)  𝑅𝑀𝑆𝐸 = ට∑ ௬೔ି௬ො೟
௡ି௣
௡
௜ୀଵ  
Eq. 3.2.2.1.6)  𝑅௔ௗ௝௨௦௧௘ௗଶ = 1 −
௡ିଵ
௡ି௣
(1 − 𝑅ଶ) 
where n is the number of dissolution data points and p is the number of parameters in 
the dissolution model.  In addition to these diagnostic statistics, slope and bias terms 
were evaluated for significance by assessing the residuals for homoscedasticity around 
0 and by testing the null hypothesis of a slope equal to 1 for an ‘actual vs. residual’ 
plot.  The unbiased pharmacokinetic parameters of the model were observed for 
deviations when they were again calculated using the plasma concentration profiles 
that were regenerated via the IVIVC modeling. 
 
3.2.2.2 Dissolution Model 
Various models were investigated for the modeling of the in vitro dissolution data.  
Those explored included the Makoid-Banakar, Weibull, first order, Hill, Higuchi, and 
Hixson–Crowell (see Costa et al. for a review of the explored dissolution models).257 
Makoid-Banakar: 
Eq. 3.2.2.2.1) 𝐶௧ = 𝐹௠௔௫ ∙ ቀ
௧
்௠௔௫
ቁ
௕/ ೘்ೌೣ
∙ 𝑒ቀ
್
೅೘ೌೣ
∙ ೟೅೘ೌೣቁ,      for t <= 𝑇𝑚𝑎𝑥  
  where, 
  𝐶௧ = 𝐹௠௔௫,     for 𝑡 > 𝑇𝑚𝑎𝑥 
 
Weibull: 
Eq. 3.2.2.2.2) 𝐶௧ = 𝐶௜௡௙ ∙ (1 − 𝑒
ିቀ ೟ಾವ೅ቁ
ംೢ೐೔್ೠ೗೗/ಾವ೅
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First Order: 
Eq. 3.2.2.2.3) ln(𝐶௧) = ln(𝐶௦௢௟) + 𝐾ଵ𝑡 
Hill: 
Eq. 3.2.2.2.4) 𝐶௧ = (𝐶௜௡௙ ∗ 𝑡ఊ)/(𝑀𝐷𝑇ఊ + 𝑡ఊ) 
Higuchi: 
Eq. 3.2.2.2.5) 𝐶௧ = 𝐾ு√𝑡 
Hixson–Crowell: 
Eq. 3.2.2.2.6) 𝑊ௗ௢௦௘
ଵ/ଷ − 𝑊௧ଵ/ଷ = 𝐾௦𝑡 
Where 𝐶௧ is the amount drug dissolved at time t, 𝐶௜௡௙ is the amount released at time 
infinity,  𝑇௠௔௫ is the time at which the dissolution profile plateaus, 𝑏 is the Makoid-
Banakar dissolution profile slope factor, 𝑀𝐷𝑇 is the mean dissolution time, 𝐾ଵ is the 
first order proportionality constant, 𝛾 is the Hill slope factor, 𝐾ு is the Higuchi 
dissolution constant, 𝑊ௗ௢௦௘ is the initial mass of the drug in the dosage form, 𝑊௧ is the 
remaining amount of drug in the dosage for at time t, and 𝐾௦ is a constant incorporating 
the surface–volume relation. Models were fit using the Levenberg-Marquardt 
algorithm (nlinfit.m) within MATLAB® (v.R2018b, MathWorks, Natick, MA).  The 
dissolution models were compared on the basis of Akaike Information Criterion (AIC) 
and evaluated for goodness of fit using the RMSE, 𝑅௔ௗ௝௨௦௧௘ௗଶ , and the slope and bias 
terms from the ‘actual vs. residual’ plot. The nonsignificance was used to assess the 
suitability of the dissolution models.  The assessment of the slope and bias terms for 
the residuals-vs-observed plot was based on the inclusion of 0 in the confidence 
intervals. 
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3.2.2.3 In vitro-In vivo Model 
A generalized linear modeling (GLM) approach was used to express the rate and 
extent of absorption for each product from section 3.1 as a function of their respective 
in vitro dissolution model parameters.  As such, two generalized linear models were 
generated that respectively correlated 𝑘𝑎 and 𝐹 with dissolution model parameters.  
This provided a means to regenerate the entire plasma concentration profile from the 
dissolution data.   The procedure used to generate the GLMs was based on stepwise 
regression and is illustrated in the following figure 3.2.4.1.   
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Figure 3.2.4.1 IVIVC Modeling 
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The first step in the IVIVC modeling process illustrated by figure 3.2.4.1 was to 
model the dissolution profiles using the array of dissolution models identified in 
section 3.2.2.2.  Only the dissolution model parameters from models that provided 
suitable fits of the dissolution profiles were carried forward as potential independent 
variables for the in vitro-in vivo GLM.  The model was then built using a stepwise 
approach within the JMP software (SAS Institute, Cary NC).  Here, the forward 
addition of variables was based on a maximum p-value threshold that a parameter 
needed have in order to be entered into the model as part of the forward addition step. 
The backward removal of a variable was based on a minimum p-value that an effect 
must have to be removed from the model during a backward step.  The critical p-
values for the forward and backward removal of parameters were 0.25 and 0.1 
respectively.  The calculation of p-values for each parameter was based on an F-test.  
This test required determining the F-ratio for each parameter, which was calculated 
by dividing the sum of squared error captured by the parameter by the mean sum of 
squares error after addition/removal of the parameter to the model.  The hierarchical 
procedure that decomposed a dissolution profile into the necessary dissolution model 
parameters, translated those parameters into 𝑘𝑎 and 𝐹, and then combined the 
absorption parameters using a first order absorption model will henceforth be referred 
to as the IVIVC. 
 
3.2.3 IVIVC Model Evaluation 
The evaluation of the IVIVC model for this project was based on regulatory 
recommendations found in existing regulatory guidance literature.13  These guidance 
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documents focus on the ability to predict two summary pharmacokinetic metrics: 𝐴𝑈𝐶 
and 𝐶௠௔௫.13  As such prediction error (𝑃𝐸) for these metrics were calculated using 
equation 3.2.3.1. 
Eq. 3.2.3.1) %𝑃𝐸 = ቀ|ை௕௦௘௥௩௘ௗ ௏௔௟௨௘ି௉௥௘ௗ௜௖  ௏௔௟௨௘|
ை௕௦௘௥௩௘ௗ ௏௔௟௨௘
ቁ ∙ 100 
The acceptability of the 𝑃𝐸 for 𝐴𝑈𝐶 and 𝐶௠௔௫ was based on FDA recommendations 
which varied depended on whether an internal or external approach to the evaluation 
of predictability was being perfromed.  Internal predictability is based on the initial 
data used to parameterize the IVIVC model, while the evaluation of external 
predictability is based on additional test data.  The FDA recommends that the on 
evaluation of the IVIVC under one or both of these approaches constitutes an evaluation 
of predictability.    The guidance documents support internal predictability when 
average absolute prediction error (𝑃𝐸) for 𝐶௠௔௫   and 𝐴𝑈𝐶 is less than or equal to 10% 
and the percent error for each individual formulation is less than or equal to 15%.13  
The criteria for satisfactory external predictability is similarly evaluated using 
regulatory recommendations that the prediction errors for 𝐶𝑚𝑎𝑥 and 𝐴𝑈𝐶 were less 
than or equal to 10%.  The time at which the maximum concentration was achieved 
(𝑇𝑚𝑎𝑥) was also used for the assessment of predictability.  This metric was included 
in the IVIVC assessment process because Olling et al. showed that, in addition to the 
degree of exposure (summarized by the 𝐴𝑈𝐶 and 𝐶𝑚𝑎𝑥 metrics), 𝑇𝑚𝑎𝑥 was correlated 
with adverse events (i.e. dizziness). Here, the same predictability criteria was used for 
this summary pharmacokinetic metric. 
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While internal predictability was based on the ability to predict the 1992 Meyer et 
al. and Olling et al. summary pharmacokinetic metrics, external predictability was 
assessed using separate in vivo-in vitro data from the 1998 Meyer et al. study.  In 
addition to the 𝑃𝐸 calculation, the 𝑅𝑀𝑆𝐸 was used for the evaluation of the 𝐼𝑉𝐼𝑉𝐶.  
Also, a plot of the predicted vs the observed was generated to assess predictability.  
Using this plot, additional suitability tests confirmed that i) the confidence interval for 
the slope term contained 1, and ii) the intercept term was non-significant. 
 
3.3 Results  
3.3.1 In vitro Dissolution Profiles 
The respective fits of the dissolution models used to fit the in vitro dissolution data 
are shown in figure 3.3.1.1.  Several models fit the dissolution data well.  The Makoid-
Banakar model performed especially well with an 𝑅௔ௗ௝௨௦௧௘ௗଶ  of 0.99 and the lowest 
𝑅𝑀𝑆𝐸 and AIC.  However, a visual inspection of the fits demonstrated that the Hixson-
Crowell and Higuchi models did not fit the data well.  This was demonstrated in table 
3.3.1.1 by the large AIC and RMSE values as well as the lowest 𝑅௔ௗ௝௨௦௧௘ௗଶ  values.  In 
this table, the RMSE for the Hixson-Crowell and Higuchi models were more than triple 
that of the next closest comparator.  Additionally, neither of the 95% confidence 
intervals for the slope nor the bias terms included 0 for these two models.  The results 
of the statistical analysis indicated that neither the Higuchi model nor the Hixson 
Crowell model was suitable for the representation of the in vitro dissolution data.   
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Table 3.3.1.1. Dissolution model fits 
 𝑹𝒂𝒅𝒋𝒖𝒔𝒕𝒆𝒅𝟐  𝑹𝑴𝑺𝑬∗ 𝑨𝑰𝑪 𝑪𝑰𝟗𝟓% (𝑩𝒊𝒂𝒔)∗ 𝑪𝑰𝟗𝟓% (𝑺𝒍𝒐𝒑𝒆)∗ 
First Order 0.98 4.48 658.1 (-2.86, 0.66) (-0.007, 0.04) 
Higuchi 0.78 15.9 941.3 (-19.3,-8.19)* (0.14, 0.30)* 
Hill 0.99 1.27 374.7 (-0.59, 0.41) (-0.006, 0.008) 
Hixson-Crowell 0.65 20.1 994.3 (-28.5, -15.7)* (0.26, 0.44)* 
Makoid-Banakar 0.99 1.21 365.5 (-0.54, 0.41) (-0.005, 0.008) 
Weibull 0.99 2.26 528.7 (-1.42, 0.68) (-0.007, 0.021) 
 * percentage dissolved
Figure. 3.3.1.1 Dissolution profile fitting 
(markers represent observed data; lines represent model fits) 
%
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lv
ed
 
Time (hr) 
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3.3.2 In vivo Plasma Profiles 
The observed plasma concentration profiles of the Olling et al. and the Meyer et al. 
studies and their respective fits using the single compartmental model for oral 
absorption are shown in Figure 3.3.2.1.  The markers in this figure represent the 
observed data digitized from the original publications.  The solid lines represent the fit 
of the pharmacokinetic model.  The profiles followed a classical single peak plasma 
concentration profile in all the cases.  A basic visual predictive check of these models 
figure demonstrated suitable fits.  The fitting accuracy was also supported by high 
R2adjusted in every case ( > 0.95), with the ratio of the RMSE to the summary 
pharmacokinetic metrics being on the order of, or below, the analytical sensitivity of 
methods originally used to quantify the plasma concentrations. 
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Table 3.3.2.1 Diagnostic Metrics for Pharmacokinetic Model Fits 
Study Meyer et al. 1992 Meyer et al. 1998 Olling et al. 
Product ID 1 2 3 4 1 2 3 4 1 2 3 4 
𝑹𝒂𝒅𝒋𝒖𝒔𝒕𝒆𝒅𝟐  0.98 0.99 0.99 0.99 0.99 0.98 0.99 0.99 0.96 0.97 0.98 0.95 
𝑹𝑴𝑺𝑬∗ 0.06 0.05 0.12 0.06 0.06 0.13 0.05 0.06 0.18 0.28 0.21 0.28 
𝑨𝑰𝑪 -33.7 -41.9 -14.6 -35.1 -24.4 -4.15 -30.9 -26.3 -5.68 11.3 -0.64 10.4 
𝑪𝑰𝟗𝟓% (𝑩𝒊𝒂𝒔)∗ 
(-0.08, 
0.06) 
(-0.06, 
0.04) 
(-0.15, 
0.11) 
(-0.07, 
0.05) 
(-0.11, 
0.08) 
(-0.26, 
0.18) 
(-0.09, 
0.08) 
(-0.11, 
0.09) 
(-0.30, 
0.13) 
(-0.44, 
0.21) 
(-0.31, 
0.19) 
(-0.50, 
0.21) 
𝑪𝑰𝟗𝟓% (𝑺𝒍𝒐𝒑𝒆) 
(-0.05, 
0.07) 
(-0.06, 
0.09) 
(-0.06, 
0.09) 
(-0.06, 
0.09) 
(-0.06, 
0.07) 
(-0.10, 
0.15) 
(-0.04, 
0.05) 
(-0.05, 
0.06) 
(-0.05, 
0.13) 
(-0.05, 
0.11) 
(-0.05, 
0.08) 
(-0.06, 
0.15) 
* units: μg/ml 
0
0.5
1
1.5
2
2.5
0 10 20 30 40 50
0
1
2
3
4
5
6
0 20 40 60 80 100
Time (hr) 
O
lling et al. 
Pl
as
m
a 
Co
nc
en
tr
at
io
n 
(u
g/
m
l) 
Figure 3.3.2.1 Plasma Data and Model Fit 
0
0.5
1
1.5
2
2.5
3
0 50 100 150
M
eyer et al. 1992 
M
eyer et al. 1998 
(Lines represent model fits and markers represent the observed data.) 
 106 
 
All of the pharmacokinetic studies used in this chapter collected data until at least 
169 hours post dose.  This provided each of the original researchers the ability to 
capture the terminal phase of the plasma concentration profile.  This was important as 
the log transformed slope of this region is the elimination rate which was in turn is used 
to calculate the absorption rate and bioavailability.   
The 1992 Meyer et al. data in figure 3.3.2.1 shows how the entire mean plasma 
concentration profile, including the terminal phase, was provided in the original 
publication (reported interval: 0 to 169 hrs).  With this interval the elimination rate 
could be solved without any reference to the results section of the original document.  
This scenario was also the case for the Olling et al. data.  However, the 1998 Meter et 
al. study only included plasma concentration data up to 50 hours post-dose in their 
figure despite collecting data until 169 hours.  Fortunately, the researchers of the 1998 
Meyer et al. study reported the mean elimination rates for each product in their study 
using the Stella II software which utilizes classical methods for the determination of 
rate constants (i.e., slope of the log transformed terminal phase).  These reported 
elimination rates were then used as the starting point for subsequent modeling efforts 
aimed at deriving the absorption rate and bioavailability for each product. 
The ranges of 𝑘𝑎 and 𝐹 values for the Olling et al. and 1992 Meyer et al. studies, 
calculated using the method of residuals and Nelder Mead least squares fitting 
algorithm, were [0.23 – 1.08] and [0.44 – 1.00], respectively.  The ranges of 𝑘𝑎 and 𝐹 
values from the 1998 Meyer et al. used to evaluate the in vitro-in vivo model were [0.9-
0.27] and [0.77-0.90], respectively.  The 𝑘𝑎 term scaled well with measurements of 
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𝑇𝑚𝑎𝑥, while the 𝐹 term scaled well with measurements of 𝐶𝑚𝑎𝑥 and 𝐴𝑈𝐶 (see tables 
3.3.2.2 and 3.3.2.3).   
 
Table 3.3.2.2. Pharmacokinetic Model Parameters 
Study Meyer et al. 1992 Meyer et al. 1998 Olling et al. 1999 
 Product ID 
 1 2 3 4 1 2 3 4 1 2 3 4 
𝒌𝒂 (𝒉𝒓ି𝟏) 0.26 (0.0190) 
0.40 
(0.0349) 
0.50 
(0.0507) 
0.23 
(0.0247) 
0.27 
(0.0249) 
0.58 
(0.0799) 
0.90 
(0.0459) 
0.47 
(0.0265) 
0.25 
(0.0236) 
0.64 
(0.059) 
1.08 
(0.110) 
0.30 
(0.0339) 
𝑭 (%) 0.76 (0.0234) 
0.44 
(0.0137) 
1.00 
(0.0324) 
0.57 
(0.0239) 
0.77 
(0.0295) 
0.88 
(0.0453) 
0.84 
(0.0116) 
0.90 
(0.019) 
0.64 
(0.023) 
1.00 
(0.030) 
1.00 
(0.019) 
0.86 
(0.0340) 
𝒌𝒆 (𝒉𝒓ି𝟏) 0.015 (0.0009) 
0.014 
(0.0010) 
0.017 
(0.0014) 
0.014 
(0.0011) 
0.012 
(0.0018) 
0.014 
(0.0029) 
0.013 
(0.0009) 
0.015 
(0.0013) 
0.0103 
(0.0011) 
0.015 
(0.0012) 
0.015 
(0.0008) 
0.012 
(0.0013) 
The values in parenthesis represent the standard error of the parameter.
 
 
 
 
Table 3.3.2.3. Summary Pharmacokinetic Metrics 
Study Meyer et al. 1992 Meyer et al. 1998 Olling et al. 
 Product ID 
 1 2 3 4 1 2 3 4 1 2 3 4 
𝑪𝒎𝒂𝒙 (𝝁𝒈/𝒎𝒍) 1.89 1.15 2.69 1.40 1.95 2.32 2.30 2.34 3.17 5.37 5.43 4.60 
𝑨𝑼𝑪 (𝝁𝒈
∗ 𝒉𝒓/𝒎𝒍) 143 86.0 162 111 157 163 159 162 246 361.4 367.2 295 
𝑻𝒎𝒂𝒙 (𝒉𝒓) 11.7 9.04 7.19 12.8 11.3 6.59 4.85 7.67 13.3 6.27 4.10 11.0 
 
The results shown in Figure 3.3.2.1 and Table 3.3.2.1 provide a basis from which 
it can be stated that the first-order pharmacokinetic models in equations 3.2.2.1.1 and 
3.2.2.1.2 adequately described the data.  Thus it was concluded that if the in vitro 
dissolution model parameters can be accurately transformed into the in vivo absorption 
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terms via the GLM-based IVIVC model, then the entire observed plasma concentration 
can be recreated in the fulfillment of a level A IVIVC. 
3.3.3 In vitro-In vivo Model 
The final step in this chapter was to model the rate and extent of in vivo 
pharmacokinetic input as a function of the rate and extent of in vitro drug release.  
The method selected for this objective was generalized linear modeling.   
The first step was to examine these model parameters for correlations.  Paired 
univariate regressions were performed for this step and the 𝑅ଶ values are shown in 
table 3.3.4.1.  The most important regions of this table are a) the column representing 
the correlations with the bioavailability term and, b) the last row representing 
correlations with the first order absorption term. 
 
Table 3.3.4.1. Correlation Table of Dissolution Model Parameters with ka and F  
First 
Order 
Cinf 0.62                   
K1 0.82 0.23            
Tscale 0.92 0.40 0.86 
          
Hill 
Gamma 0.55 0.52 0.25 0.25          
Cinf 0.59 0.00 0.67 0.64 0.22         
MDT 0.82 0.79 0.63 0.81 0.26 0.40        
Makoid 
Banakar 
Cinf 0.83 0.92 0.49 0.71 0.46 0.18 0.92       
b 0.89 0.57 0.82 0.96 0.16 0.52 0.92 0.82      
Tmax 0.94 0.81 0.71 0.84 0.54 0.47 0.94 0.93 0.89     
Weibull 
Cinf 0.58 0.37 0.47 0.73 0.28 0.30 0.73 0.62 0.82 0.56    
Gamma 0.20 0.17 0.14 0.01 0.70 0.05 0.04 0.10 0.15 0.16 0.35   
MDT 0.33 0.01 0.28 0.38 0.34 0.24 0.25 0.16 0.40 0.16 0.64 0.08  
 ka 0.61 0.05 0.88 0.60 0.43 0.61 0.32 0.22 0.49 0.51 0.01 0.02 0.07 
  F Cinf K1 Tscale b Cinf MDT Cinf Gamma Tmax Cinf Gamma MDT 
   First Order Hill Makoid Banakar Weibull 
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It is observed in table 3.3.4.1. that some of the dissolution model parameters were 
more highly correlated than others with 𝐹 and 𝑘௔, respectively.  Dissolution parameters 
were added to the respective GLMs for the prediction 𝐹 and 𝑘௔ according to the 
previously specified criteria and without any other supervision.  The modeling process 
for prediction of both 𝑘𝑎 and 𝐹 ultimately resulted in the inclusion of three terms.  The 
included terms (𝐹୫ୟ୶ , 𝑇௠௔௫, and 𝑏) were all from the Makoid Banakar model.   The 
performance of the model derived for the prediction of 𝑘𝑎 and 𝐹 is illustrated in Figures 
3.3.4.1 and 3.3.4.2.  The F-statistics in tables 3.3.4.2.a and 3.3.4.3.a demonstrated that 
the parameterized models significantly predicted 𝑘𝑎 and 𝐹.  The type III sum of squares 
test in tables 3.3.4.2.b and 3.3.4.3.b showed that when each parameter is added last, the 
resulting reduction in the sum of squares error was significant in all of the cases.  Tables 
3.3.4.2.c and 3.3.4.3.c show the final parameter estimates and the associated standard 
error of the two models. 
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Table 3.3.4.2.a Sum of Squares Analysis for the Prediction of kୟ 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Model 3 0.16088118 0.053627 303.7001 <.0001 
Error 4 0.00070632 0.000177 
  
C. Total 7 0.16158750    
 
Table 3.3.4.2.b Tests for Type III SS Error for the Prediction of kୟ 
Source Sum of Squares F Ratio Prob > F 
F୫ୟ୶(୑ୟ୩୭୧ୢ ୆ୟ୬ୟ୩ୟ୰)  0.02345937 132.8548 0.0003 
T୫ୟ୶ 0.04285786 242.7121 <.0001 
b 0.12314352 697.3848 <.0001 
 
Table 3.3.4.2.c Parameter Estimates for the Prediction of 𝒌𝒂 
Term Estimate Std Error Prob>|t| 
Intercept 0.4644768517 0.0292334485 <.0001 
𝐹௠௔௫(ெ௔௞௢௜ௗ ஻௔௡௔௞௔௥) -0.004057305 0.0003520052 0.0003 
𝑇௠௔௫ 0.0714231734 0.0045845158 <.0001 
𝑏 0.0543586598 0.0020584129 <.0001 
 
 
Figure 3.3.4.1. Model for the Prediction of 𝒌𝒂 
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Table 3.3.4.3.a Sum of Squares Analysis for the Prediction of F 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Model 3 0.32119351 0.107065 2074.0135 <.0001 
Error 4 0.00020649 0.000052 
  
C. Total 7 0.3214 
   
 
Table 3.3.4.3.b Tests for Type III SS Error for the Prediction of F 
Source Sum of Squares F Ratio Prob > F 
b  0.03080006 596.6473 <.0001 
F୫ୟ୶(୑ୟ୩୭୧ୢ ୆ୟ୬ୟ୩ୟ୰)  0.01400927 271.3824 <.0001 
T୫ୟ୶ 0.01963117 380.2877 <.0001 
 
Table 3.3.4.3.c Parameter Estimates for the Prediction of 𝑭 
Term Estimate Std Error Prob>|t| 
Intercept 0.261519 0.009931 < 0.0001 
𝑏  0.103141 0.004223 < 0.0001 
𝐹௠௔௫(ெ௔௞௢௜ௗ ஻௔௡௔௞௔௥) 0.001417 8.6E-05 < 0.0001 
𝑇௠௔௫ 0.003271 0.000168 < 0.0001 
 
 
 
 
 
Figure 3.3.4.2. Model for the Prediction of 
𝑭 
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The final error statistics for 𝐴𝑈𝐶 and 𝐶𝑚𝑎𝑥 are reported in table 3.3.4.4.  The 
mean internal percent error for 𝐴𝑈𝐶 was observed to be 35% lower than the external 
data, while the mean percent error for 𝐶𝑚𝑎𝑥 in the external data was 34% lower as 
compared to the internal data. However, the observed differences in the means were 
not statistically significant in any of the cases.  The model was also within the % PE 
criteria defined by the FDA for both internal and external 𝐴𝑈𝐶 and 𝐶𝑚𝑎𝑥 
predictions. Ultimately, the predicted vs. observed values for the 𝐴𝑈𝐶 and 𝐶𝑚𝑎𝑥 
values were well correlated with low residuals (see table 3.3.4.4.).   
 
Table 3.3.4.4. Parameter Estimates for the Prediction of AUC, Cmax and Tmax 
 Study Product ID PE: AUC PE: Cmax PE: Tmax 
In
te
rn
al
  
D
at
a 
Se
t 
Meyer et al. 1992 
1 4.20 1.06 6.2 
2 2.79 2.61 4.8 
3 7.41 4.09 7.8 
4 5.41 7.14 6.6 
Olling et al. 
1 1.22 2.19 4.2 
2 6.09 1.02 5.9 
3 4.36 4.26 8.9 
4 1.69 2.39 2.3 
Ex
te
rn
al
 
D
at
a 
Se
t 
Meyer et al. 1998 
1 3.18 5.13 2.9 
2 6.13 0.43 4.8 
3 7.55 0.43 5.2 
4 5.56 2.14 6.7  
 PE = percent error 
 
Table 3.3.4.5 Summary Statistics for the Prediction of AUC and Cmax 
Summary PK Metric Summary Statistics Values 
AUC 
(ug/ml/hr) 
Predicted vs. Observed: R2 0.99 
Predicted vs. Observed: RMSE 5.97  
Cmax 
(ug/ml) 
Predicted vs. Observed: R2  
Predicted vs. Observed: RMSE 
0.99 
0.099 
Tmax 
(hrs) 
Predicted vs. Observed: R2  
Predicted vs. Observed: RMSE 
0.99 
0.21 
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3.4 Discussion and Conclusion 
The specific aim of this chapter was to generate an IVIVC framework that could 
accurately predict mean in vivo exposure.  Under an ideal scenario, this would be 
performed using a prospective clinical trial.  Here, plasma concentration profiles would 
be generated within a consistent study population by deliberately altering features of 
the drug product in a risk-based fashion to achieve an appropriate range of in vitro-in 
vivo performance.   While the performance of a prospective clinical trial could not be 
performed for this work due to logistic reasons, actions were taken to overcome this 
limitation using the wealth of publically available paired in vitro-in vivo data (i.e. 
dissolution data and its corresponding plasma concentration data) collected on 
carbamazepine from a variety of drug product manufacturers.  The internal data used 
to calibrate the IVIVC described in this chapter was generated using eight products.  
Each product came from a unique lot that spanned across five different drug product 
manufacturers.  The data used to evaluate the external predictability of the IVIVC was 
generated using four drug products, including three drug products from unique 
manufacturers and one new lot of the reference product.  In the end, the accuracy of the 
generated model met regulatory, as well as in-house, criteria for internal and external 
predictability.  The ability to accurately generate an IVIVC using such a diverse drug 
product data set supports the generalizability of IVIVC for future applications despite 
the practical study limitations.  The reliability of this IVIVC will be assumed for the 
activities of subsequent chapters. 
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Chapter 4: “Bottom-Up” Convolution of IVIVC with 
Population-level PK Variance  
4.1 Introduction  
The previous chapter was built upon the concept that the rate and extent of per oral 
carbamazepine absorption from a tablet was primarily a function of its dissolution 
behavior.  Chapter 4 is focused on mechanistically modeling pharmacokinetic 
pathways thus allowing the observed inter-subject variability to be recovered by 
simulations.  The specific aim is to account for population level pharmacokinetic 
variance within the previously developed pharmacokinetic model of the IVIVC in a 
physiologically-based manner (see section 2.4 for a discussion on physiologically-
based pharmacokinetic modeling).   
The IVIVC developed in the previous chapter predicted a mean plasma 
concentration profile. While this was informative, the statistical assessment of 
bioequivalence ultimately requires that intersubject variability be considered.  Chapter 
4 demonstrates how this requirement was fulfilled by first embedding and refining 
physiologically-based clearance pathways within the previously developed IVIVC, and 
then performing simulations wherein the covariation of physiological parameters was 
propagated across a population in a rational manner.  The first step used the extrapolated 
results of in vitro studies using models of physiologic systems to predict systemic in vivo 
performance.258  The in vitro-in vivo extrapolation of population-based performance is 
considered a “bottom-up” approach to pharmacokinetic modelling.  This is because it 
predicts in vivo pharmacokinetic outcomes using mechanistic information that has been 
independently determined a priori.  This approach models the concentration profile of a 
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compound using i) first principles of human physiology, ii) the results of rigorously 
performed federal health interview surveys, and iii) meta-analyses focused on the 
abundance of metabolizing pathways.  The integration in vitro assays, in vivo data, and 
in silico modeling was performed to support the movement towards a more efficient 
means of estimating the pharmacokinetic conditions expressed in therapeutic populations 
during actual clinical practice.  
 
4.2 Methods and a priori Data  
4.2.1 Modeling Overview 
A five-step strategy was used in this chapter to model the systemic exposure of 
carbamazepine.  The first step was to refine the physiologically-based clearance pathways 
for carbamazepine.  This required the definition of an intravenous physiologically-based 
pharmacokinetic model wherein intravenous dosing data was ultimately used to confirm 
intrinsic clearance parameters.  The use of intravenous dosing for the evaluation and 
refinement of clearance pathways eliminates sources of bias related to absorption.  The 
second step was to model intrinsic clearance using data collected from in vitro systems.  Here, 
intrinsic clearance was defined as the rate of drug removal absent any constrains from 
limiting effects (e.g. perfusion rate of the liver).  The third step was to extrapolate the in vitro 
intrinsic clearance to whole organ clearance.  This was performed using the established 
relationship between height and weight as a function of age and gender for the calculation of 
body surface area (BSA).  The relationship between BSA and liver volume was combined 
with an understanding of liver density to derive a value for the mass of microsomal protein.  
Using the microsomal weight of the tissue and blood flow to the tissue, the last step for 
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extrapolating whole organ clearance was to scale in vitro clearance by applying the percent 
abundance of the specific metabolizing enzymes within the liver as reported by 
pharmacogenomic meta-analyses.  The fourth step for mechanistically modeling the 
systemic exposure of carbamazepine was to confirm the accuracy of the extrapolation 
process using intravenous data.  The fifth step was to recover the observed variability in the 
summary pharmacokinetic parameters 𝐴𝑈𝐶, 𝐶௠௔௫ and 𝑇௠௔௫.  This was performed updating 
a priori distributions placed overtop pharmacokinetic model parameters.  The combination 
of these steps facilitated the testing of more relevant clinical scenarios via the use of 
correlated Monte Carlo resampling. 
 
4.2.2 PBPK Modeling Software 
Physiologically-based pharmacokinetic modeling was performed using SimCYP 
Version 17 (Certara Ltd. Inc., Princeton NJ). The Simcyp®  population-based simulator is a 
platform and database that has been used for mechanistic modelling and simulation of 
physiologic processes involved with the oral absorption, distribution, metabolism, 
metabolically-based drug–drug interaction, and excretion of drugs in healthy and disease 
populations (e.g. populations categorized by age, disease, race).  Optimization algorithms 
within the platform, specifically the Nelder-Mead algorithm, were used to recover in vivo 
data via targeted parameter estimation.  
 
4.2.3 Intravenous Model 
The works of Rowland and Jones served as the foundation for the physiologically-based 
pharmacokinetic modeling of this chapter. 259-262  The modeling assumptions were as 
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follows: i) intercompartmental transport occurs via the blood, ii) drug concentrations in 
efferent blood, and blood within tissues, are equal, iii) there is instantaneous equilibrium of 
drug between tissue and blood within the tissue (i.e. perfusion rate limited clearance 
kinetics), and (d) only unbound drug is eliminated.  A structural representation of the model 
is provided in Figure 4.2.3.1.   
 
 
 
 
 
 
 
 
 
 
 
 
Two sites of elimination will be considered in the model: the gut and liver. The 
differential equations that have been selected to define the physiologically-based 
pharmacokinetic model within SimCYP® following intravenous dosing are listed in Table 
4.2.3.1.   From the first equation in this Table (4.2.3.1), is it clear that the concentration of 
drug in the liver, 𝐶௅, is an important factor for describing the change in drug concentration 
in the central compartment.  As described by Equation 4.2.3.3, the amount of drug in the 
Figure. 4.2.3.1 Structural form of the physiologically based pharmacokinetic model 
Q – blood flow rate; HV- hepatic vein; HA – hepatic artery; PV – portal vein 
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liver, 𝐴௅, is in part a function of the drug in the portal vein, 𝐴௉௏.  In Equation 4.2.3.2 it is 
seen how fraction of drug in the villous blood from that escapes gut metabolism, 𝐹 , 
shapes 𝐴௉௏. The fraction of drug that escapes gut metabolism term is described by Yang 
et al.263,279  Not only will this term differentially account for metabolic clearance from 
gut enzymes, but it will also account for permeability based clearance of drug into the 
gut lumen (𝐶𝑙௣௘௥௠).  The impact of the fraction of drug metabolized in enterocytes (1 
- 𝐹 ) is minimal for the intravenous model. 
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Table 4.2.3.1. Foundational Equations for Intravenous 
Physiologically Based Pharmacokinetic Model 
Eq .4.2.3.(see below) 
1) 
𝑑𝐴௖௘௡௧ 𝑑𝑡⁄ = 
𝑖. 𝑣.  𝑖𝑛𝑓𝑢𝑠𝑖𝑜𝑛 𝑟𝑎𝑡𝑒 +  (𝑄ு௏ ∗ 𝐶௅) −  (𝑄ு஺ ∗
஼ಽ
௄௣/[஻:௉]
) −  (𝑄ீூ.௩௔௦. ∗  𝐶௖௘௡௧)  
2) 𝑑𝐴௉௏ 𝑑𝑡⁄ = [൫𝑄௉௏ − ∑ 𝑄௩௜௟௟௜,௡) ∗ 𝐶௖௘௡௧] + ∑ 𝐹 ,௡൫𝑄௩௜௟௟௜,௡ ∗ 𝐶௖௘௡௧൯ −  (𝑄௉௏ ∗ 𝐶௉௏)  
where, 
 𝐹 = ொ೒ೠ೟
ொ೒ೠ೟ା௙௨೒ೠ೟∙஼௅௨ ಸ,೔೙೟ (ೠ೙್೚ೠ೙೏)
; 
 𝑄௚௨௧ = (𝐶𝑙௣௘௥௠ ∙ 𝑄௩௜௟௟௜,௡)/(𝐶𝑙௣௘௥௠ + 𝑄௩௜௟௟௜,௡); 
 𝐶𝑙௣௘௥௠ = 𝑆 × 𝑃௘௙௙,௡ 
3) 
𝑑𝐴௅ 𝑑𝑡⁄ = 
(𝑄ு஺ ∗ 𝐶௖௘௡௧) + (𝑄௉௏ ∗ 𝐶௉௏) −  ቀ𝑄ு௏ ∗ 𝑓𝑢஻
஼ಽ
௄௣ [஻:௉]⁄
ቁ −  ቀ𝐶𝐿௅ ∗ 𝑓𝑢஻
஼ಽ
௄௣ [஻:௉]⁄
ቁ  
4) 𝐶𝑙் = (𝑄் × 𝑓𝑢 × 𝐶𝐿்,௜௡௧ (௨௡௕௢௨௡ௗ))/(𝑄் + 𝑓𝑢 × 𝐶𝐿்,௜௡௧ (௨௡௕௢௨௡ௗ));  
where,  
 T=[liver, intestinal segment ‘n’],  fu = ‘fuB’;  
T=liver;  
T= intestinal segment ‘n’; 
Te
rm
s a
nd
 S
ub
sc
rip
ts
 Q = blood flow (L/hr) 
C = concentration 
(mg/L) 
CL = whole tissue 
clearance (L/hr) 
A = amount (mg) 
CLT,int(unbound) = 
unbound intrinsic 
clearance in tissue 
cent = central 
compartment 
T = tissue 
G = gut tissue 
L = liver tissue 
villi = villous 
vasculature 
HV = hepatic vein 
 [𝑩: 𝑷] = blood:plasma 
partition ratio 
 Kp = tissue to plasma partition 
coefficient 
 fu=fraction unbound in plasma 
 fuB=fraction unbound in blood,  
      =fu ⨉ Cp,total/CB,total 
 fugut = fraction unbound in gut 
 Peff = effective permeability 
FG = fraction of drug 
that escapes gut 
metabolism  
S = available surface 
area 
v. = venous 
u= unbound 
n = nth region in the 
GI tract 
fugut = 1; assumes insufficient time for plasma protein binding equilibrium or erythrocyte uptake before the drug is removed from the 
basolateral side of the enterocyte263
For references used to identify the center and spread of anthropomorphic inputs (i.e. drug-independent, physiological factors) of the 
ADAM model see Jamei et al.
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The tissue to plasma partition coefficient (𝐾𝑝) in Equations 4.2.3.1 and 4.2.3.3 was 
calculated using the set of equations derived by Rodgers et al. based on the ionization for a 
given molecule of interest.264  The derived equation for a neutral compound (such as 
carbamazepine) is: 
Eq. 4.2.3.5) 𝐾௣ = 𝐾௣௨ × 𝑓𝑢      
where     
𝐾௣௨ = 𝑓ாௐ + 𝑓ூௐ + (𝑃 ∙ 𝑓ே௅ + (0.3𝑃 + 0.7)𝑓ே௉)
+ (𝐾𝑎௉ோ[𝑃𝑅]்) 
 
The three major assumptions in Equation 4.2.3.5 are: i) Non-saturating conditions exist for all 
binding processes ii) Drug transport is a passive process, and iii) Each tissue has a well-stirred 
distribution model limited by blood perfusion.  Equation 4.2.3.5 required the determination of 
a compound’s affinity constant (𝐾𝑎௉ோ) for tissue binding protein where [𝑃𝑅]் is the 
concentration of protein in tissue T.  The binding protein for carbamazepine is albumin ([𝑃𝑅]்  
has been consistently reported for carbamazepine using in vitro techniques that include 
equilibrium dialysis, ultrafiltration, surface plasmon resonance, and various chromatographic 
methods 265-268).  The plasma-to-liver and plasma-to-gut ratio for albumin has been 
experimentally determined to be 11.6 and 6.33, respectively. 264,269-272  Lastly, Equation 
4.5.3.5 was parametrized with the octanol to water partition coefficient for unionised species 
(𝑃), and the fractional volume of tissue components (𝑓, where 𝐸𝑊 refers to extracellular 
water, 𝐼𝑊 refers to intracellular water, 𝑁𝐿 refers to neutral lipids and 𝑁𝑃 refers to neutral 
phospholipids; see Rodgers and Rowland [2007] and Poulin and Theil [2002] for 
experimentally determined reference values273,274).  The interstitial fluid-to-plasma 
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concentration ratio will be considered as a whole organ-to-plasma ratio, an assumption that 
aligns with the well-stirred model of the liver and gut segment.  The values and references for 
the drug specific parameters are reported in Table 4.3.1.1.  
 
4.2.4 Parameterization, Extrapolation, and Refinement of in vivo Intrinsic 
Clearance  
 
The intrinsic clearance of a tissue 𝑇 (𝐶𝑙்,௜௡௧, where the intrinsic clearance of the gut 
or liver 𝑇 equals 𝐺 or 𝐿, respectively), represents its ability to deplete the concentration 
of a compound absent rate limiting factors such as blood flow or tissue partitioning.  
The major clearance pathways for carbamzepine include metabolism cytochrome P450 
(CYP) and the Uridine 5'-diphospho-glucuronosyltransferase (UGT).  The specific 
isozymes of these pathways (discussed in section 2.2.3) have been identified as 
CYP3A5, CYP3A4, CYP2B6, and UGT2B7.   
The methodologies used for predicting organ clearance from in vitro systems (e.g., 
hepatocytes and microsomes) have been described in detail by Houston and others, and 
have been validated extensively.275-278   Briefly, the in vitro data in this work was 
collected using substrate depletion assays.  The key inclusion criteria for in vitro 
clearance studies was as follows:  
1) The use of validated in vitro systems, which included but was not limited to 
harvested liver cells and recombinant enzymes systems 
2) The reporting of unbound in vitro intrinsic clearances by accounting for free 
fraction of drug in the in vitro incubation, fu୧୬ୡ  
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3) The normalization of clearance parameters on a ‘per milligram of metabolizing 
enzyme’ basis (or per cell basis if hepatocytes are being used) as defined by the 
incubation media   
The general procedure employed by the studies was to incubate various concentrations 
of carbamazepine with a fixed concentration of commercially sourced, recombinantly 
expressed, monoclonal isozymes.  The carbamazepine was quantified for each 
incubation design point using a suitable analytical method (in most cases liquid 
chromatography coupled mass spectroscopy).  The slope for the concentration vs time 
was normalized for nonspecific binding and then recorded as the clearance of 
carbamazepine.  The process was then repeated at a subsequent carbamazepine 
concentration.  Once the process was performed at all of the carbamazepine 
concentrations for each of the isozymes the ‘clearance-vs-carbamazepine 
concentration’ profiles were modeled according to typical Michaelis–Menten kinetics.  
This type of kinetic behavior is defined by the following 
equation: 
 Eq. 4.2.4.1) 𝑟𝑎𝑡𝑒 𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 = 
௏೘ೌೣ∙[஺௉ூ]
௄೘ା [஺௉ூ]
 . 
 
Here, 𝑉௠௔௫ represents the maximum rate achieved by the system at the saturating 
substrate concentration.  This plateau was observed/reported in all of the studies. The 
Michaelis-Menten constant 𝐾௠ is the substrate concentration at which the reaction rate 
is half of 𝑉௠௔௫.  In the context of pharmacokinetic modeling, the intrinsic clearance of 
an API that follows Michaelis-Menten is defined in the following manner: 
Eq. 4.2.4.2) 𝐶𝑙௜௡௧ = 
௏೘ೌೣ
௄೘
 . 
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The unbound intrinsic clearance (i.e. 𝐶𝐿்,௜௡௧ (௨௡௕௢௨௡ௗ)) in the liver and gut was defined by 
Equations 4.2.4.1 and 4.2.4.2.  These equations follow works reported by Rowland et al. 
(2010,2011) and Almond et al. (2009,2016).262,279-281 Here, a standardized scaling 
procedure was used to determine the intrinsic clearance of whole organs/tissues (i.e. 𝐶𝐿௅ 
and 𝐶𝐿ீ) from in vitro intrinsic clearances (see Houston et al. for reviews282-286). 
 
Table 4.2.4.1. Foundational Equations for Unbound Intrinsic Clearance in the 
Physiologically Based Pharmacokinetic Model 
Eq. 4.2.4.(see below) 
1) 
𝐶𝐿𝑢 ீ,௜௡௧ (௨௡௕௢௨௡ௗ) = ∑ ൭∑ ∑
௏ౣ౗౮,೛,೐(೒ೠ೟)
௄೘,೛,೐ା௙௨೒ೠ೟
಴೒ೠ೟
಼೛ [ಳ:ು]⁄
∗ ଵ
௙௨೔೙೎
௠
௘ୀଵ
௡
௣ୀଵ ൱ଽ௦ୀଵ   
where, 
𝑉௠௔௫,௣,௘,௚௨௧ = 𝐼𝑆𝐸𝐹௣,௘ × 𝑉௠௔௫,௣,௘(௩௜௧௥௢) × 𝐸𝑛𝑧ீ,௣,௘ 
2) 
𝐶𝐿𝑢 ௅,௜௡௧ (௨௡௕௢௨௡ௗ) = ቆ∑ ∑
௏ౣ౗౮,౦,౛(ౢ౟౬౛౨)  
௄೘,೛,೐ା௙௨ಳ
಴ಽ
಼೛ [ಳ:ು]⁄
∗ ଵ
௙௨೔೙೎
௠
௘ୀଵ
௡
௣ୀଵ ቇ  
where, 
𝑉௠௔௫,௣,௘,௟௜௩௘௥ = 𝐼𝑆𝐸𝐹௣,௘ × 𝑉௠௔௫,௣,௘(௩௜௧௥௢) × 𝐸𝑛𝑧௅,௣,௘ 
Terms L= Liver; G= Gut; p = clearance pathway (e.g. CYP, UGT); e = isoform (e.g. CYP2C9, CYP3A4);  fuinc = in vitro fraction unbound in the incubation 
 
The clearance parameters derived from recombinant in vitro systems were scaled to human-
derived in vitro systems using the respective inter-system extrapolation factor (ISEF).  These 
values are reported by the suppliers of recombinant metabolizing enzyme systems and are 
based on methods described by Proctor et al.287,288  This allowed whole organ clearances to 
be calculated using the abundance of the 𝑒௧௛ isoform (𝐸𝑛𝑧௅,௣,௘) and the amount of 
microsomal protein per gram of human liver (MPPGL) or length of intestinal segment (𝑠) 
(MPPIL) multiplied by the liver mass or intestinal segment length.289-293 
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The time dependent amount of enzyme in the metabolizing tissue, 𝐸𝑛𝑧்,௣,௘ in Equations 
4.2.4.1 and 4.2.4.2, will be calculated using Equations 4.2.4.3 and 4.2.4.4.  Equation 4.2.4.3 
includes the induction terms: 𝐸௠௔௫ and 𝐸𝐶ହ଴.  The maximum fold-wise induction to the 
synthesis rate of enzyme generation is 𝐸௠௔௫, while the concentration of inducer that results 
in half max induction is 𝐸𝐶ହ଴.  These terms account for the auto-inductive effects of 
carbamazepine and any other concomitantly administered inducers.  These values were 
informed by  quantitative transcriptomics studies reported by Almond et al. in the relevant 
clearance pathways (see Chapter 2).  Verification of these values were based on the in silico 
confirmation that a mean three-fold autoinduction would be complete within a 1-2 week 
period as reported in the package insert for Tegretol.294 
The liver weight in Equation 4.2.4.4. was calculated by multiplying liver density (1.051 
g/L(295)) by individualized liver volumes.  Liver volumes and total intestinal lengths were 
individualized using the correlated Monte Carlo methods described in section 2.4.3.296  As 
previously detailed, the statistical sampling method randomly drew from prior distributions 
Table 4.2.4.2. Foundational Equations for Unbound Intrinsic Clearance in the 
Physiologically Based Pharmacokinetic Model 
Eq. 4.2.4.(see below) 
         3)  
𝑑𝐸௧ 𝑑𝑡⁄ = (𝑟𝑎𝑡𝑒 𝑜𝑓 𝑠𝑦𝑛𝑡ℎ. ) × (𝑖𝑛𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟) − (𝑟𝑎𝑡𝑒 𝑜𝑓 𝑑𝑒𝑔. ) 
= 𝐸଴ × 𝑘௦௬௡ × ቀ1 +
ா೘ೌೣ×[ூ௡ௗ]೟
ா஼ఱబା[ூ௡ௗ]೟
ቁ − 𝑘ௗ௘௚ × 𝐸௧  
        4)    
𝐸଴= 𝑏𝑎𝑠𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑒𝑛𝑧. 𝑖𝑛 𝑡𝑖𝑠𝑠𝑢𝑒 
= (𝑀𝑃𝑃𝐺𝐿 𝑜𝑟 𝑀𝑃𝑃𝐼௟)  × (𝑙𝑖𝑣𝑒𝑟 𝑤𝑡. 𝑜𝑟 𝑖𝑛𝑡𝑒𝑠𝑡. 𝑙𝑒𝑛𝑔𝑡ℎ) × (𝑒𝑛𝑧. 𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒) 
Terms 
 [𝑰𝒏𝒅] = free inducer conc.; 𝜸= Hill eqn. term;  𝑬𝒎𝒂𝒙 = max induction,  fraction of 
vehicle/control; 𝑬𝑪𝟓𝟎 = concentration that supports half-Emax  
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of covarying anthropomorphic values for height and weight.  The algorthim began by defining 
upfront the baseline patient demographics from which subsequent samples would be drawn.  
The demographics specifically included the age range and percent of female subjects within 
the trial.  Samples were drawn from height and weight crosstabs based on the synthetic 
patient’s age and gender.  BSA was calculated from these values using the previously 
discussed Du Bois Equation and individualized liver volumes were simulated using the meta-
analysis of Johnson et al. which correlated BSA with liver volume.297,298  Liver weight was 
then calculated using the liver density reported by Heinemann et al.299  Similarly, total 
intestinal lengths (where each segment, i.e. duodenum, jejunum, or ileum, is a proportion of 
the total length) were generated using the correlation between BSA and total intestinal length 
as reported by Valentin.300,301 
It is important to note that the results of rigorously conducted federal health interview 
studies (i.e. NHANES, NHIS, EHIS, etc.) have allowed the covariance structures between 
age, gender, height, weight and other anthropomorphic values to be modeled by researchers.  
Data libraries based on meta-analysis of such reports are provided with the SimCYP® 
software and regularly updated by a consortium of industry, academic, regulatory, and 
SimCYP® scientists to describe healthy and diseased populations (so called  “population 
libraries”).  The information in these libraries, coupled with the physiologically based 
pharmacokinetic models, were used to account for the physiologic characteristics that shape 
drug exposure. This enabled the representative simulation of inter-individual drug exposure 
variability.302  The remaining drug specific data necessary to perform the PBPK modeling of 
carbamazepine, as per Equations 4.2.3.1 - 4.2.4.4, is provided in Table 4.3.1.1.  (see results 
section). 
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4.2.5 Intravenous Dosing Studies 
Data on plasma concentration profiles and pharmacokinetic parameters following 
intravenous dosing was collected from the 2012 intravenous dosing study by Marino et 
al.122  The details of this study are covered in  chapter 2 section 2.2.3.  Briefly, the study 
used liquid chromatography-coupled mass spectroscopy to quantify the elimination of a 
single 100mg intravenous dose of radio-labeled carbamazepine.   
 
4.2.6 Refine and confirm clearance parameters using intravenous dosing 
studies 
Evaluation of the intravenous physiologically based pharmacokinetic model accuracy 
was performed relative to the mean responses observed in the Marino et al. study.303  The 
summary pharmacokinetic metric used for this activity was apparent systemic plasma 
clearance (𝐶𝐿௦௬௦).304 Each 𝐶𝐿௦௬௦ was calculated by 𝐶𝐿௦௬௦ = 𝑘௘ ∙ 𝑉ௗ, where 𝑘௘ is terminal 
rate constant of each simulated profile and 𝑉ௗ = 𝐷𝑜𝑠𝑒/(𝑘௘[𝐴𝑈𝐶]଴ஶ).  Here, a mean response 
was collected from simulations run using the age range and the proportion of females 
reported in the Marino et al. study as the starting point for the previously described correlated 
Monte Carlo algorithm.  These basis values were 18-61 years (similar to those reported in 
the per orally dosed in vitro-in vivo studies by Meyer et al. and Olling et al.) and 51%, 
respectively.  The 𝐶𝐿௦௬௦ generated from the simulations were compared to those observed 
in the study on the basis of the percent error.  Ultimately, a test for zero slope of residuals vs. 
observed plot was used as the test for model fit of the intravenous data and to justify 
successful physiologically-based modeling of the clearance pathways.   
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After verifying the accuracy of the clearance model, it was then inserted into the 
pharmacokinetic model for per oral absorption.  The accuracy assessment was again 
undertaken.  This time the evaluation was performed using the mean results from the per 
orally dosed Meyer et al. and Olling et al. studies to confirm Equations 4.2.4.1 and 4.2.4.2 
that had been appropriated, parameterized and integrated within a physiologically based 
pharmacokinetic model now based on a per oral route of administration (see Equations 
4.2.6.1 and 4.2.6.2).  
 
Table 4.2.6.1. Equations for Physiologically Based Pharmacokinetic Model  
Based on a Per Oral Route of Administration 
Eq 4.2.6.(see below) 
1) 𝑑𝐴௖௘௡௧ 𝑑𝑡⁄ = (𝑄ு௏ ∗ 𝐶௅) −  (𝑄ு஺ ∗
஼ಽ
௄௣/[஻:௉]
) −  (𝑄ீூ.௩௔௦. ∗  𝐶௖௘௡௧)  
 
2) 
 
𝑑𝐴௉௏ 𝑑𝑡⁄ = 
[൫𝑄௉௏ − ∑𝑄௩௜௟௟௜,௡) ∗ 𝐶௖௘௡௧] + ∑𝐹 ,௡൫𝑄௩௜௟௟௜,௡ ∗ 𝐶௖௘௡௧൯ + (𝐹 ∙ 𝑘௔ ∙ 𝐷𝑜𝑠𝑒)
−  (𝑄௉௏ ∗ 𝐶௉௏) 
where, 
 𝐹 = ொ೒ೠ೟
ொ೒ೠ೟ା௙௨೒ೠ೟∙஼௅௨ ಸ,೔೙೟ (ೠ೙್೚ೠ೙೏)
; 
 𝑄௚௨௧ = (𝐶𝑙௣௘௥௠ ∙ 𝑄௩௜௟௟௜,௡)/(𝐶𝑙௣௘௥௠ + 𝑄௩௜௟௟ ,௡); 
 𝐶𝑙௣௘௥௠ = 𝑆 × 𝑃௘௙௙,௡ 
 
Once the per oral model was demonstrated to be appropriately centered on the mean 
responses from small, strategically selected in vivo trials, the goal of recovering 
intersubject response variance was pursued. 
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4.2.7 Perform Simulation to Recover Observed Levels of Pharmacokinetic 
Variance 
 
Having the ability to simulate inter-subject variance within an IVIVC via Monte 
Carlo resampling algorithms is important.  Such capabilities allow stochastic variability 
to be accounted for during the prediction of plasma concentration profiles thus 
providing a means by which traditional variance-based biostatistical assessments can 
be performed.  However, it is critical that variance estimates concerning the respective 
system/drug dependent components of the physiologically based pharmacokinetic 
model be informed by data-driven means.  The plasma concentration-vs-time profile 
following oral administration of carbamazepine is largely a function of three 
components: the rate of elimination (i.e. apparent systemic plasma clearance, 𝐶𝐿௦௬௦), the 
rate of absorption (i.e. first order absorption rate constant, 𝑘௔), and the extent of 
absorption (i.e. bioavailability, 𝐹).  The accurate incorporation of inter-subject variance 
began with running simulations until convergence. This was defined as the mean and 
standard deviation of the distributions of pharmacokinetic metrics being < 1% upon the 
addition of an additional in silico trial.  For the pharmacokinetic parameters of interest, 
reported vs. simulated comparisons of variance were performed using Levene’s test.305   
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The Levene test is defined as: 
 𝐻଴: 𝜎ଵଶ = 𝜎ଵଶ = ⋯ = 𝜎௞ଶ  
  𝐻௔: 𝜎௜ଶ ≠ 𝜎௝ଶ   for at least one pair (𝑖, 𝑗) 
 
Test   Given a group of responses 𝑌 with sample of size 𝑁 
divided  
Statistic: 
into 𝑘 subgroups, where 𝑁௜ is the sample size of the 
  
𝑖௧௛ subgroup, the Levene test statistic is defined as: 
 
  𝑊 = 
௡ି௞
௞ିଵ
∙ ∑ ௡೔(௓
ത೔.ೖ೔సభ ି௓ത..)మ
∑ ∑ (௓ത೔.
೙೔
ೕసభ
ೖ
೔సభ ି௓ത..)మ
 
where 𝑍௜௝ has the following definition: 
   𝑍௜௝ = ห𝑌௜௝ − 𝑌෨௜.ห 
where 𝑌෨௜. is the mean of the 𝑖௧௛ subgroup. 
  
  ?̅?௜.  are the group means of the 𝑍௜௝ and ?̅?.. is the overall mean of the 
𝑍௜௝. 
 
Critical The Levene test rejects the null hypothesis if: 
Region: 
   𝑊 > 𝐹ఈ,௞ିଵ,ேି௞ 
where 𝐹ఈ,௞ିଵ,ேି௞ is the upper critical value of the 𝐹 
distribution with 𝑘 − 1 and 𝑁 − 𝑘 degrees of freedom at a 
significance level of α = 0.05. 
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The approach used to recover the coefficient of variation in clearance reported for 
each product in the Meyer et al and Olling et al. studies followed the work of Ke et al.306  
Specifically, the process began by modifying the Simcyp®  default value for the liver volume 
coefficient of variation, 𝐶𝑉௟௜௩௘௥ ௩௢௟௨௠௘ .  The modification was based on the distribution of 
values for liver weight as a percentage of body weight (simulated using the patient 
demographics reported by Meyer et al and Olling et al. and the liver weight individualization 
routine described in chapter 4 section 4.2.4).  The range of liver weight as a percentage of 
body weight reported by Johnson et al. served as the target during the 𝐶𝑉௟௜௩௘௥ ௩௢௟௨௠௘ 
optimization process.  In a similar manner, the 𝐶𝑉 for microsomal protein per gram of liver 
(MPPGL) as a function of age was modified to recover the range reported by Barter et al. in 
the age range studied by Meyer et al and Olling et al.293   Lastly, default values for the 𝐶𝑉 of 
the isozyme abundance were modified equally on a percent of default-basis for the recovery 
of the 𝐶𝑉 in clearance reported for each product in the Meyer et al and Olling et al. studies. 
Neither 𝐶𝑉ி nor 𝐹 was directly reported by Meyer et al or Olling et al.  Therefore, after 
𝐹 was calculated in-house using digitization software and noncompartmental analysis (see 
chapter 3).  The objective following the determination of 𝐹 was i) the determination 𝐶𝑉ி for 
each product and, ii) the derivation of a pair-wise model relating 𝐹 and 𝐶𝑉ி.  This 
relationship would provide the ability to build upon the IVIVC’s dissolution-based prediction 
of 𝐹 by assigning a 𝐶𝑉ி for a given 𝐹 value.  The basis for this model was observed clinical 
data, specifically the 𝐶𝑉′𝑠 for 𝐴𝑈𝐶 and 𝐶௠௔௫ reported by Meyer et al. or Olling et al. for 
each product.  This was because sensitivity analysis demonstrated a strong correlation 
between these summary pharmacokinetic metrics and 𝐹 which was independent of 𝑘𝑎 in the 
ranges observed in the studies (R2 for 𝐴𝑈𝐶 or 𝐶௠௔௫ vs 𝐹 was > 0.95 in both cases and < 0.20 
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when 𝑘௔ was the regressor for 𝐴𝑈𝐶 or 𝐶௠௔௫).  Therefore, 𝐶𝑉ி was assigned for a known 
value of 𝐹 and the relationship was modeled according to the following procedure. 
 
1. Determine 𝐹௔௩௘௥௔௚௘ for each product in the Meyer et al and Olling et al studies 
a. Performed by digitizing the plasma concentration profiles and 
performing noncompartmental analysis with a priori information on the 
volume of distribution to derive the critical pharmacokinetic parameters 
including 𝐹 for the recovery of the observed plasma concertation profile 
and thereby 𝐴𝑈𝐶 and 𝐶௠௔௫ (see chapter 3)  
2. Run simulations where each individual product’s 𝐹 value is sampled from a 
normal distribution centered on its respective 𝐹௔௩௘௥௔௚௘ where the spread is 
defined by an iteratively varied 𝐶𝑉ி 
a. Simulations were defined by the number of trials and the number of in 
silico patients within each trial 
b. The number of in silico patients was representative of that used in the 
Meyer et al. and Olling et al. studies (n=25) 
c. The number or trials was dictated by the convergence upon stable pooled 
mean of 𝐶𝑉஺௎஼  and 𝐶𝑉஼೘ೌೣ, respectively.  
3. For each simulation performed at a defined 𝐶𝑉ி the distribution of outputs (i.e. 
plasma concentration profiles) were recorded and the 𝐶𝑉஺௎஼  and 𝐶𝑉஼೘ೌೣ was 
recorded. 
4. The 𝐶𝑉஺௎஼  and 𝐶𝑉஼೘ೌೣ was plotted as a function of 𝐶𝑉ி 
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5. A 𝐶𝑉ி was individually assigned, based on this relationship, to each product’s 
𝐹௔௩௘௥௔௚௘ on the basis of recovering the reported product’s respective 𝐶𝑉஺௎஼  and 
𝐶𝑉஼೘ೌೣ  
a. Recovery is based on the Levene test for equal variance 
 
The last correlation to be modeled was between 𝑘௔ and the 𝐶𝑉 for 𝑘௔, 𝐶𝑉௞ೌ.  Sensitivity 
analysis shows that 𝑇௠௔௫ following a one-time dose is almost exclusively a function of ka 
when clearance pathways are held constant.  Meyer et al. and Olling et al. calculated 𝑇௠௔௫ 
as the time at which 𝐶௠௔௫ occurs.  They reported mean 𝑇௠௔௫ values for each product and 
the respective 𝐶𝑉 for 𝑇௠௔௫, 𝐶𝑉 ೘்ೌೣ.  Thus, the 𝑘௔ vs 𝐶𝑉௞ೌrelationship was established using 
a similar procedure for the refinement of the 𝐹 vs 𝐶𝑉ி, this time 𝐶𝑉 ೘்ೌೣ took the place of 
𝐶𝑉஺௎஼ and 𝐶𝑉஼೘ೌೣ and 𝑘௔/ 𝐶𝑉௞ೌ took the place of 𝐹/ 𝐶𝑉ி.   
 
4.3 Results and Discussion 
4.3.1 Recovery of Systemic Clearance: Mean and Variance 
The Simcyp® platform was able to successfully integrate: 
i) data generated using in vitro enzyme and cellular systems (as part of typical 
preclinical drug discovery activities), with  
ii) the relevant physicochemical attributes of carbamazepine (i.e. LogP value) and, 
iii)  demographic, physiological and genetic information of patients  
for the prediction in vivo pharmacokinetic parameters and profiles.    
An intrinsic functionality of the Simcyp®  platform is the inclusion of population 
variability that, with proper consideration of the covariation of parameters, allows for the 
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performance of virtual clinical trials and capturing of inter-individual differences in drug 
exposure where they occur. Using robust data the software provided a framework to 
model the covariation of physiological parameters and propagation of the respective 
variability across an in silico population in a rational manner using correlated Monte 
Carlo sampling to preserve the observed gender-age-weight-height-BSA-liver volume 
relationship (see chapter 2 section 2.4).  Thus, the fidelity of virtual individuals to real 
people was maximized by preventing the impossible combination of physiologic 
parameters.  For further reading on the history, development, computer science, and 
application examples of the software see Jamei et al.307 
Devising a physiologically based clearance model within the Simcyp®  platform that 
would accurately simulate plasma concentration profiles following intravenous dosing was 
the first step pursuant to the goal of this chapter (i.e. the  incorporation of physiologically 
based clearance pathways within the previously developed IVIVC for the mechanistic 
recovery of intersubject variance using correlated Monte Carlo simulations). The results of 
the literature search of drug specific data necessary to perform the physiologically based 
pharmacokinetic modeling of carbamazepine, as per Equations. 4.2.4.1 - 4.2.6.2, is provided 
in Table 4.3.1.1. 
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Table 4.3.1.1. Drug Specific Parameters of Carbamazepine in Physiologically Based Pharmacokinetic 
Model 
PK Property In vitro System Parameter Valuea Comments and References 
3A4 
(Enzyme Kinetics) HLM & Recombinant CYP 
(Baculovirus-Insect-
Cell-expressed) 
 
  Vmax 
  Km 
1.2 
120 Formation of Epoxide  
(Major metabolite)  
ISEF ≈ 1 
Cazali et al.308  
Huang et al.309 
Henshall at al. 310 
Pearce et al. 311 
Egnell et al.312 
Kerr et al. 313 
Korzekwa et al.314 
Pearce et al.315 
3A5 
(Enzyme Kinetics) 
Vmax 
  Km 
1.17 
119 
2C8 
(Enzyme Kinetics) 
Recombinant CYP 
(Baculovirus-Insect-
Cell-expressed) 
    Vmax                      0.67 
     Km                         760 
Formation of Hydroxylated 
Metabolites 
ISEF ≈ 1 
Cazali et al.Error! 
Bookmark not defined. 
Kerr et al. Error! 
Bookmark not defined. 
Pearce et al.Error! 
Bookmark not defined. 
UGT 
(Enzyme Kinetics) 
UGT2B7 V79 cells   Vmax 
  Km 
0.79 
200 
Also measured Vmax/Km in HLM, 
HIM and HKM. Allowed calculation 
of UGT tissue scalars for Liver, 
Intestine and Kidney (no need for 
ISEF) 
Staines et al 316 
Free fraction of 
CBZ in hepatocytes HLM  0.98  
Egnell et al. Error! 
Bookmark not defined. 
unbound percent in 
plasma  
plasma samples fup 25% 
Association constant (KA) = 5.3 × 103 
M−1 
Hooper et al.317 
Bonneton at al.318 
Tong et al.319 
Volume of 
Distribution in 
Central 
Compartment 
In vivo studies using 
IV dosing (L/kg)   V 0.8 
Rawlings et al.320  Eichelbaum et al.321 
Graves et al.322  Meyer et al.  
Olling et al.  
blood to plasma 
partition ratio 
Whole blood 
samples BP 1.07  Christiansen et al.323 
Log P   2.42 Octanol in water partition coefficient Novartis324 
Fraction unbound in 
incubations 
ultrafiltration 
following incubation fuinc 1 
Reference inclusion criteria: a) 
unbound intrinsic clearances be 
reported, or b)  fuinc be reported (see 
Pearce et al.). The majority reported 
unbound Clint. 
(see above) and… 
Egnell et al.Error! 
Bookmark not defined. 
Austin et al.325  
Fraction unbound in 
liver 
୔୐ୖ∗
౜౫౦
భశ౜౫౦
ଵା(୔୐ୖିଵ)∗
౜౫౦
భశ౜౫౦
    =    fu୪୧୴ୣ୰                    
0.76 
PLR: plasma-to-liver ratio of binding 
proteins; equal to 11.6 according to a 
unified algorithm by Peyret et al.326 for 
predicting partition coefficients in 
PBPK modeling studies 
Poulin et al.327 
Fraction unbound in 
gut 
Assumed to 
equilibrate with free 
concentration in 
blood  
fu୥୳୲   1 
Albumin is the binding protein for 
CBZ, it is made by hepatocytes, is 
contained mainly in the central 
compartment 
Tong et al.Error! 
Bookmark not defined. 
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After including the data from Table 4.3.1.1 into Equations 4.2.4.1 - 4.2.6.2, predictions 
were made using the 100mg i.v.  dosing strategy of Marino et al.  Figure 4.3.1.1.b 
demonstrates good agreement between the mean plasma concentration profile observed from 
the intravenous data in the Marino study and the profile generated from the simulations.  The 
Marino data used a clinical population.  This means that the population was already induced.  
The full profile of the data from Figure 4.3.1.1.b (data not shown) demonstrated that mean 
autoinduction ceased at 235.2 hours during chronic administration.  The accurate recovery 
of a the 100 mg intravenous dose under autoinduced conditions was apparent by a visual 
predictive check of Figure 4.3.1.1.b.  These results confirmed the accuracy of the  𝐸௠௔௫ and 
𝐸𝐶ହ଴ of 2.1 and 211 uM used in this study. 
The R2 for a plot of the observed vs simulated was 0.98 and the 95% confidence interval 
for the slope and bias terms for the data contained in Figure 4.3.1.1.b contained 1 and 0 
respectively (see Figure 4.3.1.1.c).  Additionally, the percent error for the simulated 𝐶𝑙௦௬௦ 
was 2.3% when compared to the reported value (see Figure 4.3.1.1.a). This demonstrated the 
initial suitability of the physiologically based model parameters for clearance.  The results 
from the modeling effort is graphically reported in Figure 4.3.1.1.c.  
 
 
 
 
 
 
   Terms: HLM: human liver microsomes; Vmax: Michaelis-Menten maximum rate of metabolite formation (pmol/min/mg of 
rCYP);  
Km: Michaelis-Menten constant (µM of substrate concentration); V: L kg-1
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The next step was to insert the physiologically based clearance model into the model for 
per oral carbamazepine administration used by the IVIVC of the previous chapter.  This 
activity had two requirements i) the accurate mean elimination rate prediction for each of the 
formulations reported by the formative per oral studies, and ii) an accurate recovery of the 
variance reported in these studies.   
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Horizontal axis: product ID - Vertical axis: ke (hr-1) - Whiskers: 95% CI 
Light bar: simulated results – Dark bar: observed results 
Figure 4.3.1.2. Observed and Simulated 𝒌𝒆 Values 
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The Figure 4.3.1.2 visually demonstrates how the simulated elimination rates aligned 
well with those observed.  The variance in the outcomes were refined by decreasing the 
default 𝐶𝑉 for 𝑀𝑀𝑃𝐺𝐿, liver volume, and reported isozyme abundances (i.e. 3A4, 3A5, 
2C8, and UGT 2B7) by 75% .  The final distributions for the liver weights are represented in 
Figure 4.3.1.3. as a percentage of body weight. 
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Table 4.3.1.2. presents the data used to construct Figure 4.3.1.2.  The ranges spanned by 
the 95% confidence intervals were all observed to overlap.  This signified that the differences 
between the mean 𝑘௘ reported for each product in the studies and those 𝑘௘ generated by the 
respective simulations were statistically insignificant.  Futhermore, the Levene test for equal 
variance was used to test for the equality of variances.  Here, the n of the test statistic was 
defined by the average number of patients in the Olling and Meyer studies (N=24).  It was 
observed that none of the variances were statistically significant (p > 0.05 for all of the cases).   
 
Figure 4.3.1.4. Distribution of Individualized MPPGL values  
Red lines represent the range of expected MPPGL values for the age interval investigated 
as reported by Barter et al.293 
MPPGL (mg/g) 
Figure 4.3.1.3. Distribution of Liver Weights  
Solid red lines represent the range of liver weight as a percentage of body weight values for the age 
interval investigated as reported by Johnson et al.254, the dashed line represented the reported median 
Liver weight as a percentage of body weight (%) 
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Table 4.3.1.2. Observed and  Predicted Values for 𝑘𝑒  
  Observed Simulated 
Study Product ke CV ke CV 
M
ey
er
 1
99
8 1 0.0178 0.19 0.017 0.17 
2 0.018 0.21 0.018 0.18 
3 0.0178 0.21 0.017 0.17 
4 0.0181 0.22 0.017 0.17 
M
ey
er
 1
99
2 1 0.01725 0.15 0.017 0.17 
2 0.01818 0.19 0.018 0.17 
3 0.01721 0.16 0.017 0.17 
4 0.0163 0.16 0.016 0.17 
O
lli
ng
 
1 0.0155 0.18 0.015 0.16 
2 0.017 0.18 0.016 0.16 
3 0.016 0.16 0.015 0.17 
4 0.0153 0.15 0.015 0.16 
 
 
It should be noted that the Olling et al. study did not directly report elimination rates.  
However, the study did report elimination half lives allowing 𝑘௘ to be calculated using the 
equation: 𝑘௘ = ln(2) /𝑡ଵ/ଶ .  Additionally, the 1998 Meyer et al. data was held back to be 
used for evaluating external predictability after the refinement process.  Despite this,  the 
model developed using the 1992 Meyer et al study and the Olling et al. could still accurately 
predict the center and spread of the clearances from the 1992 Meyer et al.  study. 
Once the clearances parameters, and their respective 𝐶𝑉 converged on values that 
satisfied the desired accuracy criteria, the final step was to refine the model that would 
accurately provide a 𝐶𝑉ி and 𝐶𝑉௞ೌ based on the predicted mean of 𝐹 and 𝑘௔.  As a review, 
this was achieved by: 
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i) varying the 𝐶𝑉 for 𝐹 and 𝑘௔ in a full factorial scheme from 0% to 150% for each 
of the four products reported by Meyer and Olling (total = 8) 
ii) recording the post-simulation 𝐶𝑉஺௎஼, 𝐶𝑉஼௠௔௫, and 𝐶𝑉்௠௔௫ 
iii) identify the 𝐶𝑉ி that returned the observed 𝐶𝑉஺௎஼ and 𝐶𝑉஼௠௔௫  
iv) identify the 𝐶𝑉 to each 𝑘௔ that returned the observed 𝐶𝑉்௠௔௫ 
v) constructing models that captured the respective 𝑘௔-vs.-𝐶𝑉௞௔ and 𝐹-vs.-𝐶𝑉ி 
relationships   
It is worth noting that one feature of the plasma profile simulation process was to preserve 
the analytical features of each study.  Specifically, the process used the same plasma 
concentration time points as those reported in the studies.  The analytical error reported for 
each respective study was also accounted for within the simulations.  This was accomplished 
by randomly adding the noise to the profile which was on the order of the observed analytical 
precision reported in the quality control sections for each study.   
The importance of using simulation time points that were consistent with those reported 
in the respective studies was to maximize the fidelity of the simulation.  Without this the 𝐶𝑉 
for the pharmacokinetic parameters would be conflated with the analytical error.  This is 
particularly important when considering the recovery of the 𝐶𝑉 for 𝐶௠௔௫ and 𝑇௠௔௫.  To 
illustrate this, consider Figure 4.3.1.5. which was taken from the original 1992 Meyer et al. 
study. 
 
 
 
 
Figure 4.3.1.5. Plasma Concentration Profiles from 1992 Meyer et al. 
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The square generated by the intersection between the red lines in Figure 4.3.1.5 indicates the 
region of 𝐶௠௔௫, and by extension 𝑇௠௔௫, that occurs in product 4.  Given that the authors of 
this study directly defined 𝐶௠௔௫as the largest concentration determined during drug-plasma 
quantification, noise in the analytical procedure method directly propagates to the reported 
variance in the 𝐶௠௔௫ metric.  Furthermore, it can be seen in the peak plasma concentration 
profile for product 4 is relatively broad.  While this type of performance makes capturing the 
true 𝐶௠௔௫less of an issue, it can result in estimations of 𝑇௠௔௫ which are sensitive to the 
sampling interval.  Therefore, it was important that the simulations in this chapter accounted 
for the procedural contributions to variance that were present in the 𝐶𝑉𝑠 for 𝑇௠௔௫ and 
𝐶௠௔௫reported by the formative studies. 
The resulting models are reported in Figure 4.3.1.6. a. and b. The accuracy with which 
the variance in 𝐴𝑈𝐶, Tmax, and 𝐶௠௔௫ was predicted is demonstrated in Table 4.3.1.3. The 
Figure 4.3.1.5. Mean carbamazepine plasma concentration. (○) Product 1; (●) 
Product 2; (■) Product 3; (▲) Product 3; Adapted from Meyer et al 139 
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ability to predict the mean 𝐴𝑈𝐶, Tmax, and 𝐶௠௔௫ was unchanged from the previous chapter 
since the center of the 𝑘௔ and 𝐹 were not altered. 
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The primary indicator for 𝑘𝑎 variance was the variance in 𝑇௠௔௫.  This was due to the 
strong correlation between 𝑘𝑎 and 𝑇௠௔௫across the range of bioavailabilities and clearance 
rates observed in this work (R2 > 0.95, individual simulation studies not shown). From 
Figure 4.3.1.6.a it was observed that as 𝑘𝑎 decreased, 𝐶𝑉௞௔ decreased.  Thus, it followed 
that quicker releasing carbamazepine products had earlier 𝑇௠௔௫values and were of higher 
variability.  This increased variability at faster release rates could have been driven by a 
host of factors, including those related to the scenario of higher concentrations being 
reached in the gut by faster dissolving products.  These higher concentrations could have 
lead to transient deviations from the sink conditions typically associated with drugs of 
higher permeability as is the case with carbamazepine.  Thus the higher variability in 
𝑇௠௔௫could have been driven by intersubject differences in permeability and gastrointestinal 
tract transit transiently defining the rate of absorption in such cases.  However, when the 
drug was released as slower rates, the saturated concentrations required to cause a 
temporary loss of sink conditions would not have been achieved.  Thus, the rate of systemic 
absorption would follow classical BCS class II behavior, i.e. dissolution existing as the 
rate-limiting step in absorption.  Given that the products were all marketed drug products, it 
is conceivable that they were manufactured under consistent conditions resulting in 
minimal within batch differences in performance.  Thus, the decreased variability of in vivo 
performance for products with a slower release was expected. 
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The observed trend in Figure 4.3.1.6.b was that as 𝐹 increased the 𝐶𝑉ி bioavailability 
decreased.  To explain this relationship, consider how, similar to the 𝑇𝑚𝑎𝑥-vs.-𝑘𝑎 
relationship, a strong correlation existed between 𝐹 and 𝐴𝑈𝐶, 𝐹 and 𝐶𝑚𝑎𝑥 (R2 > 0.95, 
individual simulation studies not shown). Thus, variability in 𝐴𝑈𝐶 and 𝐶𝑚𝑎𝑥 could be used 
as surrogates of 𝐶𝑉ி.    Thus, it was observed that as 𝐹 increased, the 𝐶𝑉ி required to recover 
the observed variabilities in 𝐴𝑈𝐶 and 𝐶𝑚𝑎𝑥, decreased.  This was likely due to the 
logarithmically increasing relationship of 𝐹 as a function of 𝑘𝑎.  This is to say that as 𝑘𝑎 
increases, 𝐹 increases and approaches 1.  Thus, significant variation in large 𝑘𝑎 values result 
in only minimal changes to 𝐹.  By extension, if an immediate release drug that is highly 
permeable quickly enters into solution (as was the case for drug with a high 𝑘𝑎) the 
probability of it not being thoroughly absorbed over its residence time in the gastro intestinal 
tract is minimal.  Since, carbamazepine undergoes little gut metabolism intersubject 
differences in permeability and GI transit do not substantially impact 𝐴𝑈𝐶.  It is only at slow 
dissolution rates (i.e. low values for 𝑘𝑎) where the drug has difficulty escaping the dosage 
form and thus variability in transit times and other physiologic factors begin to more 
substantially vary the value of 𝐹. 
 
 
 
 
Table 4.3.1.3. Observed vs Simulated CVs for Summary 
Pharmacokinetic Metrics 
 
 
  Observed CV Simulated CV 
Study Product AUC Cmax Tmax AUC Cmax Tmax 
 146 
 
O
lli
ng
 1 0.24 0.31 0.41 0.21 0.21 0.53 
2 0.31 0.29 1.05 0.28 0.25 0.72 
3 0.28 0.27 1.13 0.26 0.24 1.18 
4 0.20 0.16 0.47 0.21 0.21 0.53 
M
ey
er
 
19
92
 
1 0.15 0.20 0.51 0.22 0.22 0.53 
2 0.47 0.62 0.74 0.47 0.63 0.53 
3 0.2 0.18 0.72 0.21 0.21 0.57 
4 0.29 0.39 0.78 0.26 0.35 0.53 
M
ey
er
 
19
98
 
1 0.18 0.16 0.45 0.21 0.20 0.53 
2 0.19 0.15 0.43 0.21 0.19 0.61 
3 0.19 0.21 0.42 0.21 0.21 0.58 
4 0.17 0.15 0.31 0.21 0.19 0.50 
 
 
On average, the typical behavior of quicker dissolving drug products being absorbed at 
faster rates and to a consistently larger extent of absorption was observed.  While slower 
releasing products were possibly less sensitive to physiologic differences, the risk of 
incomplete absorption became higher.  Ultimately, the 𝐶𝑉 reported by Meyer (1992) and 
Olling differed insignificantly (p > 0.05) from the 𝐶𝑉 for 𝐴𝑈𝐶, 𝐶𝑚𝑎𝑥 ,and 𝑇𝑚𝑎𝑥 that 
were respectively simulated.  The products and reported 𝐶𝑉 for 𝐴𝑈𝐶, 𝐶𝑚𝑎𝑥 ,and 𝑇𝑚𝑎𝑥 
from the 1998 Meyer study were used as a test for external predictability.  Here the 
differences were again insignificant (p > 0.05) 
4.4 Conclusion 
This work leveraged the results of in vitro DMPK studies that are commonly performed 
during preclinical development to mechanistically identify metabolism pathways.  The 
product of these activities augmented the results of conventional clinical pharmacokinetic 
studies performed in vivo.  The combined product allowed for the systematic development 
of a physiologically based IVIVC.  While several researchers have attempted to construct 
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IVIVCs for Carbamazepine, this work is unique in that it i) achieved an acceptable level A 
prediction ii) while accounting for mechanistic metabolism pathways and iii) recovering the 
observed population level variance.  This work also accounted for the analytical error 
reported by the conventional clinical pharmacokinetic studies in the clinical trial simulation 
process.  Here, the analytical error reported in the referenced clinical trials was added to the 
in silico clinical trials to maximiz the fidelity of the simulation.  Following the successful 
development of this level of IVIVC it will be used as a tool to support the establishment and 
assurance of bioequivalence in a more clinically relevant manner by the mechanistic 
description of inter-subject variability. 
 
 
 
 
 
 
 
 
Chapter 5: Assuring Consistent Performance:  
F2 vs. Physiologically Based IVIVC – Associated Differences in 
Bioequivalence Errors and Design Spaces  
 
5.1 Introduction  
Chapter five represents the zenith of this project.  The quality attribute of interest 
discussed throughout this document has been consistent drug product performance wherein 
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dissolution tests are used as a means of assessment.  In this final chapter, a comparison was 
made between two methods for defining specifications of the dissolution performance.  The 
methods were based on the use of the conventional F2 statistic and the outputs of a 
physiologically based IVIVC nested within a clinical trial simulation (PB-IVIVC-CTS) 
platform.  As such, three core assessments were performed.  First, the difference between the 
respective dissolution specifications was assessed.  Second, the difference between the 
resulting product/process parameters design spaces was assessed.  Finally, a post hoc 
assessment of F2-based dissolution profiles using the PB-IVIVC-CTS platform for type I (α) 
and type II (β) errors in bioequivalence was performed pursuant to the central hypothesis of 
this work: 
  For an immediate release carbamazepine product, 
when a physiologically based IVIVC is coupled with a clinical trial 
simulation platform and used to assure the bioequivalence of an 
immediate release carbamazepine tablet, fewer errors for 
bioequivalence will be observed when compared to an approach that 
relies on the F2 criteria. 
Many of the current tenants of pharmaceutical quality were inspired by the work of 
Joseph Juran.  He was a luminaire of quantity management theory during the transitional 
period between the 20th and 21st centuries.    Juran’s definition of product quality (and indeed 
many other’s) can be distilled into two principles: first the presence of attributes within a 
product which confer user satisfaction following exposure/interaction, and second the 
reliability of such critical attributes.  The FDA rarely defines pharmaceutical quality 
explicitly.   At most, the FDA references a product’s quality in the context of its “suitability 
for an intended use”.  However, a survey of FDA guidances related to pharmaceutical quality 
provides further resolution of this definition.  Here, the “intended use” of a drug product is 
defined by the approved “label claims”.   The context of these claims are based, to a great 
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extent, on the clinical studies submitted by the product manufacturer and verified by FDA 
review.  Thus, the first aspect of a more integrated and resolved definition for pharmaceutical 
quality includes the product’s ability to meet the dosing, safety, and efficacy criteria 
identified in the labeling; and, by extension, used in the investigational batches used during 
clinical development.  Furthermore, the statutory requirement of drug products and 
substances to comply with the Federal Food, Drug and Cosmetic Act allows Juran’s second 
concept of quality, consistency, to be considered within an operational definition of 
pharmaceutical quality.  This act states that a drug not made in accordance with current good 
manufacturing processes (cGMP) is deemed "adulterated." CGMP regulations assure that 
drugs meet the safety, identity, and strength requirements of the Federal Food, Drug, and 
Cosmetic Act as well as the quality and purity characteristics that the product purports to 
possess.328 As part of cGMP, firms must perform validation procedures to demonstrate that 
their manufacturing processes can consistently produce a product that meets established 
quality attributes.  
In an op-ed article, Dr. Janet Woodcock (director of the FDA’s Center for Drug 
Evaluation and Review) stated how conventional validation procedures are often empirical 
in nature. Assessing the suitability of this practice is an aim of this work.8 Dr. Woodcock 
additionally discussed how the Act viewed from the context of overall quality regulation, is 
a statutory CGMP requirement that can be viewed as a legal representation of the frequent 
statement that quality must be built-in.8  This concept is the basis for the pharmaceutical 
industry’s adaptation of another of Juran’s concepts, i.e. quality by design. 
The concept of quality by design, along with the utilization of design spaces and 
the probabilistic assessment of risk (of propagating excessively wide or unnecessarily 
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narrow specifications) are key aspects of this project.  The term quality by design (QbD) 
was first coined by Juran in his 1991 publication entitled Juran on Quality by Design and 
has since been invoked by a variety of fields.  According to Juran, achieving quality by design 
during industrial manufacturing is the result of three central activities (i.e. Juran’s Trilogy) 
which make up Juran’s philosophy for quality management. These activities include quality 
planning, quality control, and quality improvement.  Paralleling the previous axiom 
articulated by Dr. Woodcock, the FDA contextualizes Juran’s concept of quality by design 
within the field of pharmaceutical manufacturing by stating that QbD is the process of 
building quality into the product.  The FDA expands on the importance of achieving quality 
by design by emphasizing the recognition on the part of sponsors that quality “cannot be 
tested into products”.  While this position may seem counter intuitive, its reasoning is related 
to the implication that such strategies (i.e. those based on “testing of quality into a product”) 
represent a reactive, rather than proactive, position towards the assurance of quality and that 
reliance upon which is a result of limited product/process understanding.  This type of a 
strategy is not in pursuit of maximizing efficiency. Thus, it is considered to increase the risk 
of unnecessary waste, increased hold times, and higher cost.  For these and other reasons, the 
more holistic perspective on quality assurance is encouraged by the FDA.  The 
administration specifically stresses the objectives for quality measurements be risk-based and 
predefined.  In this way, the assessment of critical product/process parameters provides a 
path towards improved product understanding and more appropriate process controls.  
The process of modeling the quality attributes of a drug product or substance as a 
function of its critical product/process parameters is known as design space development.  
The ICH Q8 definition of design space used by the FDA is “the multidimensional 
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combination and interaction of input variables (e.g., material attributes) and process 
parameters that have been demonstrated to provide assurance of quality.” Working within an 
FDA approved design space is not considered as a change.  Thus, the utilization of design 
spaces can confer greater regulatory flexibility and confer improvements to efficiency.  
Movement out of the design space, however, is considered to be a change and normally 
initiates a regulatory post approval change process.  The post approval change process can 
be extremely costly to a sponsor and to patients.  Therefore, the criteria used to define the 
limits of a CQA is of great importance.   
As introduced at the beginning of this chapter, dissolution performance was the CQA of 
interest and two competing methodologies were used to define the upper and lower 
acceptability limits of dissolution.  Specifically, the methods used were the F2 criteria 
and the previously developed IVIVC.  Upper and lower limits on dissolution were made 
with respect to the dissolution performance of the reference labeled product (RLP).  The 
focus on dissolution performance was motivated by the considerable regulatory significance 
placed on this measurement of quality.  This high degree of importance is a result of 
dissolution being considered the rate limiting step for the absorption of BCS class II 
substances like carbamazepine.  While the F2 metric was used for the sole purpose of 
defining an empirical region of dissolution profile similarity, the IVIVC usage illustrated in 
this chapter was twofold.   First the IVIVC was used to propagate a distribution of clinical 
responses that, based on the range of F2 defined dissolution performance.  Additionally, the 
IVIVC was used to directly derive specifications on dissolution.   
The final step of this work was to illustrate the implications of selecting one CQA 
refinement methodology over the other in terms of the i) resulting dissolution specifications 
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and design spaces, and ii) the associated risk to bioequivalence with either method. Design 
space development began with the development of a knowledge space.  Here the term 
knowledge space means the intervals over which critical product/process attributes have been 
systematically investigated and the dependent performance of the critical quality attribute is 
known (also referred to as the calibrated range).  A design space exists within a knowledge 
space.  The critical product attributes which defined the design and knowledge spaces used 
in this work were: binder concentration, disintegrant concentration, and porosity.  These three 
factors were considered high risk and are known to significantly affect the dissolution of a 
solid oral dosage form which could ultimately impact clinical performance. 
In statistics, risk is a measure of the association between a binary occurrence and set of 
continuous and/or binary predictors.  The concept of risk is directly related to probability.  
The probability of event 𝑎 occurring out of 𝑎 and 𝑏 possible events is defined as 𝑎/(𝑎 + 𝑏).  
This is the same calculation for the (absolute) risk of event 𝑎 occurring.  Monte Carlo-based 
modeling techniques, such as that employed by the clinical trial simulation platform in this 
work, have been widely used for the purpose of probabilistic risk assessment.  This is due to 
their ability to propagate the a priori variability associated with model parameters through 
the model resulting in a distribution of outputs.  In the context of a physiologically-based 
IVIVC, such methods provide the ability to propagate the variability of physiologic systems 
over an array of product performance inputs and generate a posterior probability distribution 
of clinical effects.  In this way, the risk of errors in bioequivalence can be compared between 
the two identified CQA specification methodologies using a predefined objective of what 
constitutes a clinically significant difference.  This required estimating a probability density 
function for the distribution of clinical responses resulting from an F2 defined range of 
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dissolution profiles, and comparing the function with a PDF that represents an estimated 
distribution of all possible bioequivalent responses. 
 
5.2 Methods and Materials  
5.2.1 Summary PK Metrics of Interest  
  Cmax and AUC at time 170 (AUC∞) were initially selected as the summary 
pharmacokinetic metrics of interest.  This was because of their widely accepted use as 
markers for the extent of drug exposure.  The importance of these characteristic was 
demonstrated by works of Tothfalusi et al. and Olling et al. who reported how a 
predictor of toxic events was the magnitude of drug absorption.  Olling et al. 
additionally showed that the differences in absorption rate evidenced by deviations in 
𝑇௠௔௫ were also used.  Lastly, after considering that carbamazepine is administered in a 
chronic fashion, the concentration at steady state (𝐶ௌௌ) was assessed along with the 
minimum and maximum (𝐶௦௦,ெ௜௡, and 𝐶௦௦,ெ௔௫) concentration at steady state.  The 
concentrations at steady state was defined in this work as the average concentration 
over the last 5 days of a 30 day dosing period. 
5.2.2 F2-based Dissolution Limits and the resulting PDF of Clinical 
Responses  
Identifying dissolution model parameter limits using the F2 statistic and 
transforming the resulting range of in vitro performance into a distribution of clinical 
responses was accomplished according to Figure 5.2.2.1.   
 
 
F2 Equation Makoid Banakar 
Dissolution Model 
Create dissolution parameter 
response-surface trimmed to 
Figure 5.2.2.1. Work-flow for Generating a Distribution of Clinical Responses  
from F2-based Dissolution Limits  
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Defining the range of F2 defined dissolution began by nesting the Makoid Banakar 
dissolution model within the F2 Equation.   
Eq. 5.2.2.1 
100}] )T-(R(1/n)+log{[150=f 0.5-
2n
1)=(t tt2
   
where 
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Eq. 5.2.2.2 𝑇௧ = 𝐹௠௔௫ ∙ ቀ
௧
்௠௔௫
ቁ
௕ಾಳ
∙ 𝑒ቀ௕ಾಳ∙
೟
೅೘ೌೣቁ,      for t <= 𝑇𝑚𝑎𝑥  
and where for 𝑡 > 𝑇𝑚𝑎𝑥,  𝑇௧ = 𝐹௠௔௫      
 
This allowed limits to be defined for the dissolution model parameters to achieve an F2 
> 50 dissolution profile given the performance of a reference drug product.  The 
reference labeled drug product for carbamazepine is Tegretol.  Its dissolution 
performance served as a benchmark for the comparisons performed in this study and 
was based on the 1992 Meyer et al. study (see Figure 5.2.2.2).  The dissolution test in 
that study used the compendial dissolution test for  carbamazepine (see Chapter 3 
section 3.2.1).   
Using the referenced performance of Tegretol, the F2 metric was calculated for any 
set of dissolution parameters.   Dissolution profiles are identical if F2 is 100.  FDA 
guidance states that generally, F2 values greater than 50 (50-100) ensure sameness or 
equivalence of the two curves and, thus, of the performance of the test (e.g. postchange) 
Figure 5.2.2.2. Dissolution profiles of four 200mg 
carbamazepine Tablet products. (○) Tegretol [adapted from 
Meyer et al.(1992)139] 
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and reference (e.g. prechange) products.  The range of acceptable dissolution profiles 
was thus defined as those with an F2 value > 50.  This allowed any dissolution profile 
of a simulated test product to be identified as either equivalent or nonequivalent.   
The combination of dissolution parameters that resulted in an F2 > 50 provided an 
asymmetric shape and volume.  To process the infinite number of dissolution parameter 
combinations using an IVIVC within the Simcyp®  platform, a sampling strategy was 
developed.  The sampling routine was performed in two steps and was based on the 
assumption that all possible F2 > 50 dissolution parameter combinations were equally 
likely.  From this assumption, the first step was guided by the principle that points on 
the surface of the shape were of particular importance.  This is because those points 
represent dissolution profiles that were maximally different from the profile of the 
reference product and when processed using the IVIVC would define the tails of the 
distribution of clinical responses.  Therefore, the surface of the shape (which describes 
all of the possible combinations of 𝑏, 𝐹𝑚𝑎𝑥, and 𝑇𝑚𝑎𝑥 that resulted in an 𝐹2 >  50) 
was sampled until the volume occupied by the samples was within 5% of the maximum 
possible volume.  The volume of the shape was defined using the alphaShape.m and 
volume.m functions in MATLAB.  To determine the maximum volume, ranges of [60 
: 100%], [13 : 24000 sec], and [0.18 : 2.5] were respectively assigned to 𝐹𝑚𝑎𝑥, 𝑇𝑚𝑎𝑥, 
and 𝑏.  Sampling commenced and proceeded by increments of 50 samples until the 
change in the volume occupied by the 𝐹2 >  50 region was < 1.0%.  The surface of 
the resulting shape was then sampled by rank ordering the respective F2 values (from 
smallest to largest, i.e. 50 to 100).  Beginning with the first 10 samples (i.e. single series 
of 𝐹𝑚𝑎𝑥, 𝑇𝑚𝑎𝑥, and 𝑏) whose F2 value closest to 50,  subsequent samples were added 
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until the volume of the subsamples converged to the max volume according to the 
previous criteria (i.e. 5%).   
The second step of the sampling algorithm was to sample the interior of the shape. 
This was performed as per the assumed ability of dissolution parameters to exist 
anywhere within the specification limits.   The number of samples randomly drawn 
from the interior was set equal to the number needed to represent the surface.  
 With the surface and interior samples drawn, each set of dissolution model 
parameters was processed using the IVIVC and transformed into a rate and extent of 
absorption.  Using the outputs the IVIVC, the clinical trial simulation platform was 
then used to generate distributions plasma concentration profiles.  These distributions 
were then pooled into a single probably density distribution and saved for the 
subsequent assessment bioequivalence errors.   
 
5.2.3 Deriving an encompassing PDF of Bioequivalent Observations 
Before bioequivalence errors associated with the use of the F2 statistic could be 
assessed two activities needed to performed. First, the criteria for a clinically significant 
difference first needed to be defined.  Next, an encompassing PDF of bioequivalent 
observations needed to be derived based on this criteria.   
 
5.2.3.1 Defining the Criteria for a Clinically Significant Difference 
It is extremely unlikely for a test and reference product to perform identically.  
Therefore, the determination of bioequivalence requires that a threshold be defined for 
what constitutes a clinically significant difference for metrics of interest.  There are a 
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variety of ways to assess the significance of an observed difference in test-vs-reference 
responses for 𝐴𝑈𝐶, 𝐶௠௔௫ , 𝑇௠௔௫, 𝐶௦௦,ெ௔௫, 𝐶௦௦,ெ௜௡, and 𝐶௦௦. The approach taken in this 
work was to base the threshold on the width of the therapeutic window for 
carbamazepine as reported by Shargel et al. and supported by others. 37  Here, the 
authors stated how the effective concentration for carbamazepine was 9 + 3 ng/ml 
wherein concentrations below 6 ng/ml and above 12 ng/ml would be subtheraputic and 
toxic, respectively.  To translate this into a threshold for bioequivalence, the range was 
normalized by the target concentration.  This was performed according to reports which 
discuss how while a target concentration can vary between subjects, the normalized 
therapeutic window remains relatively constant.  The resulting window was 
𝑇𝑒𝑔𝑟𝑒𝑡𝑜𝑙 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒 ±  33%.  Additionally, the within subject variation has been 
reported to be approximately 10%.329  While this value is considered low by the FDA, 
it was nevertheless accounted for within the acceptance window by subtracting it from 
the normalized therapeutic index to ensure consistent clinical performance despite a 
patient’s inherent variability.  Thus, the threshold for considering a difference to be 
clinically significant in mean responses of 𝐴𝑈𝐶, 𝐶௠௔௫ , 𝑇௠௔௫, 𝐶௦௦,ெ௔௫, 𝐶௦௦,ெ௜௡, and 𝐶௦௦ 
was > + 23%.  This window for the accepted difference in the median is illustrated in 
Figure 5.2.3.1.1.   
 
 
 
 
 
Based on therapeutic index carbamazepine 
9 + 3 ug/ml and within subject variability of 10% 
E(ref) 
0.77*E(ref) 
E(test) 
1.23*E(ref) 
E(test) 
Region representing  
95% of the observations 
X-axis: value of 𝐴𝑈𝐶,  𝐶𝑚𝑎𝑥, 𝑇𝑚𝑎𝑥,  
𝐶𝑠𝑠, 𝐶௦௦ெ௔௫, 𝐶௦௦ெ௜௡ 
Y-axis: frequency of responses  
            (i.e. probability) 
Figure 5.2.3.1.1. Introduction of the interval for bioequivalence 
(E(X): expected value for the X-product’s responses) 
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5.2.3.2 Deriving the Encompassing PDF of Bioequivalent Observations 
Figure 5.2.3.1.1. makes reference to a region representing 95% of the observations.  
When placed in the context of frequentist statistics this interval is the functional 
equivalent of the prediction interval for a single observation.  In the context of Bayesian 
statistics, this interval is the credible interval for a single observation.  Deriving the 
probability density function along this interval was accomplished according to the 
procedure illustrated in Figure 5.2.3.2.1.  This process ultimately allowed the primary 
research question of this work to be assessed. 
For carbamazepine, (and indeed many other drug substances) there is a dynamic 
relationship between the mean drug exposure and the observed variability in drug 
exposure given this metric of central tendency. With this understanding, the procedure 
for deriving the probability density function of bioequivalent observations was guided 
by three underlying principles.  First, the pharmacokinetic parameters concerning 
absorption, i.e. 𝐹௔ and 𝑘௔, are largely dependent upon the dissolution performance of 
the final drug product. Additionally, the coefficient of variation for these parameters 
are a function of their central tendency.  Finally, the elimination kinetics of 
carbamazepine are not zero-order, and, therefore, the clearance, and thus the variation 
in clearance, is also a function of the exposure.  
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𝐹௔ upper limit 
lower 
limit 𝑘௔ 
upper 
limit 
lower 
limit 
Calibrated Clinical 
Trial Simulation 
Platform 
𝐶𝑉ிೌ = 𝑓(𝐹௔) 𝐶𝑉௞ೌ = 𝑓(𝑘௔) 
Sample from a uniform distribution 
over 𝐹௔ and 𝑘௔ respectively  
Predict 𝐶𝑉ிೌ  and 𝐶𝑉௞ೌ given 𝐹௔ and 
𝑘௔, respectively (see chapter 4) 
Process each set of 𝐹௔, 𝐶𝑉ிೌ , 𝑘௔, and 
𝐶𝑉௞ೌ using the CTS platform 
Process each set of 𝐹௔, 𝐶𝑉ிೌ , 𝑘௔, and 
𝐶𝑉௞ೌ using the CTS platform 
Does the expected value for the 
PDF of 𝐶௠௔௫, 𝐴𝑈𝐶, and 𝐶௦௦  Is 𝐸൫𝑃𝐷𝐹௜೟೓௣௞ ௠௘௧௥௜௖൯  within ±45% 𝑜𝑓 N 
Figure  5.2.3.2.1. Derivation of the PDF describing individual bioequivalent responses 
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The first step in the process outlined by Figure 5.2.3.2.1. was to assign uniform 
distributions to the values of 𝐹௔ and 𝑘௔.  Samples from this distribution were referred 
to as 𝐹௔,௧௔௥௚௘௧ and 𝑘௔,௧௔௥௚௘௧. The goal was that after samples were drawn and processed 
using the clinical trial simulation platform, the distributions of clinical responses would 
cover the interval  responses bioequivalent to  𝐹௔ = 0.78 and 𝑘௔ = 0.28 hr-1 (i.e. the 
values for the reference product Tegretol; see chapter 3).  The range of possible 
𝐹௔,௧௔௥௚௘௧  values was [58% : 98%] while the range for 𝑘௔,௧௔௥௚௘௧ was [0.18 hr -1 : 0.37 hr 
-1].   
With the ranges of 𝐹௔,௧௔௥௚௘௧ and 𝑘௔,௧௔௥௚௘௧ defined, the next step was to draw a 
random sample from each uniform distribution.  Once the 𝐹௔,௧௔௥௚௘௧ and 𝑘௔,௧௔௥௚௘௧ values 
 162 
 
were sampled, the corresponding intersubject variability for a given 𝐹௔,௧௔௥௚௘௧ and 
𝑘௔,௧௔௥௚௘௧ (i.e. 𝐶𝑉ிೌ ,೟ೌೝ೒೐೟   and 𝐶𝑉௞ೌ,೟ೌೝ೒೐೟) were determined using the models derived in 
chapter 4.  The set of 𝐶𝑉ிೌ ,೟ೌೝ೒೐೟ , 𝐶𝑉௞ೌ,೟ೌೝ೒೐೟ , 𝐹௔,௧௔௥௚௘௧ and 𝑘௔,௧௔௥௚௘௧ were then used as 
inputs to the clinical trial simulation platform.  Here, in silico patients were generated 
following the procedure described in Chapter 4.  Individual values for 𝐹௔ and 𝑘௔ being 
assigned to each generated patient based on a random draw for a normal distribution 
defined by a mean of 𝐹௔,௧௔௥௚௘௧ and 𝑘௔,௧௔௥௚௘௧ respectively, and a variance equal to the 
respective coefficients of intersubject variation as per Chapter 4.  This method allowed 
the absorption parameter-vs-𝐶𝑉௔௕௦௢௥௣௧௜௢௡ ௣௔௥௔௠௘௧௘௥   relationship to be preserved 
across all the possible 𝐹௔,௧௔௥௚௘௧ and 𝑘௔,௧௔௥௚௘௧ values. 
Two types of in silico clinical trials were run.  The first was similar to a traditional 
bioequivalence trial in that it was based on a single 200mg dose.  The average 𝐶௠௔௫ 
and AUC∞ values were assigned to a given set of 𝐹௔,௧௔௥௚௘௧ and 𝑘௔,௧௔௥௚௘௧ values using 
the results of these simulations. The second study was based on dosing of the 200mg 
strength three times a day for 30 days.   The results of this trial were used to assign a 
Css value to a given set of 𝐹௔,௧௔௥௚௘௧ and 𝑘௔,௧௔௥௚௘௧ values.  Both simulations were 
performed using 50 trials of 24 patients each drawn from the calibrated population 
described in Chapter 4.  The number of patients per trial was based on the number of 
patients included in the foundational studies performed by Meyer et al and Olling et al.  
The number of trials was selected to ensure convergence to a stable distribution of 
pooled clinical responses.  The resulting distribution of clinical responses for each 
𝐹௔,௧௔௥௚௘௧ and 𝑘௔,௧௔௥௚௘௧ sampled in the first step of this process was saved for subsequent 
pooling if it satisfied the criteria described in section 5.2.3.1. 
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5.2.4 Comparison of F2-based Clinical Responses to the Encompassing PDF 
of BE responses  
The product of the clinical trial simulations performed according to sections 5.2.2 
and 5.2.3.2 were two distributions of clinical responses.  The first distribution 
represented the clinical responses originating from the processing of F2 > 50 
dissolution profiles using the IVIVC nested within a physiologically based clinical trial 
simulation platform.  This was considered the F2 distribution.  The second distribution 
was the distribution of responses bioequivalent to the performance of Tegretol.  This 
was considered the reference distribution.  The distributions were fit using the fitdist.m 
function within Matlab (2016)).  Within this function, a kernel function was used to fit 
the distributions.  For any real values of 𝑥, the kernel density estimator’s formula is 
given by, 
𝑓መ௛(𝑥) =
1
𝑛ℎ
෍ 𝐾
௡
௜ୀଵ
ቀ
𝑥 − 𝑥௜
ℎ
ቁ 
were, 𝑥ଵ, 𝑥ଶ, … , 𝑥௡ are random samples from an unknown distribution, 𝑛 is the sample 
size, 𝐾(·) is the kernel smoothing function, and ℎ is the bandwidth.  The kernel estimate 
for the cumulative distribution function (CDF) of the results was given by,  
𝐹෠௛(𝑥) = න 𝑓መ௛(𝑡)𝑑𝑡
௫
ିஶ
=
1
𝑛
෍ 𝐺
௡
௜ୀଵ
ቀ
𝑥 − 𝑥௜
ℎ
ቁ 
where  
𝐺(𝑥) = න 𝐾(𝑡)𝑑𝑡
௫
ିஶ
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Here, a non-parametric kernel smoothing function was selected for 𝐾(·) to minimize 
bias.  The bandwidth was selected based on assessing the root mean squared error in 
cross validation (RMSECV).  Using a random 25% hold back of the data, the error 
between the predicted CDF value and an observed CDF value was assessed across 
varying bandwidth window sizes.  The window size ultimately decided upon was 150. 
With the F2 and reference probability densities defined, the probability of an 
observation over a specific interval could be calculated and the differences between the 
two distributions could be assessed.  The probability over an interval for a given 
distribution was assessed by, 
௔௥௘௔ ௨௡ௗ௘௥ ௧௛௘ ௜௡௧௘௥௩௔௟ ௙௢௥ ௔ ௉஽ி 
௧௢௧௔௟ ௔௥௘௔ ௨௡ௗ௘௥ ௉஽ி
.   
The area under the PDF was calculated using the Runge-Kutta algorithm within the 
ode45.m function in MATLAB.   The interpretation of probabilistic differences 
between two distributions supported the use of Bayesian methologies.  In Figure 
5.2.4.1, the green PDF represents the encompassing (i.e. maximum) distribution of 
bioequivalent responses.  It was defined as the reference probability distribution of 
equivalent responses centered on the performance of a reference product.  The blue 
PDF represents the clinical responses (propagated via a clinical trial simulation) 
stemming from the use alternative, dissolution based, criteria for equivalence, e.g. the 
𝐹2 metric.  In this Figure there are three different scenarios examined to identify 
exactly how differences will be categorized.  All differences were made with respect 
to the reference distribution as it was explicitly derived according to observed degrees 
of intersubject variability and clinically significant differences in clinical performance 
(see sections 5.2.3.1 and 5.2.3.2).  The categories used were type I or type II errors 
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(failures) for bioequivalence.  The Bayesian concept of credible intervals was used for 
the assessment of these errors.  The intervals for the distributions were defined using 
their respective 𝐶𝐷𝐹.  The upper and lower 2.5% were excluded resulting in what was 
defined as the 95% credible interval for the distribution.  These intervals were defined 
along the x-axis with values of 𝐶𝐼௟௢௪௘௥,௜ and 𝐶𝐼௨௣௣௘௥,௜ where 𝑖 =
[𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 (𝑟𝑒𝑓), 𝑎𝑙𝑡𝑒𝑟𝑛𝑎𝑡𝑖𝑣𝑒 (𝑎𝑙𝑡)].  Errors were assessed at both ends of the 
intervals.  Scenarios when either (CIlower,ref – CIlower,alt) or (CIupper,ref - CIupper,alt) was 
positive or negative, respectively, type I errors were said to exist.  The probability of 
type I errors in these cases were ∫ 𝑃𝐷𝐹௥௘௙
஼ூ೗೚ೢ೐ೝ,ೌ೗೟
஼ூ೗೚ೢ೐ೝ,ೝ೐೑
 and ∫ 𝑃𝐷𝐹௥௘௙
஼ூೠ೛೛೐ೝ,ೝ೐೑
஼ூೠ೛೛೐ೝ,ೌ೗೟
 , 
respectively.  Type I errors represent the false rejection of bioequivalence for a given 
clinical response on the basis of excessively tight alternative equivalence criteria at a 
given boundary condition (i.e. upper or lower).  Type II errors were identified when 
either (CIlower,ref – CIlower,alt) or (CIupper,ref - CIupper,alt) was negative or positive, 
respectively.  The probability of type II errors in these cases were ∫ 𝑃𝐷𝐹௔௟௧
஼ூ೗೚ೢ೐ೝ,ೝ೐೑
஼ூ೗೚ೢ೐ೝ,ೌ೗೟
 
and ∫ 𝑃𝐷𝐹௔௟௧
஼ூೠ೛೛೐ೝ,ೌ೗೟
஼ூೠ೛೛೐ೝ,ೝ೐೑
 , respectively.  Type I errors represent the false acceptance of 
bioequivalence for a given clinical response on the basis of excessively wide alternative 
equivalence criteria at a given boundary condition (i.e. upper or lower).  In a scenario 
where when both (CIlower,ref – CIlower,alt) or (CIupper,ref - CIupper,alt) was negative, the 
∫ 𝑃𝐷𝐹௥௘௙
஼ூ೗೚ೢ೐ೝ,ೌ೗೟
஼ூ೗೚ೢ೐ೝ,ೝ೐೑
 would represent the probability of type I errors while the 
∫ 𝑃𝐷𝐹௔௟௧
஼ூ೗೚ೢ೐ೝ,ೌ೗೟
஼ூ೗೚ೢ೐ೝ,ೝ೐೑
would represent the probability of type II errors. 
 
 Figure 5.2.4.1. Illustration for the interpretation of differences in distributions of clinical responses 
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5.2.5 Comparison of F2 Dissolution Specification with IVIVC-based 
Specification  
The comparison of dissolution profile specifications was performed on the basis of 
the area occupied by the respective specifications.  The F2 area was calculated by 
simulating to convergence a stable population of dissolution profiles whose F2 value 
was greater than or equal to 50 when compared to the dissolution profile of Tegretol as 
per section 5.2.2. The simulated dissolution profiles were made on a minute-wise basis 
up until 2 hours.  The area under the minimum amount dissolved for each time point in 
the population of simulated responses was calculated using the trapz.m function in 
MATLAB.  This function uses the trapezoidal method for calculating the area under 
the curve.  This value was then subtracted from the area under a curve defined by the 
minimum value for each time point in the population of responses.   
PDFBlue – alt. responses 
           - n% credible interval 
PDFGreen – reference responses 
           - n% credible interval 
CIn,alt is narrower than CIn,ref.  
Therefore, P(CIn,ref) - P(CIn, alt) = 
probability of falsely rejecting 
BE based on the “test” 
equivalence criteria  
(i.e. P(type I error)). 
P(Type II) P(Type I) P(Type II) 
P(Type I) 
CIn,alt wider than CIn,ref.  
Therefore, P(CIn,alt) - P(CIn, ref) = 
probability of falsely accepting 
BE based on the “test” 
equivalence criteria  
(i.e. P(type II error)). 
At the upper limit of CIn,ref: 
CIn,alt > CIn,ref resulting in the 
occurrence of type II error 
 
At the lower limit of CIn,ref: 
CIn,alt < CIn,ref resulting in the 
occurrence of type I error 
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To calculate the area of a dissolution profile specification defined using the IVIVC, 
the range of 𝑘𝑎 and 𝐹𝑎 values that resulted in performances that were bioequivalent to 
Tegretol as per section 5.2.3.2 were recalled.  With these ranges of the acceptable 
absorption parameters, the IVIVC of Chapter 2 could then be used to solve for the of 
dissolution parameters that would equal the upper and lower limits of 𝑘𝑎 and 𝐹𝑎.  
Simulations were then run across the range of acceptable dissolution parameters to 
generate a population of dissolution responses just as before.  The area occupied by this 
population of dissolution profiles was calculated in the same way as with the F2 > 50 
dissolution profiles. 
 
5.2.6 Comparison of F2 Dissolution Design Space with IVIVC-based Space  
The comparison of design spaces derived from the dissolution specifications based 
on F2 and IVIVC required the development of a knowledge space.  The knowledge 
space was defined by the binder concentration, disintegrant concentration, and porosity 
of a four component tableted carbamazepine drug product. The binder used was 
hydroxypropyl methylcellulose (HPC; Nippon Soda Co., Ltd. Tokyo, Japan).  The 
disintegrant used was crospovidone (CP; BASF Corporation, Ludwigshafen, 
Germany).  The formulation also included microcrystalline cellulose (MCC; Sigm 
Aldrich, St. Louis, MO).  Lastly, the carbamazepine was sourced from Cayman 
Chemical (Ann Arbor, MI). Only a single lot of each product was used in the study. 
In this study the carbamazepine concentration was held constant at 50%.  A 3 x 3 
full factorial design was used to define the binder and disintegrant concentrations of 
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tableted products used for the dissolution experiments in this study (see Table 5.2.6.1).  
Any remaining concentration to reach a total of 100% was made up of MCC. 
 
Table 5.2.6.1. Design of Dissolution experiments 
  
  Disintegrant (w/w %) 
  6.25 3.75 1.25 
Bi
nd
er
 (w
/w
 %
) 17 High [CP] High [HPC] 
Med [CP] 
High [HPC] 
Low [CP] 
High [HPC] 
14 High [CP] Med [HPC] 
Med [CP] 
Med [HPC] 
Low [CP] 
Med [HPC] 
11 High [CP] Low [HPC] 
Med [CP] 
Low [HPC] 
Low [CP] 
Low [HPC] 
 
Each design point was weighed directly into 100 ml plastic jars to reach a sufficient 
quantity of 80 grams.   The materials were agitated using a benchtop vortex mixer for 
30 seconds and then mixed for 20 minutes using a retrofitted bin blender.  To ensure 
homogeneity, this process was performed in triplicate.     
A direct compaction method was selected to prepare tablet formulations. Tablets of 
400 mg (200 mg of carbamazepine) were prepared by a compaction simulator 
(Presster®, Metropolitan Computing Co., USA) using a 10-mm flat-faced punch.  The 
rotary press Korsch 336 with 36 stations was simulated at a speed of 0.5 m/s. 
Compaction force was between 6 and 10 kN for all tablets.   
 
The porosity was varied across three levels: 8%, 11% and 14%.  This was achieved 
by altering the punch distances in the press. Porosity (ε) was calculated according to 
the following equation based on volume. 
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𝜀 = ൬1 −
𝑚
𝑉௧ ∙ 𝜌௧
൰ 100 
In the porosity equation, 𝑚 is the tablet mass and 𝑉௧ the tablet volume, and 𝜌௧ is the 
true density of the powder blends. Density of the powder blends was calculated as the 
weighted mean from the true density of each component. True density was assessed by 
a gas displacement pycnometer (AccuPyc 1330, Micromeritics, USA).  
 Tablets were allowed to completely relax (approximately 1 week) before 
dissolution tests were performed.  Relaxation was verified by measuring the tablet 
dimensions over a series of several days until values became stable.  All tablets used 
for dissolution tests were within + 10% of the target porosity.  Additionally, dissolution 
tests were performed in triplicate and the mean was used as the response. 
The dissolution test was performed with a USP Apparatus II  (Distek, Inc., North 
Brunswick, NJ). The conditions were set according to the USP monograph for 
carbamazepine immediate release tablets. The paddle speed was 75 rpm and media was 
900 mL water containing 1% sodium lauryl sulfate (w/v) at 37°C. Samples were 
analyzed every 3 minutes by UV-VIS Spectrophotometry (Agilent, Santa Clara, CA) 
at 287 nm via an autosampler and flow through cell. 
JMP (SAS Institute Inc., Cary, NC) was used to model the percent dissolved as a 
function of time, binder concentration, disintegrant concentration, and porosity.  Here, 
the neural platform was used due to its inherent flexibility (see Hertz et al neural 
network theory).330,331   Cross validation of the model was performed by randomly 
dividing the original data into the training and cross validation sets.  The proportion of 
the original data used for cross validation was 20%.  The use of up to two layers was 
provided by the software with an unlimited number of nodes to either layer.  The 
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activation functions available to be applied at the nodes of the hidden layers were the 
hyperbolic tangent function, a linear function, and the Gaussian function (see Table 
5.2.6.2). The models selection was made on the basis of minimizing the negative log-
likelihood. 
 
Table 5.2.6.2. Available Activation Functions for Modeling % Dissolved 
Title Formula Description 
Hyperbolic 
tangent 
function 
(TanH) 
𝑒ଶ௫ − 1
𝑒ଶ௫ + 1
 
Sigmoid function that transforms values to 
be between -1 and 1, and is the centered and 
scaled version of the logistic function. 
Linear identity function The linear combination of the X variables is not transformed. 
Gaussian 
function 𝑒
ି௫మ 
Helpful when the response surface is 
Gaussian in shape. 
 
 𝑥 is a linear combination of the 𝑋 variables 
An important step of the modeling process was to assess not only the accuracy, but 
also the generalizability of the model.  Model generalizability is a concept frequently 
invoked in the neural modeling domain.  This concept is referred to as the avoidance 
of overfitting the model to the data.  It was assessed by means of a visual predictive 
check as described by Jann et al. using the “prediction profiler” function within JMP.332  
The visual predictive check is made not only using the inputs and outputs of the 
calibration and cross validation samples, but also using interpolated inputs wherein the 
outputs are observed for adherence to trends known a priori. 
Accuracy of the final model was accessed on the basis of RMSEC, RMSECV and 
R2.    Overfitting of the data was assessed by first selecting binder, disintegrant, and 
porosity values that existed between the design points of Table 5.2.6.1.  These 
interpolated values were then processed using the model.  The generalizability of the 
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model was supported if the resulting output of dissolution profiles were similarly 
interposed in a consistent manner that followed the classically observed trends (i.e. 
porosity, disintegrant ∝ dissolution rate; binder ∝ 1/dissolution rate).  Additionally, 
overfitting was assessed by profiling the marginal effects of binder, disintegrant and 
porosity and examining them across their respective ranges for deviations from smooth, 
predictable behavior.   
With the generalizability of the model supported, the development of the respective 
product parameter design spaces was performed.  The use of the three product 
parameters in this work resulted in three dimensional design spaces.  Thus, 
comparisons between the design spaces were  on the basis of volume.  Additionally, a 
comparison of the binder vs disintegrant design space area at porosity values of 8, 11, 
and 14% was performed. 
The F2 design space was refined by nesting the % 𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 =
𝑓(𝑡𝑖𝑚𝑒, [𝐻𝑃𝐶], [𝐶𝑃], 𝑝𝑜𝑟𝑜𝑠𝑖𝑡𝑦) model within the F2 equation.  Values for HPC, CP, 
and porosity were then randomly sampled and F2 values were calculated.  The points 
that resulted in F2 > 50 were saved until a stable design space was converged upon as 
per section 5.2.2.   
The IVIVC based design space was defined using a MATLAB function developed 
in-house that a randomly defined a set of binder, disintegrant, and porosity values and 
translated them into ka and F values.  These absorption parameters were then compared 
to the bioequivalent range of ka and F defined after the activities of section 5.2.3.2.  
Those sets of binder, disintegrant, and porosity values that resulted in bioequivalent 
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performance were then saved and the processes was repeated until a stable design space 
was converged upon. The specifics of the routine are described in Figure 5.2.6.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[𝐵𝑖𝑛𝑑𝑒𝑟] [𝐷𝑖𝑠𝑖𝑛𝑡𝑒𝑔𝑟𝑎𝑛𝑡] 𝑃𝑜𝑟𝑜𝑠𝑖𝑡𝑦 
% 𝐷𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 =   
𝑓(𝑡𝑖𝑚𝑒,  [𝑏𝑖𝑛𝑑𝑒𝑟], [𝑑𝑖𝑠𝑖𝑛𝑡𝑒𝑔𝑟𝑎𝑛𝑡],  𝑝𝑜𝑟𝑜𝑠𝑖𝑡𝑦) 
Makoid Banakar Dissolution Model 
0
20
40
60
80
100
0 0.5 1 1.5
Time (hr)
Sample from a uniform 
distribution for each parameter 
Predict dissolution profile using 
the model based on the process 
parameters 
Model predicted dissolution 
profile using Makoid Banakar 
Model  
Figure 5.2.6.1. Generating a Product Parameter Design Space using IVIVC 
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5.3 Results and Discussion 
5.3.1 Comparison of Dissolution Specifications: F2 vs IVIVC 
The combinations of Makoid Banakar dissolution model parameters that resulted 
in an F2 of > 50 are demonstrated in Figure 5.3.1.1.  The a. pane in the Figure is a 
representation of the approximately 8k points satisfying the F2 criteria.  The b. pane is 
the three dimensional shape that captures these points.  The volume of this shape was 
9.6716e+04 arbitrary units (A.U.).   
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A distribution of dissolution profiles was generated by inputting each set of points 
from Figure 5.3.1.1 into the Makoid Banakar dissolution model.  The resulting profiles 
are shown in Figure 5.3.1.2.  In this figure, the red dots represent the dissolution 
performance of the reference product.  The blue region is the product of each 
dissolution profile being plotted on the same graph. 
 
 
 
 
 
 
 
 
b
Figure 5.3.1.1. Combinations of Makoid Banakar Dissolution Parameters with F2 > 50 
  
a. 
  
b. 
  
Figure 5.3.1.2. Dissolution Profiles with F2 > 50 
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The area occupied by the blue region of Figure 5.3.1.2 was 3.2612e+03 (%*min).  It is 
important that the y-range not be interpreted as the acceptable range of values.  To 
demonstrate why, consider two dissolution profiles where one is defined by the minimum 
y-values for each timepoint and the other is defined by the maximum values. In either case 
the, the F2 metric is far less than 50.  This is because the conventional F2 > 50 criteria 
assured that the average difference across all the time points is < 10%.  Thus the upper and 
lower limits of the blue region in Figure 5.3.1.2 are define by dissolution profiles that may 
have high error at certain time points but very low error at the others.  While the area of 
the blue region is useful for comparison is it important to keep in mind that the 
interpretation that any dissolution profile falling within the blue region will have an F2 > 
50 is incorrect.  It is acceptable however, to consider that any combination of dissolution 
model parameters that falls within the shape of Figure 5.3.1.1.b. will result in a F2 > 50. 
For this reason, the more representative measure of the acceptance space is the volume 
metric calculated in Figure  5.3.1.1.b.   
To refine dissolution parameter limits using the IVIVC, the first step was to recall the 
𝑘𝑎 and 𝐹 terms for Tegretol: Fa = 0.78, ka = 0.28.  These terms were then incrementally 
varied across the respective ranges of [0.2 : 1.0] and [0.01 : 2.0].  The median response for 
𝐴𝑈𝐶, 𝐶𝑚𝑎𝑥, 𝑇𝑚𝑎𝑥, 𝐶𝑠𝑠, 𝐶𝑠𝑠𝑚𝑎𝑥, and 𝐶𝑠𝑠𝑚𝑖𝑛 were assessed using the + 33% window 
described in  section 5.2.3.1 
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Identifying Makoid Banakar dissolution model parameters that were bioequivalent 
began with defining the range of F and ka values that would provide 𝐴𝑈𝐶, 𝐶𝑚𝑎𝑥, 𝑇𝑚𝑎𝑥, 
𝐶𝑠𝑠𝑚𝑎𝑥, 𝐶𝑠𝑠𝑚𝑖𝑛, and 𝐶𝑠𝑠 values that were bioequivalent to that of Tegretol.  The 
combination of absorption parameter values is represented by Figure 5.3.1.2.a.  In this 
figure, the red region represents the bioequivalent values for ka and F. The dissolution 
parameters, that (when processed using the IVIVC) returned F and ka values that were 
within the bioequivalent region of Figure 5.3.1.2.a are shown in Figure 5.3.1.2.b.  The 
resulting shape was not tractable in every dimension.  However, when Fmax/b, Fmax, and 
Fmax,Tmax were plotted against one another a tractable shape emerged (see Figure 
5.3.1.2.c.).  This allowed a discrete encompassing volume to be calculated.  The bounds 
were based on the max and min parameter values of the F2 based shape.  That decision was 
made in order to normalize the volume comparison.  As such, the volume of the IVIVC 
dissolution parameter acceptance space was 1.2666e+09 A.U. and the volume occupied by 
the associated dissolution profiles was 4.6100e+08 A.U. (see Figure 5.3.1.2.d.).  From this 
data it is evident that the use of the IVIVC provides the opportunity to have a wider 
dissolution specification (see Figure 5.3.1.2.e.). 
 
 
 
 
 
 
 
Figure 5.3.1.2. Combinations of IVIVC defined Dissolution Parameters  
  
a. 
 
b. 
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5.3.2 Comparison of Product Parameter Design Spaces: F2 vs IVIVC 
The IVIVC-vs-F2 comparison of product parameter design spaces began by 
establishing a model that predicted the amount dissolved based on binder 
concentration, disintegrant concentration, and porosity.  The results of the dissolution 
tests performed according to the design of experiments in Table 5.2.6.1. are shown in 
c. 
  
d. 
  
e. 
  
b. Dissolution parameters that return 
bioequivalent combinations of F and ka  
  
a. Bioequivalent region (red) 
  
c. Ratios of dissolution parameters that return 
bioequivalent combinations of F and ka  
  
d. Ratios of dissolution parameters that return  
F2 values >50   
  
e. percent dissolved vs. time (min): 
F2 > 50  region - red; 
Bioequivalent dissolution profiles - blue; 
Tegretol dissolution - black points; 
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Figure 5.3.2.1.  In this Figure, the model fits are also superimposed over the observed 
dissolution profiles.  
The number of dissolution profiles, and time points per profile, was 27 and 11 
respectively.  Therefore, using 20% random subset cross validation the number of time 
points in the cross validation set was 60.  The summary statistics for the product 
parameter dissolution model demonstrated suitable accuracy. The R2 for the calibration 
and cross validation were both > 0.99.  The RMSEC and RMSECV was 0.88% and 
1.47% respectively.  The final model was built with two hidden layers each consisting 
of 3 TanH nodes, 2 linear nodes, and 3 Gaussian nodes.  The generalizability of the 
model was demonstrated by the ability to predictably interpolate between time points 
and design points as demonstrated by Figure 5.3.2.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.2.1. Combinations of IVIVC defined Dissolution Parameters  
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Figure 5.3.2.2. Calibration and Cross Validation Models 
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Table 5.3.2.3. Neural Model for the Prediction of % Dissolved 
 Calibration Cross Validation 
Measures Values 
R2 0.999 0.998 
RMSE 0.88 % 1.47 % 
-Log Likelihood 307.6 108.4 
N 237 60 
 
    
  
 
 
 
 
 
 
 
 
 
 With the demonstration of acceptable accuracy and generalizability of the product 
parameter dissolution model, the next step in was to generate product parameter F2 metric 
and IVIVC design spaces.  After nesting the developed dissolution model inside of the F2 
calculation, the design space that resulted is presented in Figure 5.3.2.4.  The volume of 
this shape was 49.4013 A.U.   
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Figure 5.3.2.4. Example Response Surface Interpolated using 
 Product Parameter Dissolution Model 
 
[Disintegrant] = 1.355%;  Porosity = 8.5% 
(Black points are observed dissolution time points) 
 
Figure 5.3.2.4. Product Parameter design spaced based on F2 > 50 
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When the product parameter dissolution model was nested within a bioequivalence 
(IVIVC-based) loss function, the volume of the acceptable product parameter shape was 
40.8200 A.U. (see Figure 5.3.2.5). 
 
   
 
 
 
 
 
 
 
 
The bioequivalence loss function was constructed by:  
i. Modeling the dissolution profiles generated by the product parameter 
dissolution model reported in Figures 5.3.2.2 through 5.3.2.4 using the 
Makoid Banakar dissolution model 
Figure 5.3.2.5. Product Parameter design spaced based on IVIVC 
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ii. Transforming the dissolution model parameters into absorption rate and 
bioavailability terms using the IVIVC from chapter 3  
iii. Identifying whether or not the paired absorption rate and bioavailability 
terms existed within the bioequivalence region identified in Figure 
5.3.1.2.a. and saving the product parameter values if true 
 
To understand why the IVIVC design space was smaller than the F2 design space despite 
the former having a wider dissolution specification, one must evaluate the dissolution 
profiles resulting from each model.  Figure 5.3.2.6. illustrates the respective dissolution 
profile ranges.  The red range in this Figure corresponds to the F2 product parameter design 
space and the blue range corresponds to the IVIVC design space.  Within Figure 5.3.2.6 
the most apparent difference was that the F2 criteria allowed for release rates that were 
faster than those provided with the IVIVC.  By combining this observation with the 
information contained within Figure 5.3.2.1. the reason for the differences between the 
product parameter design spaces becomes clearer.  The earlier Figure demonstrates how 
faster dissolution rates can be achieved by a wider variety of product parameter 
combinations.  This allows the larger F2 design space to align with the observed results of 
the faster releasing F2 dissolution profiles. 
 
  
  
 
 
Figure 5.3.2.6. Dissolution Profile Ranges for the F2 and IVIVC Design Spaces 
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An additional feature of the profiles that made up Figure 5.3.2.6 was that when each 
profile was fit using the Makoid Banakar dissolution model, the slope parameter (𝑏) was < 
1 in all cases.  This scenario meant that the profiles were all mono-exponential as opposed 
to a combination of mono-exponential and sigmoidal profiles as was the case in Figure 
5.3.1.2.e.  This was interpreted to mean that, while sigmoidal release rate can occur (as 
evidenced by the slowest releasing products of Figure 5.3.1.2.e.) in the ranges of interest 
the release characteristics are most realistically represented by Makoid Banakar slope terms 
of < 1.  This characteristic of the model drug product was carried forward to the simulations 
of the next section. 
5.3.3 Post hoc Assessment of F2 Dissolution Spec using the PB-IVIVC-CTS 
Platform  
 
The population of F2 > 50 dissolution profiles from Figure 5.3.2.6. were processed 
using the IVIVC of Chapter 3 coupled with the clinical trial platform of Chapter 4 to 
create distributions of pharmacokinetic profiles.  The summary metrics for these 
profiles were individually calculated and the results are shown in Figures 5.3.3.1. 
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Figure 5.3.3.1. Bioequivalent Pharmacokinetic Responses and  
Responses Resulting from F2 > 50 Dissolution Profiles 
a. 
 
b. 
 
c. 
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Interpreting the calculated F2 distributions shown Figures 5.3.3.1. was 
accomplished by recalling several concepts:  
i) The observations which made up the distributions were paired 
ii) Errors for bioequivalence were assess at both the upper and lower limits 
of the distribution of bioequivalent responses (upper and lower green 
lines) 
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iii) F2 associated type I errors for bioequivalence could only occur at the 
upper or lower limits if there were no type II errors at those limits for 
any of the summary pharmacokinetic metrics 
iv) F2 associated type II errors were defined as red observations made 
outside upper and lower boundaries identified by the green lines  
v) If an in silico subject from the red distribution had a single 
pharmacokinetic metric that was outside the upper and lower boundaries 
for what constituted a bioequivalent response, the subject’s experience 
was recorded as type II error for bioequivalence. 
 
In Figure 5.3.3.1.e it is observed that the lower limit for the 95% credible interval 
associated F2 (𝐿𝐿ଽହ%஼ூ,ிଶ) distribution is below that of the lower limit for the 95% CI 
defined by the distribution of truly bioequivalent responses (𝐿𝐿ଽହ%஼ூ,஻ா).  The red 
area occupied by the region between the 𝐿𝐿ଽହ%஼ூ,ிଶ and 𝐿𝐿ଽହ%஼ூ,஻ா thus constitutes 
the probability of type two errors at the lower limit of bioequivalence (𝑃(𝛽௅௅) =
5.8%).  
 In graphs a., b., c., d., and f. of Figure 5.3.3.1. it is observed that the upper limit 
for the 95% credible interval associated F2 (𝑈𝐿ଽହ%஼ூ,ிଶ) distribution is above that of 
the upper limit for the 95% CI defined by the distribution of truly bioequivalent 
responses (𝑈𝐿ଽହ%஼ூ,஻ா).  The red area occupied by the region between the 𝑈𝐿ଽହ%஼ூ,ிଶ 
and 𝑈𝐿ଽହ%஼ூ,஻ா thus constitutes the probability of type two errors in bioequivalence 
at the upper limit (𝑃(𝛽௎௅)).  Internal assessment of the paired responses showed that 
the greatest occurrence of unique type II errors at the upper limit of bioequivalence 
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occurred for the 𝐶௠௔௫ metric.  The 𝑃(𝛽௎௅) for this term was 6.6%.  With such errors 
for bioequivalence occurring at both the upper and lower limits, it can be stated that 
the results of this work indicate that only type II errors for bioequivalence are 
associated with the use of the F2 statistic. Furthermore, the probability of 
biononequivalence occurring was calculated to be 12.3% (𝑃(𝛽௧௢௧௔௟) =  𝑃(𝛽௎௅) + 
𝑃(𝛽௅௅)). The significance of  𝑃(𝛽௧௢௧௔௟) associated with the use of the F2 statistic can 
be placed into context by considering that approximately 3.4 million Americans suffer 
from epilepsy, approximately 280k+ adults suffer from trigeminal neuralgia, and 
approximately 31 million Americans suffer from mood disorders – all of which can 
be treated using carbamazepine.333-336  With an estimated 12.3% of patients being put 
at risk for biononequivalence when the F2 statistic is selected to justify similar product 
performance, over 400,000 patients could be affected by the strategic decision.  
However, if the IVIVC is used to justify similar product performance, the risk of 
biononequivalence can be directly controlled.   
 
 
5.4 Conclusion 
The activities of this chapter focused on comparing design spaces and specifications 
derived from the use of the F2 statistic with those defined using a physiologically 
based IVIVC.  This was performed in three steps:  
1st) Dissolution specifications were defined using the F2 and IVIVC methods 
respectively without constraining the possible parameters for the Makorid 
Banakar dissolution model,  
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2nd) A product parameter design space was constructed using dissolution profiles 
expressed by the  product parameter dissolution model, and  
3rd) The F2 product parameter design space was processed using the IVIVC and 
the distribution of clinical responses were compared against the distribution 
of clinical responses explicitly controlled by the use of the IVIVC from the 
onset of design space refinement.   
The first step showed that IVIVC allowed for a larger range of Makoid Banakar 
dissolution model parameters when compared to the F2 range. This lead to an initial 
expectation that the IVIVC would similarly allow for a larger space of acceptable 
product parameter values.  However, the second step exposed that upon using 
dissolution profiles that were based on the performance of a real world tablet system, 
the opposite was observed to be true: the IVIVC product parameter design space was 
smaller than the F2 design space.  This observation was due to the effect of the binder, 
disintegrant, and porosity plateauing within the ranges examined by the design of 
dissolution experiments.  Steps one and two highlighted the importance of using the 
principles of experimental design to develop experimentally informed knowledge 
spaces for a pharmaceutical tablet.   
The final step of this chapter illustrated how in order to minimize the probability of 
setting specifications for quality measurements that are excessively wide or 
unnecessarily narrow development tools must be linked back to clinical performance.  
The F2 statistic did not provide a connection back to clinical performance and resulted 
in an expected 12.3% occurrence of biononequivalent events.  This expectation could 
be avoided, however, through the use of a physiologically based IVIVC as it allows 
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the risk of biononequivalence to be directly controlled for through the refinement of 
product parameters with the knowledge of their impact on dissolution.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6: Summary and Conclusion 
Heraclitus (Greek philosopher c. 500 BCE) wrote, “The only thing constant is change.”  
This concept is especially true for the development, and lifecycle management, of 
pharmaceutical products.  Here, change can result from modification to facilities, utilities, 
equipment, computer systems, formulations, analytical methods, specifications, 
manufacturing and cleaning processes, vendors and components, and documentation.  With 
the pharmaceutical industry being one of the most tightly regulated industries in the world, 
managing change is often a challenging part of a sponsor’s pharmaceutical quality system.337   
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Modeling and computer simulation offer significant opportunities for enhancing both 
quality and efficiency in our industry.  The physiologically-based IVIVC and the F2 method 
are mathematical modeling approaches used to bridge product development activities over 
changes that can occur to a pharmaceutical product’s formulation or manufacturing process.  
It was hypothesized in this work that the use of an IVIVC provided superior estimation of 
bioequivalence relative to the F2 statistic.  This superiority was posited despite reliance upon 
the F2 statistic being more efficient and not requiring a paradigm shift away from 
conventional biowaiver strategies.  Regardless of the industry’s conventional use of the F2 
statistic, and its  advantage in efficiency, this work demonstrated a clear performance 
advantage for the IVIVC approach.  
Since 1997, when the FDA adopted the F2 test proposed by Moore and Flanner, the F2 
metric has conventionally been used to assess the test-vs.-reference dissolution performance 
similarity.338    Currently, sponsors rely on the historical track record of the F2 metric.  Users 
of this metric benefit from its efficiency.  When a formulation or manufacturing process 
change occurs, the F2 metric allows a sponsor to move through the resulting decision point 
via a method that is straightforward and thoroughly familiar to regulatory agencies.  
However, such practice does not provide a clear link back to clinical significance; thus, the 
criticality of such a change cannot be accurately assessed using the F2 metric.  The major 
limitation of the F2 statistic is that it does not account for the inter-subject variance required 
for the effective in vivo assessment of similarity for a test vs. reference comparison.  
An IVIVC allows for the direct linkage between a dissolution change and its clinical 
effects (see Specific Aim I - Chapter 3).  Indeed, by nesting an IVIVC within a clinical trial 
simulation platform, as shown by the work herein, the prediction of inter-subject variability 
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can also be accomplished.  The performance of such simulations has historically required 
that a large-scale clinical trial be conducted so that population pharmacokinetic analysis 
could be carried out on the results (see discussion on NLME modeling in Chapter 2 section 
2.4.1).  However, such trials are demanding of resources and require extended timelines. The 
work presented demonstrates how the consideration of inter-subject variability was achieved 
without the need for such population level clinical trials.  Here, physiologically based 
pharmacokinetic modeling and DMPK assays were relied upon for the mechanistic 
prediction of such variability (Specific Aim II – See Chapter 4).  Ultimately, this work 
supports the justification of the increased cost associated with IVIVC development by 
demonstrating a scenario wherein the use of the F2 was associated with a higher risk of 
bioequivalence failures.   
The IVIVC method confers equivalence by directly controlling errors for 
biononequivalence.  Alternatively, the F2 method confers similarity when its value is 
> 50.  This assures that the average test vs. reference difference between dissolution 
profiles is < 10%.  However, using the F2 criterion fails to emphasize the link between 
a quality measurement and clinical significance.  Additionally, it does not directly 
control the risk of biononequivalence, nor does it provide sponsors an opportunity to 
assess the risk of setting excessively narrow quality measurement specifications.  This 
work demonstrated how bioequivalence could be directly built into the design space 
development process (see Specific Aim III - Chapter 5).  The project illustrated the 
superiority of a carbamazepine product development strategy based on IVIVC 
methods, over F2 methods, by quantifying the increased risk associated with the use of 
the F2 (see Specific Aim IV - Chapter 5).  Future efforts should be conducted on 
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incorporating physiologically based pharmacodynamic models within the PB-IVIVC 
for a further, more mechanistic, refinement of clinically significant deviations in 
performance. It is intended that this work support the movement of product/process 
optimization practices away from methods that result in rigid factors of unknown clinical 
significance, and towards those that are focused on efficiently achieving specific clinical 
objectives.   
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